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1 INTRODUCTION  
 
1.1 AUTOPHAGY –  A BULK DEGRADATION P ATHWAY  
 
Even though eukaryotic cells are constantly exposed to changing environmental conditions, a 
dynamic turnover of protein and organelle synthesis, degradation and recycling enables the 
maintenance of their cellular homeostasis. To adjust the level of intracellular material, 
eukaryotic cells developed two major degradation pathways. The ubiquitin-proteasome 
system controls degradation of cytoplasmic short-lived proteins [1]. In contrast, degradation 
and recycling of long-term proteins and organelles is regulated by a bulk degradation process 
called autophagy (Greek: auto-, "self" and phagein, "to eat") by which the cytosolic cargo is 
delivered to lysosomes for degradation [2]. Both pathways result in the release of the 
macromolecular breakdown products back into the cytoplasm in order to restore the cellular 
homeostasis. 
Unlike the ubiquitin-proteasome system, the term autophagy refers to a collection of distinct 
self-eating processes (Figure 1-1). Based on the molecular pathways, autophagy is classified 




FIGURE 1-1:  SCHEMATIC DEPICTION OF MAIN TYPES OF AUTOPHAGY (MODIFIED FROM [3])  
Autophagy represents a tightly regulated catabolic process targeting cytoplasmic content to lysosomes for 
degradation. Due to distinct molecular mechanisms, autophagy can be broadly classified in three classes: 




Lysosomal delivery through chaperone-mediated autophagy occurs independently of vesicle 
formation [4]. Substrate proteins, containing a KFERQ-like pentapeptide motif, are selectively 
recognized by the heat shock-cognate protein of 70 kDa (Hsc70)-containing 
chaperone-complex and targeted to the lysosomal membrane. Substrate-mediated 
multimerization of the lysosome-associated membrane protein type 2A (LAMP-2A) facilitates 
the substrate translocation into the lysosomal lumen for its degradation.  
Cytoplasmic content is also trapped in vesicles which are directly formed through the 
invagination of the lysosomal membrane [5]. This non-selective degradation pathway, called 
microautophagy, represents the least understood type of autophagy.  
In contrast, macroautophagy is the most prevalent form of autophagy in eukaryotic cells and 
was intensively studies during the last two decades [6, 7]. A membrane sac, called isolation 
membrane, initially sequesters the cytoplasmic constituents. Further elongation of the 
isolation membrane generates the phagophore. The phagophore ultimately closes and results 
in a double-membraned compartment called autophagosome. Fusion with lysosomes to 
autolysosomes finally enables lysosomal degradation of the autophagic content.  
 
1.2 MACROAUTOPHAGY  
 
 
The present study focuses on mammalian macroautophagy, which is hereafter referred as 
autophagy, and reviews the molecular mechanism as well as the physiological function of 
autophagy in more detail. 
 
1.2.1 THE MO LE CU LAR COR E MA C HI NER Y  
 
Deciphering of the molecular mechanisms underlying autophagy was primarily based on the 
discovery of autophagy-related (ATG) genes in yeast and mammalians.  
Focusing on mammalian homologues, an essential subset of ATG proteins regulates the initial 
steps of autophagosome formation and is thus referred as the molecular core machinery [8].  
Upon amino acid deprivation, as classical stimulus for canonical autophagy, distinct 
multimeric protein complexes mediate the initiation of autophagosome formation. Besides 
the UNC51-like kinase (ULK) and class III phosphatidylinositol 3-kinase (PI3P) complexes [9, 
10], two ubiquitin-like conjugation systems were discovered to be essentially required for 








FIGURE 1-2:  UBIQUITIN-LIKE CONJUGATION SYS TEMS INVOLVED IN AUTOPHAGOSOME BIOGENESIS  (MODIFIED FROM 
[11]) 
Elongation of the autophagic isolation membrane requires two ubiquitin-like conjugation systems, the 
ATG12-ATG5-ATG16L1 conjugation complex and the LC3-PE conjugation system. See text for more details. 
ATG - autophagy-related protein, LC3 - microtubule-associated protein 1 light chain 3, 
PE - phosphatidylethanolamine 
 
At first, localization of the ATG12-ATG5-ATG16L1 complex to the isolation membrane 
participates in autophagosome formation [12]. In detail, ATG7-dependent activation of the 
ubiquitin-like protein ATG12 subsequently leads to the transfer of ATG12 to the E2 ubiquitin 
conjugating enzyme-like protein ATG10 [13]. This mechanism facilitates the covalent binding 
of ATG12 to ATG5, which finally conjugates with the autophagy-related protein 16 like 1 
(S. cerevisiae) (ATG16L1) to form an 800-kDa multimeric complex [12, 14]. Recently it was 
reported that recruitment of this multimeric complex to the isolation membrane is obtained 
by the direct binding of ATG16L1 to the WD-repeat phosphatidylinositol 3-phosphate effector 
protein 2b (WIPI2b) [15]. Acting in an E3 ubiquitin ligase-like manner, the 
ATG12-ATG5 ATG16L1 complex subsequently defines the site of conjugation for the second 
ubiquitin-like conjugation system by promoting lipidation of the microtubule-associated 
protein 1 light chain 3 (LC3) [16]. Synthesized as precursor, LC3 is proteolytically cleaved by 
ATG4 into its cytosolic form, namely LC3-I [17]. Similar to ATG12, LC3-I is activated by the E1 
ubiquitin activating enzyme-like protein ATG7 and transferred to an E2 ubiquitin conjugating 
enzyme-like protein, in this case ATG3 [18]. Finally, LC3-I is conjugated to 
phosphatidylethanolamine (PE) and thus converted in its membrane-bound form LC3-II 
which specifically localizes to the autophagosomal double-membrane [19]. Depletion of 
either ATG7 or one of the components of the ATG12-ATG5-ATG16L1 complex results in an 
impaired conversion of LC3 meaning a strong accumulation of LC3-I with a concurrent 
































Upon completion of the autophagosome formation, the ATG12-ATG5-ATG16L1 complex and 
the outer-membrane associated LC3-II dissociates from the autophagic membrane [12, 19]. 
However, following the autophagosome-lysosome fusion, lysosomal hydrolytic enzymes 
degrade intra-autophagosomal LC3-II. Thus, the turnover over of LC3-I to LC3-II is a well-
established marker to investigate the autophagic flux in mammalian cells [23].  
 
1.2.2 SE LE CT IV E AUT OP HA G Y  B Y S PE CI F IC CAR G O RE C EP TOR S  
 
Whereas autophagy, in response to nutrient deprivation, is a non-selective bulk degradation 
of cytosolic material, several forms of selective autophagy have been identified upon other 
stresses like removal of aggregated proteins (aggrephagy), damaged organelles e.g. 
mitochondria (mitophagy) or invading bacteria e.g. Salmonella enterica (xenophagy) [24]. 
Autophagic selectivity is conferred by autophagy cargo receptors which bind the cargo 
earmarked with degradation signals [25]. In mammalians, Lys63-linked poly-ubiquitination is 
the most prevalent degradation signal and can be bound by the ubiquitin-binding domain 
(UBD) of the cargo receptors [26]. Additionally, these receptors commonly possess a LC3 
interacting region (LIR) to bridge the captured cargo, targeted for degradation, to the 
autophagosomal membrane. Sequestosome-1 (SQSTM1, hereafter referred as p62) was the 
first identified adaptor protein which directly binds LC3 to facilitate degradation of 
ubiquitinated protein aggregates [27]. Importantly, p62 also has other functions (see 5.2.4). 
Following the discovery of p62, several other selective autophagy receptors such as neighbor 
of BRCA1 gene 1 protein (NBR1) [28] and nuclear dot protein 52 kDa (NDP52) [29] were 
discovered. As reported for p62-/- mice, absence of autophagy cargo receptors results in 
hyper-accumulation of insoluble Lys63-ubiquitinated proteins [30].  
Most of the autophagic receptors undergo constant degradation even in an unloaded state. 
Activation of these receptors is mainly regulated on transcriptional level. Besides amino acid 
depletion, activation of TLR4 and TLR2/6, for example, strongly induces the expression of 
p62 [31, 32]. On the other hand, cellular localization and spatial organization have an impact 
on their activation. In this case, oligomerization of p62 and NBR1 triggers sequestration and 
clustering of the autophagic cargo [28, 33]. Although autophagic receptors lack a unique 
specialization, cooperation between them is important for the selectivity of a specific cargo.  
 
1.2.3 AUTOP HA GY AND I T S P HY S IO LO G ICA L FU NCT IO NS  
 
Based on its various cellular functions in adaptive responses to starvation, quality control of 
proteins and organelles as well as elimination of invading pathogens, impaired autophagy has 
been implicated in a wide range of human diseases [34]. In this context, in vivo studies in mice 
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enlightened the multifaceted functions of autophagy in physiological processes and gave first 
insights in the complex phenotypic consequences caused by the impairment of autophagy. 
Mice deficient in components of the ULK or PI3P complex, initiated upstream of the two 
ubiquitin-like conjugation systems in autophagosome biogenesis, die early in embryogenesis 
[35, 36]. Interestingly, mouse models harboring a constitutive homozygous knock-out of 
essential autophagy-related genes, such as Atg7, Atg5 or Atg16l1, were born at the expected 
Mendelian frequency [20-22]. However, neonatal lethality of these mice demonstrated the 
physiological relevance of autophagy during the early neonatal starvation period. In contrast, 
mice deficient in Lc3b, one of the two isoforms of Lc3, did not show any phenotypic 
abnormalities [37]. 
Conditional mouse models lacking Atg genes in the particular tissue revealed a crucial role for 
autophagy in cell differentiation. Besides increased mortality at the age of 8-14 weeks and a 
severe anemia, mice with a conditional depletion of Atg7 in hematopoietic cells showed a 
significant decrease in T and B lymphocyte counts [38]. T cell-specific knock-out of either 
Atg5 or Atg7 resulted in reduced numbers of peripheral T cells and enhanced apoptosis of 
mature T lymphocytes presumably based on impaired mitophagy [39, 40]. Similarly, studies 
in mice lacking Atg5 in B cells displayed a role for autophagy in B cell development in the 
bone marrow and B cell survival in the periphery [41].  
Studies in mice deficient for Atg genes in terminally differentiated cell types additionally 
implied a substantial role for autophagy in tissue homeostasis. Tissue-specific ablation of 
Atg5 or Atg7 e.g. in liver and brain caused severe phenotypes characterized by hepatic 
dysfunctions [21, 42] and neurodegeneration associated with accumulation of ubiquitinated 
proteins [43, 44], respectively. Within the intestinal epithelium, homeostasis of particularly 
Paneth cells is strongly dependent on an intact autophagic machinery [45]. 
In accordance with the intracellular removal of invading pathogens via the autophagosomal 
pathway, mice particularly lacking Atg5 or Atg7 in myeloid cells showed an increased 
susceptibility to infections with Mycobacterium tuberculosis [46, 47] but also Candida albicans 
[48] or Toxoplasma gondii [49]. 
 
1.3 THE AUTOPHAGY PROTEIN  ATG16L1   
 
The Atg16l1 gene (human: 3411base pairs (bp), RefSeq. NM_030803; mouse: 3149bp, 
RefSeq. NM_029846) is located on chromosome 2 on position 37.1. The encoding protein was 
originally obtained in a yeast-two hybrid screen as a potential interaction partner of yeast 
atg12 [50]. However, detailed studies demonstrated that yeast atg16 (previously known as 
apg16) directly interacts with atg5 via its N-terminal coiled-coil domain being indirectly 
associated with atg12. Absence of atg16 hinders the recruitment of the atg12-atg5 conjugate 
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to the autophagic isolation membrane. Studies in mammalian cells further showed that 
formation of this multimeric complex is essentially involved in autophagosome biogenesis 
from yeast to mice and men [12, 51, 52].  
Named after the weak but significant homology in its N-terminal region with yeast atg16, the 
mammalian ATG16 like 1 protein (ATG16L1) contains an N-terminal ATG5-binding region 
and a coiled-coil domain required for self-oligomerization [12, 53, 54]. Additionally, the 
C-terminal region consists of seven tryptophan-aspartic acid (WD) repeats exhibiting a β-
propeller structure. WD repeats are protein interaction domains found in functionally diverse 
proteins [55] suggesting that there might be undiscovered binding partners of ATG16L1 that 
interact with this region. Recent reports also suggested a protein-binding region for 
autophagy components, e.g. focal adhesion kinase family-interacting protein of 200 kD 
(FIP200) and WIPI2b, in between the coiled-coil and WD40 domains without affecting the 
integrity of the ATG12-ATG5-ATG16L1 complex [15, 56, 57].  
Generated by alternative splicing, multiple isoforms of ATG16L1 were identified. Whereas at 
least four isoforms were reported for human ATG16L1 [53], Mizushima et al. confirmed that 
the murine Atg16l1 gene encodes for at least three isoforms [12]. Interestingly, although 
ATG16L1 is ubiquitously expressed in murine tissue, ATG16L1α (lacking exon 8 and 9, 
appr. 63 kDa) and ATG16L1β (lacking exon 9, appr. 71 kDa) were preferentially expressed in 
liver, kidney, spleen, thymus and testes. The third murine isoform ATG16L1γ (complete 
sequence of exon 8 and 9, 75 kDa) was mainly expressed in the brain. Mouse ATG16L1β and 
human ATG16L1-1 share 90 % identity and 93 % similarity of their amino acid sequence 
showing a high degree of homology. The cellular functions of these isoforms are hardly 
investigated. However, findings of a recently published study indicate that the distinct 
isoforms of ATG16L1 might contribute to different autophagic properties [58]. 
 
1.3.1 ROL E O F ATG16L1  I N  I M MUN E RE SP ON S ES  
 
Besides xenophagy [46, 59], autophagy has also been reported to play a diverse role in other 
immunological processes, e.g. in modulation of signal transduction [60, 61] and regulation of 
cytokine secretion [22, 62, 63]. In this context, one of the best functionally studied 
disease-associated single nucleotide polymorphisms (SNPs) is rs2241880 in the human 
ATG16L1 gene, which is highly associated with Crohn´s disease, a chronic inflammatory 
disorder of the gastrointestinal tract [64, 65]. This SNP results in an exchange from threonine 
to alanine in the amino acid sequence of ATG16L1 at position 300 and is thus called T300A 
allelic variant. Studies in mice showing an impaired expression of Atg16l1 in the intestinal 
epithelium, due to conditional depletion or hypomorphic expression, exhibit abnormalities in 
the ultrastructure of Paneth cells with an altered architecture of secretory vesicles loaded 
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with antimicrobial peptides such as lysozyme and defensins [66, 67]. This finding was 
confirmed in Crohn's patients harboring the homozygous ATG16L1 risk allele T300A. 
Importantly, work by Murthy and colleagues demonstrated that the T300A variant of 
ATG16L1 represents a hypomorphic allele [68]. Using knock-in mouse models bearing either 
the human (T300A) or murine (T316A) missense variant Murthy et al. showed an increased 
sensitivity to caspase-3-dependent cleavage leading to a defective autophagic capacity and 
augmented pro-inflammatory cytokine production in the ileum. In this context, 
ATG16L1-deficient cells showed in vitro an increased replication of the Crohn´s 
disease-associated adherent-invasive Escherichia coli strain LF82 [69]. Human peripheral 
blood mononuclear cells (PBMCs) bearing the T300A allele showed increased production of 
IL1β upon muramyl dipeptide (MDP) stimulation [70]. Similar findings were obtained in 
macrophages derived from Atg16l1 chimeric mice in response to LPS [22]. The latest links 
assume a variety of molecular mechanisms, by which ATG16L1 and autophagy may modulate 
inflammasome-dependent IL1β secretion, e.g. due to impaired degradation of the 
inflammasome itself [71] or a regulatory function of damaged mitochondria activating the 
inflammasome via production of reactive oxygen species (ROS) [72]. Interestingly, ATG16L1 
was also identified as regulator of IL1 receptor signaling in fibroblasts by modulating 
IL1β-induced MAPK and NF-κB activation pointing to a potential immunomodulatory 
function independent of inflammasome activation [60].  
Elucidation of the molecular mechanisms of ATG16L1 might deepen the understanding of its 
regulatory capacity in immunomodulatory processes and its role within human diseases. 
 
1.4 INFLAMMATION  
 
The World Health Organization defines health as “a state of complete physical, mental and 
social well-being and not merely the absence of disease or infirmity” [73]. From the biological 
point of view an organism´s health is stated as the dynamic physiological homeostasis of all 
biological systems resisting environmental changes and thus preserving life [74].  
Within this complex network, the host´s immunity is a major component maintaining the 
healthy state. Besides the continuous control of steady-state conditions ensuring the host´s 
cellular and molecular functionality, the immune system patrols physical barriers preventing 
the invasion of foreign agents. In case of noxious stimuli or conditions like infections or injury 
the immune system immediately initiates a protective immune reaction called inflammation 
(Latin: inflammare, “to set on fire”).  
Inflammation is traditionally defined by its five cardinal signs: redness (rubor), increased 
heat (calor), swelling (tumor), pain (dolor) and loss of function (functio laesa). The aim of the 
induced inflammatory cascade is in first line the elimination of the initial cause and the 
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ensuing restoration of tissue homeostasis. Inflammation can be classified in two subtypes: 
acute and chronic inflammation.  
Acute inflammation is typified by a rapid onset and a short duration lasting from a few 
minutes to a couple of days. The pathophysiological mechanisms are well understood and 
represent a controlled and self-limiting inflammatory cascade [75, 76]. At first, blood flow 
increases through vasodilation. As a consequence, increased vascular permeability facilitates 
on the one hand the leakage of plasma proteins and on the other hand the migration of 
leukocytes, mainly neutrophils, to the site of inflammation. The release of pro-inflammatory 
mediators, like cytokines and chemokines, activates recruited leukocytes and finally induces 
the elimination of the noxious agent followed by a resolution and a repair phase. A 
dysregulation of this preprogrammed inflammatory cascade, due to a failed elimination of the 
invading agent or a malfunction of the affected tissue, results in persisting inflammatory 
conditions, called chronic inflammation [75, 76].  
In contrast to an acute inflammation, chronic inflammation lasts from weeks to years. 
Representing the switch from the innate to the adaptive immunity, the predominantly 
invading leukocytes shift from neutrophils to mononuclear cells, mainly macrophages and 
lymphocytes causing characteristic tissue damage based on their continuous secretion of 
pro-inflammatory mediators. Tissue repair involves the processes of new blood vessel 
formation (angiogenesis) and fibrosis. 
Importantly, inflammation is critical for the development of a variety of complex human 
diseases including metabolic disorders [77], cardiovascular diseases [78], neurodegenerative 
diseases [79], autoimmune diseases [80], intestinal diseases [81] but also cancer [82]. Thus, a 
profound knowledge about the initiation and the molecular mechanisms of (chronic) 
inflammation is of central interest in numerous clinical disciplines. 
 
1.4.1 SEP S I S  
 
One of the oldest inflammatory symptoms in human medicine can be traced back until the 
age of the Ancient Greeks (4th century B.C.). Hippokrates observed a phenomenon by which 
flesh rots and wounds fester, called sepsis (Greek: σηπω, “to rot”) [83]. Until the 19th century, 
sepsis was claimed as a result of the invasion of pathogenic organisms spreading into the 
host´s blood stream and thus was often described as “blood poisoning” [84]. Nowadays, 
immunopathogenesis of sepsis is assumed to be caused by an over-activation of the host´s 
innate immune system and the following pro-inflammatory cascade. In 1992 and 2003, an 
international consensus panel defined sepsis as “systemic inflammatory response to 
infection” [85, 86]. Septic patients might manifest several symptoms including increased or 
decreased body temperature, elevated blood cell count, increased heart rate, rapid 
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respiratory rate but also an altered mental status. However, clinical manifestations of sepsis 
exhibit great interindividual variations depending on patient factors like age, gender, 
underlying health state and genetic predisposition [84, 87]. On the other hand, load and 
virulence of the causative organism but also the initial site of infection play a decisive role in 
the course of disease. Sepsis complicated by acute organ dysfunction and finally multiple 
organ dysfunction is further clinically classified as severe sepsis and septic shock, 
respectively [85, 86]. 
Even after centuries of research, sepsis remains worldwide the leading cause of death in 
critically ill patients [84-86]. The overall mortality rate varies from 30 % up to 50 % in 
elderly patients [88]. In Germany, a prevalence of 12.4 % for sepsis and 11.0 % for severe 
sepsis was determined in intensive care units [89]. In 2010, the worldwide incidence was 
estimated up to 19 million cases per year emphasizing the immense medical and health 
economic burden due to sepsis [90]. 
The most common infectious diseases causing sepsis are pneumonia followed by 
intra-abdominal and urinary tract infections as well as primary infections of the blood stream 
[88]. Moreover, clinical data demonstrate a number of long-term consequences for survivors 
of (severe) sepsis [91, 92]. Besides cognitive and physical impairments, survivors also show 
an increased susceptibility to sequelae like ischemic stroke and myocardial infarction [93].  
As discussed in the following chapters, investigations of initiating microbial components, the 
regulatory role of innate immune cells and their secreted inflammatory mediators as well as 
underlying molecular mechanisms of innate immune receptor signaling achieved great 
advances in the understanding of the immunopathogenesis of sepsis. However, sepsis still 
remains a major challenge in medicine and the development of new effective therapeutical 
approaches is necessary to increase the survival rate following (severe) sepsis. 
 
1.5 MYELOID CELLS -  THE FIRST LINE OF DEFENSE  
 
In adult mammalians, the bone marrow acts as the predominant reservoir of hematopoietic 
stem cells (HSCs) giving continuously rise to all types of blood cells: erythrocytes, leukocytes 
and platelets [94]. Classification of leukocytes is typically based on their hematopoietic 
lineage (Figure 1-3). Natural killer (NK) cells as well as T and B lymphocytes derive from a 
common lymphoid progenitor (CLP) [95]. Myeloid cells arise from a common myeloid 






FIGURE 1-3:  SCHEMATIC STEPS OF LE UKOCYTE DIFFERENTIATION (MODIFIED FROM [98,  99])   
Leukocytes derived from hematopoietic stem cells of the bone marrow are generated by either common myeloid 
progenitor (CMP) cells or common lymphoid progenitor (CLP) cells. See text for more details. 
 
Once released from the bone marrow, myeloid cells circulate through blood and the 
lymphatic system and are rapidly recruited to the site of tissue damage or infection. Myeloid 
cells are not only distinguished by their morphology but also by their recruitment kinetics 
and cellular functions during infection and inflammation. 
 
1.5.1 NEU TROP HI L S  
 
Granulocytes are morphologically distinguishable from other myeloid cells due to their 
segmented nucleus and characteristic cytoplasmic granules. Besides macrophages, 
granulocytes were first discovered as “microphages” by Ilya Metchnikoff in the 19th century 
and were later on categorized by Paul Ehrlich in basophilic, neutrophilic and eosinophilic 
polymorphonuclear cells due to their distinct staining characteristics [100]. Whereas 
basophils and eosinophils are mainly involved in the pathogenesis of allergic disease, 
neutrophils represent the first myeloid cell population during tissue damage or infection.  
Neutrophils are well-characterized terminally differentiated myeloid cells with a short 
half-life of 6-12 hours and are the most abundant myeloid cell type [101]. During 
inflammatory processes neutrophils migrate in response to chemo-attractants, like 
interleukin-8 (IL8), to the site of inflammation [102, 103]. Using flow cytometry, neutrophils 
can be identified by their specific cell surface co-expression of CD11b and Ly6G [104]. As 
phagocytic cells, the general function of neutrophils relies in first line on the engulfment of 
extracellular pathogens and agents and its ensuing intracellular clearance (phagocytosis). 
Besides phagocytosis, neutrophils possess a variety of extracellular microbizidal mechanisms 
Hematopoietic stem cell
CLPCMP






to eliminate bacteria [101, 105]. The major pool of antimicrobial substances is captured in 
cytoplasmic granules which are secreted upon neutrophil activation and can be classified in 
two major subtypes: primary or azurophilic granules and secondary or specific granules 
[106]. Azurophilic granules are the major storage site of the myeloperoxidase (MPO) and 
other cytotoxic molecules like serine proteases and defensins. Among other components, 
peroxidase-negative secondary granules mainly contain lysozyme and lactoferrin. Besides the 
degranulation response, neutrophils exhibit a second extracellular destruction process called 
neutrophil respiratory burst. By increasing the consumption of oxygen during phagocytosis, 
neutrophils generate ROS with a high antimicrobial potential [107]. Additionally, 
neutrophil-derived cytokines, like macrophage inflammatory protein-1 α (MIP1α) [108], 
make an important contribution to activation, differentiation and recruitment of other 
myeloid cells like macrophages and dendritic cells [101, 109]. Recent findings further 
implicate a role for neutrophils in the resolution of inflammation as neutrophils also secrete 
anti-inflammatory cytokines like interleukin-10 (IL10) [110]. Additionally, a subset of 
neutrophils, called myeloid-derived suppressor cells (MDSCs), mediates immune suppression 
by inhibiting T cell response during systemic inflammatory conditions [111]. 
 
1.5.2 MONOC YT E S AND MA CR OPH AG E S  
 
Monocytes are directly generated from myeloid progenitor cells in the bone marrow and 
afterwards released in the blood circulation where they represent 4-10 % of the peripheral 
leukocytes. In 1968, van Furth and colleagues established the mononuclear phagocyte system 
by which monocytes serve as precursor of tissue-resident macrophages under steady-state 
conditions [112]. Distinguished by their cell surface markers, these so called classical 
monocytes exclusively express CD14 in humans and are defined as Ly6Chigh myeloid cells in 
mice [113, 114]. In the meantime, it is known that two independent systems evolved to 
renew myeloid cells. Classical monocytes mainly serve as systemic reservoir for macrophages 
and dendritic cells under inflammatory conditions [115]. In contrast, embryonic myeloid 
precursors are the resource of tissue-resident macrophages in various organs, like brain, liver 
and epidermis, enabling a continuous self-renewal within the native tissue [116, 117]. 
Tissue macrophages reside in most lymphoid and non-lymphoid organs where they are 
involved in steady-state tissue homeostasis via clearance of apoptotic cells and production of 
growth hormones [118]. Among others, tissue-resident macrophages include alveolar 
macrophages in the lung, osteoclasts in the bone, Kupffer cells in the liver and microglia in 
the brain. However, according to the variable microenvironment of the local milieu, there is a 
high demand on functional specificity for resident macrophages to maintain tissue 
homeostasis. Intestinal macrophages, for example, are constantly exposed to changing 
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environmental and microbial conditions by food uptake. To avoid an over-reaction to the 
host´s commensal gut flora under healthy conditions, intestinal macrophages, in contrast to 
splenic macrophages, spontaneously produce high amounts of the anti-inflammatory 
cytokine IL10 mediating a hypo-responsiveness towards bacterial and viral components and 
in turn an impaired production of pro-inflammatory cytokines like IL12 [119].  
First discovered by Ilya Metchnikoff, macrophages are traditionally defined as phagocytic 
cells [100]. Their broad range of immune receptors on the plasma membrane and in the 
cytoplasm facilitates an early and efficient recognition and ingestion of a wide array of 
bacterial, viral and fungal pathogens ([120], see also chapter 1.6). Upon engulfment of the 
extracellular pathogens in (phago-) lysosomes, immunogenic peptides were immediately 
processed and loaded on major histocompatibility complex II (MHCII) molecules [121]. The 
ensuing MHCII-mediated antigen presentation at the cell surface of activated macrophages 
finally drives naïve T cells into T helper cells. In this way, macrophages are able to 
communicate the nature of the invading pathogen to the adaptive immune system mediating 
a long-lasting antigen-specific response. Simultaneously, activated macrophages secrete 
pro-inflammatory cytokines like tumor necrosis factor-alpha (TNFα) [122], interleukin 12 
(IL12) [123] as well as IL8/CXCL1 [124, 125] initiating the recruitment of additional innate 
and adaptive immune cells to the site of local infection [103, 126]. Besides MHCII expression 
at the cell surface as classical activation marker [127], expression of CD95/Fas is upregulated 
on activated macrophages [128]. Although it is best known for its role as death receptor 
inducing apoptosis [129], CD95/Fas is able to promote secretion of pro-inflammatory 
cytokines like CXCL1. Especially upon activation through lipopolysaccharide, a constituent of 
the outer layer of the outer membrane of gram-negative bacteria, macrophages increase 
CD14, an accessory protein of the Toll-like receptor 4 (TLR4), at their cell surface [130-132] 
(see also chapter 1.6.1). 
Besides their crucial role within the initiation of the appropriate immune response, 
macrophages are also essentially involved in the resolution of inflammation by eliminating 
apoptotic cells and regulate wound healing [133, 134].  
 
1.6 TOLL-LIKE RECEPTORS IN IN NATE IMMUNE RESPONSES  
 
In 1989, Janeway revolutionized the research field of immunology, proposing a concept by 
which innate immune cells sense conserved microbial structures, so called 
pathogen-associated molecular patterns (PAMPs), by a limited number of pattern recognition 
receptors (PRRs) [135]. After several decades of intensive studies in a variety of model 
organisms and humans, it is nowadays well-known how myeloid cells use PRRs as 
sophisticated tool to protect the host against an enormous diversity of microbial classes such 
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as viruses, bacteria and fungi. Besides specific tissue expression patterns and distinct cellular 
localizations, PRRs recognize a broad spectrum of ligands subsequently inducing specific 
intracellular signaling pathways and downstream gene expression to initiate an appropriate 
immune response.  
One of the major subfamilies of PRRs is represented by mammalian Toll-like receptors 
(TLRs). However, the first Toll protein was originally discovered in 1985 by the group of 
Christiane Nüsslein-Vollhard who reported the involvement of Toll in the dorsoventral 
polarity of the developing Drosophila melanogaster embryo [136]. Although the homology 
between the cytosolic domain of Toll and the human interleukin 1 receptor (IL1R) was 
already predicted in 1991 [137], the impact of Drosophila Toll in host defense was still 
unsolved as the molecular mechanism by which the IL1R presumably signals was still 
unclear. One of the important steps in this research field was the characterization of the plant 
N protein in 1994 [138]. Besides an N-terminal domain homolog to the cytosolic Toll and 
IL1R domain, the plant N protein was described to mediate the resistance against the tobacco 
mosaic virus. This finding provided one of the first evidences for a crucial role of proteins 
containing the evolutionarily conserved Toll-IL1 receptor (TIR) domain in host defense. Due 
to their structural relation, the mammalian Toll homologues were called Toll-like 
receptors [139]. In the meantime, ten TLR genes in humans (TLR1-10) and 12 murine Tlr 
genes (Tlr1-9, Tlr11-13) were identified [140].  
Mammalian TLRs have now been studied for over 20 years and their complex signaling 
network is well-understood [140-142] (Figure 1-4). Mammalian TLRs are type I 
transmembrane receptors exhibiting an extracellular domain containing leucine-rich repeats 
(LRRs), a single membrane-spanning segment and the above mentioned intracellular TIR 
domain [143]. They can be broadly subdivided by their cellular localization. TLR1, TLR2, 
TLR4, TLR5, TLR6 and TLR11 are exclusively expressed at the cell surface and mainly 
recognize bacterial components like flagellin [144] and bacterial lipopeptides [145, 146]. On 
the other hand, TLR3, TLR7,TLR8, TLR9 and TLR13 are located in endosomes sensing non-
self nucleic acids like double-stranded (ds) and single-stranded (ss) viral RNA [147, 148] but 
also CpG-rich hypomethylated bacterial DNA [149]. Neither a ligand nor a role for TLR10 has 
been reported so far [141, 150]. Activation of mammalian TLRs is initiated by ligand binding 
to their ectodomain followed by the formation of homo- or hetero-dimers [151]. The 
rearranged TIR domains subsequently act as scaffold for the recruitment of TIR 
domain-containing signaling adaptors that bridge TLRs to proteins of the downstream 
signaling cascades. Interestingly, TLRs as well as members of the IL1R family signal in part 
through identical components like the adaptor molecule myeloid differentiation primary-
response protein 88 (MyD88) [152], the downstream activated interleukin 1 receptor-
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associated kinases (IRAKs) [153] and the E3 ubiquitin protein ligase TNF receptor-associated 
factor 6 (TRAF6) [154] (see also chapter 1.6.1.) 
 
FIGURE 1-4:  MAMMALIAN TOLL-LIKE RECEPTOR (TLR)  SIGNALING  (TAKEN FROM[142]) 
Mammalian TLRs possess distinct ligand specificities and cellular localizations. However, TLR-induced signaling 
pathways share common features like the TIR-domain containing adaptor molecules MyD88 and TRIF but also the 
downstream activation of transcription factors like NF-κB and IRF3/7. See text for more details. 
IRF3/7: interferon regulatory factor 3/7; MyD88: myeloid differentiation primary-response protein 88; 
NF-κB: nuclear factor 'kappa-light-chain-enhancer' of activated B-cells; TRIF: TIR-domain-containing 
adapter-inducing interferon-β 
 
As one of the major PRR families, TLRs are key regulators of innate immune responses. Thus, 
an appropriate (de-)activation of TLR signaling is of prime importance and dysregulation of 
the signaling leads to several infectious and inflammatory diseases in humans like 




1.6.1 TOL L-LI KE R EC EPT OR 4  (TLR4)  SI GNA L IN G   
 
TLR4, originally named hToll, was the first identified human homologue of Drosophila Toll 
[160]. Within the family of mammalian TLRs, TLR4 adopts an exceptional position due to the 
unique ligand recognition and cellular translocation that is directly linked to the replacement 
of adaptor molecules and the activation of individual signaling pathways. 
The first and best-characterized ligand of TLR4 is LPS [161-163]. However, during the last 
decades it was demonstrated that recognition of LPS by TLR4 is complex and involves 
additional non-TLR components. In detail, detection of LPS is mainly mediated by a stable 
hetero-dimer of TLR4 and its essential co-receptor myeloid differentiation factor 2 (MD2) 
[164, 165]. The accessory proteins CD14 and LPS-binding protein (LBP) further enhance LPS 
detection by direct binding and ensuing presentation of LPS to TLR4-MD2 complexes [166-
168]. 
Unlike the majority of TLRs which directly signal through the adaptor molecule MyD88, 
TLR4-MyD88 interaction is indirectly mediated by the bridging adaptor TIR 
domain-containing adaptor protein (TIRAP, also known as Mal) (Figure 1-4). LPS-induced 
TLR4 dimerization initially triggers the assembly of a submembraneous signaling complex 
consisting of MyD88-Mal and IRAKs. In brief, recruitment of IRAK4 to MyD88-Mal mediates 
the (auto-)phosphorylation of IRAK1/2 through its intrinsic kinase activity [169-171]. Based 
on its hyper-phosphorylation, IRAK1 dissociates from the initial receptor complex and 
associates with the E3 ubiquitin ligase TRAF6 [172, 173]. Upon activation, self-oligomerized 
TRAF6 joins a complex with the Lys63-specific E2 conjugation enzymes Ubc13 and Uev1A 
enabling the attachment of non-degradative Lys63-linked ubiquitin chains to TRAF6 
substrates and TRAF6 itself [174]. In turn, poly-ubiquitinated TRAF6 dictates the recruitment 
of the transforming growth factor β-activated kinase 1 (TAK1) and the TAK1 binding 
proteins 1/2/3 (TAB1/2/3) [175, 176]. The TRAF6-TAB-TAK1 complex formation culminates 
in the phosphorylation and thus activation of TAK1 [175, 177].  
Upon activation, TAK1 acts as kinase which phosphorylates and activates the IκB kinase 
(IKK) and MAPK kinases (MKKs) pathway [175]. MKKs induce downstream kinases like p38, 
c-Jun N-terminal kinase (JNK) and extracellular signal-regulated protein kinases (ERK) which 
finally regulate the activity of transcription factors like the activator protein-1 (AP-1) [175]. 
On the other hand, the activated IKK complex, consisting of the subunits IKKα, IKKβ and IKKγ 
(also known as NEMO), induces the transcriptional activation of transcription factors of the 
nuclear factor 'kappa-light-chain-enhancer' of activated B-cells (NF-κB) family [178, 179]. In 
brief, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor (IκB) 
proteins are phosphorylated by the activated IKK complex which is directly associated with 
the ubiquitination and proteasomal degradation of IκB proteins [180, 181]. Under 
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physiological conditions, NF-κB transcription factors are bound in their inactive form by IκB 
proteins retaining them in the cytoplasm [182]. The induced degradation of IκB proteins 
finally enables the translocation of NF-κB dimers into the nucleus. In mammalians, the NF-κB 
family includes five members: p50, p52, p65 (RelA), RelB and c-Rel, [183]. The most abundant 
NF-κB heterodimer is p65-p50 which is primarily targeted by IκBα [184]. The nuclear 
transcriptional activity of NF-κB can be further influenced by posttranslational modifications 
such as phosphorylation and acetylation. In case of LPS-induced NF-κB activation, it is known 
that IKK-dependent phosphorylation at serine 536 plays a crucial role for the transactivation 
potential of p65 [185]. Due to the complexity of heterodimers and posttranslational 
modifications, the NF-κB transcription factor family is able to induce the expression of a 
broad range of genes in response to the appropriate stimuli. LPS stimulation, for example, 
induces the NF-κB-controlled expression of pro-inflammatory cytokines like Il8/Cxcl1 [160]. 
Upon internalization of TLR4 from the plasma membrane into the early endosomal 
compartment (Figure 1-4), a second adaptor molecule, namely TIR-domain-containing 
adapter-inducing interferon-β (TRIF), is recruited [186, 187]. Similar to Mal, the TRIF-related 
adaptor molecule (TRAM) bridges TLR4 and TRIF. The newly formed receptor complex 
initiates the recruitment of the downstream E3 ubiquitin ligase TNF receptor-associated 
factor 3 (TRAF3) [188]. Ubc13-mediated Lys63-polyubiquitination of TRAF3 orchestrates the 
activation of the downstream IKK-related kinases TRAF-associated NF-κB activator 
(TANK)-binding kinase-1 (TBK1) and IKKε [188, 189]. TBK1 and IKKε then phosphorylate the 
interferon-regulatory transcription factors (IRF) IRF3 and IRF7 leading to their nuclear 
translocation which finally stimulates the transcription of type I interferons (IFN), such as 
IFNB [190-192]. Additionally, TRIF directly engages TRAF6 to activate canonical NF-κB and 
MAPK signaling in a MyD88-independent manner [187, 193] (Figure 1-4). Since 
MyD88-deficient cells revealed a delayed activation kinetic of NF-κB and MAPK signaling, the 
TRIF-dependent activation cascade is called ´late phase activation´ [187]. 
 
1.6.2 NE GA TIV E RE GU LAT IO N  OF TLR4  SI G NAL IN G  
 
TLR signaling is tightly controlled by comprehensive negative regulation to prevent an 
overwhelming of the host´s immune response. For this reason, numerous inhibitory 
mechanisms, ranging from extracellular decoy receptors to intracellular inhibitors, contribute 
to a complex regulatory network in the surveillance of TLR-mediated signal transduction. The 
following chapter introduces a small excerpt of the broad mechanistic repertoire of the cell to 
shut down TLR4-induced signaling on distinct hierarchical levels. 
As an extracellular decoy receptor, the naturally occurring soluble form of the TLR4 enables 
the binding of LPS and thus inhibits NF-κB signaling [194]. In vivo studies in mice 
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demonstrated that the observed effect is even more pronounced in a combinational 
treatment of the recombinant soluble forms of TLR4 and MD2 [195]. Scavenger receptors 
such as macrophage scavenger receptor 1 (MSR1) also co-operate in the recognition of LPS 
and thus suppress TLR4 signaling [196]. 
Further, TLR4 signaling can be shut down by intracellular dominant-negative signaling 
factors. One of these factors is an LPS-inducible splice variant of MyD88 (MyD88s) which 
abrogates the interaction of MyD88 and IRAK4 due to a lacking intermediate domain [197, 
198]. Similarly, expression of the inactive IRAK homologue IRAK-M is initiated upon LPS 
stimulation and avoids the IRAK-TRAF6 complex formation [199].  
Lys63-linked poly-ubiquitination is a critical step within the signaling cascade of either NF-κB 
or IRF activation (see chapter 1.6.1). Therefore, deubiquitinase enzymes (DUBs) play a 
crucial role in the negative regulation of TLR4 signaling. One of the best studied DUBs is the 
TNFα-induced protein 3 (TNFAIP3, hereafter referred as A20) [200]. Among others, the 
deubiquitinase activity of A20 targets IKK activators like TRAF6 and IKKγ [201, 202]. As the 
expression of A20 is directly controlled by NF-κB [203], A20 constitutes a characteristic 
example for an autoregulative pathway. Cylindromatosis (turban tumor syndrome) (CYLD) is 
a second DUB attenuating NF-κB signaling by deubiquitinating a range of signaling mediators 
like TRAF6 and TAK1 [204, 205].  
Another negative feedback loop takes place in the nucleus and is initiated by the NF-κB 
dependent gene expression of its inhibitory binding partner IkBa [206]. After entering the 
nucleus, newly synthesized IκBα abrogates the NF-κB-DNA binding and, due to its 
nuclear-export sequence, exports NF-κB back into the cytoplasm [207]. 
Although the down-regulation of TLR4 signaling is ensured by a wide range of negative 
regulators on distinct levels of the signal transduction cascade, the absence of one of these 
principles often has far-reaching consequences. Deficiency of e.g. A20 or IkBa in mice causes 
lethal inflammation [208, 209]. Similarly, single-nucleotide polymorphisms (SNPs) in human 
genes encoding for anti-inflammatory signaling molecules such as IRAKM and A20 are 










2 AIMS OF THE STUDY  
 
Autophagy is involved in various fundamental processes like survival during nutrient-
deprivation, intracellular quality control of proteins and organelles but also 
immunoregulatory functions such as bacterial defense and cytokine secretion.  
Specifically for the autophagy protein ATG16L1, recent in vivo studies implicated a regulatory 
role in secretory pathways. Deletion of Atg16l1 in the intestinal epithelium resulted in a 
disrupted formation of lysozyme-containing granula in Paneth cells as well as a diminished 
production of antimicrobial peptides which might point to a disturbed secretion in Paneth 
cells [67]. On the other hand, ATG16L1 was suggested as negative regulator of 
inflammasome-mediated IL1β and IL18 secretion [22]. However, little is known about the 
exact molecular mechanisms by which ATG16L1 affects inflammatory responses. 
The aim of the present study was to investigate the role of ATG16L1 in the secretory pathway 
of myeloid cells, particularly of macrophages. Using a conditional mouse model lacking 
Atg16l1 in myeloid cells (Atg16l1LysM), which includes deletion in granulocytes, 
macrophages and dendritic cells, the following major questions were addressed: 
 
I) Does the loss of Atg16l1 affect secretory pathways of myeloid cells under 
baseline conditions? 
 
To verify the role of ATG16L1 in myeloid cells under baseline conditions, the present study 
characterized the basal phenotype of Atg16l1LysM mice, particularly of the immune relevant 
organs. Based on the literature, the IL1 cytokine family and IL1 receptor signaling 
represented the starting point for the investigation. 
 
II) Does ATG16L1 have an impact on secretory pathways of myeloid cells under 
inflammatory conditions? 
 
Bone marrow-derived macrophages from Atg16l1LysM mice were used for in vitro studies. 
The present study investigated a putative role of ATG16L1 in secretory pathways in 
macrophages under inflammatory conditions, notably upon LPS stimulation. The in vivo 








3 MATERIAL AND METHODS  
 
3.1 MATERIAL  
 
All materials used including buffers, media, kits, reagents, devices and consumables are listed 
in the appendix (chapter 8). Antibodies and primers are listed in the appropriate 
methodological chapters. 
 
3.2 METHODS  
 
3.2.1 ANI MA L-HOU SI NG  
 
Mice were housed under specific-pathogen-free (SPF) conditions in individual ventilated 
cages (IVCs) under a 12 h light-dark cycle. Food and water were provided ad libitum and 
environmental conditions were maintained at 21 °C ± 2 °C with 60 % ± 5 % humidity. 
 
3.2.2  GEN ERA TI ON O F AT G16L1  COND ITI ONA L K NO CK -O UT M IC E  
 
The conditional Atg16l1 knock-out mouse line was generated in collaboration with GenOway 
(Lyon, France) using the Cre/lox technology [67]. Briefly, the Cre/lox system is based on a 
recombination mechanism in P1 bacteriophages with two components: (i) a Cre recombinase 
and (ii) loxP sites [212]. LoxP sites are specific 34 bp sequences flanking the gene region in 
which the Cre-mediated recombination takes place. The tissue-specific knock-out is achieved 
by expressing the Cre recombinase under the control of a tissue-specific promoter.  
The generated conditional Atg16l1 knock-out mouse line includes a single distal loxP site 
upstream of the first exon, within the promoter region of the Atg16l1 gene as well as a loxP 
site together with an FRT flanked neomycin selection cassette within intron 1 (Figure 3-1). 
Breeding with deleter-mice constitutively expressing the Flp recombinase removed the 
neomycin selection cassette and consequently generated the conditional Atg16l1 knock-out 
mouse line in which exon 1 of the Atg16l1 gene is flanked by loxP sites (Atg16l1fl/fl). 
Translation of all isoforms of the Atg16l1 gene is disrupted by a Cre-mediated excision of 
exon 1. To obtain a specific Atg16l1 knock-out model in myeloid cells means macrophages 
and granulocytes (Atg16l1LysM), Atg16l1fl/fl mice, backcrossed onto C57BL/6J mice (Jackson 
Laboratory, Bar Harbour, USA), were bred with LysMcre mice (B6.129P2-Lyz2tm1(cre)Ifo/J; 
Jackson Laboratory, Bar Harbour, USA) expressing the Cre recombinase under the control of 





FIGURE 3-1:  TARGETING STRATEGY FOR THE CONDITIONAL ATG16L1  MOUSE LINE  
For the deletion of Atg16l1 a targeting vector containing exon 1 flanked by loxP sites and a neomycin selection 
cassette were inserted into murine blastocysts. Breeding with Flp deleter-mice removed the neomycin cassette 
and created an Atg16l1 floxed mouse line (Atg16l1fl/fl). Mating of Atg16l1fl/fl mice with mice possessing a Cre 
recombinase under the control of the Lyz2 promotor revealed a myeloid-specific knock-out of Atg16l1 
(Atg16l1LysM). 
 
3.2.3  GEN OT YP IN G O F AT G16L1LYSM  M IC E  
 
Isolation of genomic DNA of ear or tail biopsies was performed in 150 µL of 50 mM NaOH 
solution for 1 h at 94 °C. Samples were centrifuged for 1 min at 1,000 x g and the DNA 
containing supernatant was transferred into a fresh tube and stored at – 20 °C. Insertion of 
loxP sites within the Atg16l1 gene as well as the LysMcre (LysM) transgene were validated 
using specific primer pairs (Table 1).  
 
TABLE 1:  PRIMER SEQUENCES FOR GENOTYPING OF ATG16L1FL/FL  AND ATG16L1∆MΦ MICE  





floxed: 537 bp 
wild type: 444 bp 
LysM + (for) 




LysM - (for) 





For amplification by means of a polymerase-chain reaction (PCR), 0.5 µL of the isolated DNA 
was added to the following standard PCR mixture: 
 
- 13 µL nuclease-free water (Qiagen, Hilden, Germany) 
- 4 µL 5X Green GoTaq® Reaction Buffer (Promega, Mannheim, Germany) 
- 0.5 µL deoxynucleotide triphosphates (dNTPs) (Thermo Scientific, Darmstadt, 
Germany) 
- 0.5 µL primer pair (10 µM each) 
Atg16l1
Exon 1 Exon 2 Exon 3 Exon 4
Neo
loxPloxP
Exon 1: endogenous locus
Exon 1: recombined locus





- 0.5 µL DreamTaq DNA polymerase (Thermo Scientific, Darmstadt, Germany) 
 
Following an optimal annealing temperature and different amplicon sizes per primer pair, 
different PCR programs were used for genotype assessment using the GeneAmp PCR System 
9700 (Applied Biosystems, Darmstadt, Germany) (Table 2).  
 
TABLE 2:  PCR  PROGRAMS FOR GENOTYP ING OF ATG16L1FL/FL  AND ATG16L1∆MΦ MICE  
Step Temperature  Duration Cycles 




- LysM +/- 
Elongation 
- Atg16l1 


















Extension 72 °C 8 min 1 
 
For visualization, the DNA amplicons were loaded onto a 1 % (w/v) agarose gel in 100 mL 
0.5 x Tris-acetate (TAE) buffer supplemented with 10 x SYBR® Safe DNA gel stain (Life 
Technologies, Darmstadt, Germany). Gel electrophoresis was carried out at 100 V for 30 to 
60 min. Using the ChemiDoc XRS system (Bio-Rad, Munich, Germany) and the associated 
QuantityOne® 1-D Analysis Software (Version 4.6.8, Bio-Rad, Munich Germany) the amplified 
DNA was visualized with UV-light and documented (Figure 3-2). 
 
FIGURE 3-2:  AGAROSE GEL ELECTROPH ORESIS OF GENOTYPING PCRS FOR ATG16L1FL/FL AND ATG16L1LYSM  
Genomic DNA was isolated from mouse tissue and specific sequences were amplified by PCR. Based on the 
amplicon size, loxP sites (A), the LysMcre transgene (LysM -/- = wild type, LysM +/+ = LysMcre) were identified. 

























3.2.4 ANI MA L E XP ERI M ENT S  
 
All animal experiments were approved by the Animal Investigation Committee of the 
University Hospital Schleswig-Holstein (Campus Kiel, Germany) (acceptance no.: V 242-
7224.121-33 (125-9/13)). Gender-matched mice between 8 and 14 weeks of age were used. 
Mice were sacrificed by cervical dislocation or, in case of cardiac puncture for collection of 
serum, mice were intraperitoneally injected with a narcotic mixture of 100 mg/kg body 
weight ketamine and 16 mg/kg body weight xylazine. For RNA and protein extraction, tissues 
were snap-frozen in liquid nitrogen and stored at - 80 °C. For immunohistochemistry, tissues 
were fixed in 10 % formalin at 4 °C for at least 24 h. 
3.2.4.1 ANAK INRA  T HER AP Y  
For a duration of 14 days, gender-matched Atg16l1fl/fl and Atg16l1LysM mice (n=8 per 
genotype) at the age of 9-13 weeks received a daily intraperitoneal injection of 200 µg 
Anakinra (Kineret®, Swedish Orphan Biovitrum AB, Stockholm, Sweden), a recombinant 
human interleukin-1 receptor antagonist (IL1Ra), which was shown to interact with the 
murine interleukin-1 receptor [214]. Control mice (n=4-5 per genotype) received a daily 
injection of 200 µL 0.9 % (w/v) NaCl (Fresenius Kabi Deutschland GmbH, Bad Homburg, 
Germany). Body weight was monitored every second day. After 14 d mice were sacrificed. 
Organs and cells were collected and subsequently analyzed or stored at – 80 °C. 
3.2.4.2 SUBL ET HA L END OTO X I N- IN DUC ED S EP S I S  
Ultrapure lipopolysaccharide (LPS) from Escherichia coli (KPM53) was a generous gift by Dr. 
Nicolas Gisch (Research Center Borstel, Borstel, Germany). Endotoxin-induced sepsis in 
gender-matched Atg16l1fl/fl and Atg16l1LysM mice at the age of 9-14 weeks was achieved by 
an intraperitoneal injection of 5 mg/kg body weight ultrapure LPS for the indicated duration 
of 1, 3, 6, 24 or 72 h (n=5-7 per genotype). Control mice (n=5-7 per genotype) received an 
intraperitoneal injection of 5 µL/g body weight PBS (Gibco, Darmstadt, Germany). Loss of 
body weight was monitored every 8 h as an index of disease progression. Animals were 
excluded from the experiment as soon as the weight loss exceeded 20 % of the initial body 
weight or if animals showed a severely impaired general state of health, e.g. apathy and 
horrent coat. Mice were sacrificed after the indicated time point. Serum and organs were 
collected for further analyses and stored at – 80 °C. 
3.2.4.3 ANTIB IO TI C TRE AT ME N T  
Within the age of 8-11 weeks, gender-matched Atg16l1fl/fl and Atg16l1LysM mice (n=5 per 
genotype) were treated for 4 weeks with an antibiotic cocktail of 1 g/L ampicillin (Sigma 
Aldrich, Munich, Germany), 0.5 g/L vancomycin (Hikma Pharma GmbH, Gräfelfing, Germany), 
1 g/L neomycin (Sigma Aldrich, Munich, Germany) and 1 g/L metronidazole (Sigma Aldrich, 
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Munich, Germany) diluted in sterile filtered drinking water [215]. Neomycin was removed 
from the antibiotic cocktail at day 7. Antibiotic water was refreshed every 4-5 days due to the 
half-life of the diluted antibiotics. Control animals (n = 3 per genotype) obtained untreated 
drinking water. Body weight was recorded daily. Feces were collected on day 0, 1, 3, 5, 7, 14, 
21 and 28 to analyze the composition and decrease of microbiota (see chapter 3.2.5). 
Collected feces were stored at – 80 °C. After 4 weeks mice were sacrificed. Serum and organs 
were collected and stored at – 80 °C for further analysis. 
3.2.4.4 PREV ENT IV E ANT IBI OT I C  TREA TM EN T  
Atg16l1fl/fl and Atg16l1LysM breeding pairs and offsprings were treated with a broad-
spectrum antibiotic cocktail consisting of 1 g/L ampicillin (Sigma Aldrich, Munich, Germany), 
0.5 g/L vancomycin (Hikma Pharma GmbH, Gräfelfing, Germany), 200 mg/L Ciprofloxacin 
(Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany) and 1 g/L metronidazole 
(Sigma Aldrich, Munich, Germany) supplemented with 2 % (w/v) sucrose (Roth, Karlsruhe, 
Germany) [216]. The control groups received solely 2 % (w/v) sucrose in the drinking water. 
Drinking water was refreshed every third day. Antibiotic treatment persisted until weaning 
of the offsprings. Offsprings were sacrificed at the age of 3-4 weeks. Serum, organs and feces 
were collected and stored at – 80 °C for further analysis. 
 
3.2.5 BACT ERIA L DNA  E XTRA CTI ON FR O M M OU S E F EC ES  
 
Bacterial DNA extraction from mouse feces was performed applying a modified protocol of 
the PowerSoil® DNA Isolation Kit (MoBio, Carlsbad, USA). Feces were pulverized with a 
mortar, transferred into PowerBead Tubes and incubated in 60 µL Solution C1 and 20 µL 
Proteinase K for 2 h at 50 °C in a heating block rotating at 400 U/min. Further extraction 
steps were performed according to manufacturer´s instruction. Extracted DNA was quantified 
using the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, Darmstadt, Germany). 
 
3.2.6 16SRDNA  S EQU ENC IN G  FOR BA CT E RIA L ID EN TI FI CAT ION  
 
Sequencing, preparation and amplification of the bacterial DNA was performed in our 
in-house sequencing platform. After isolation of the bacterial DNA, the variable regions V3 
and V4 of the 16S rRNA gene were amplified using dual indexed primers. The forward primer 
consisted of a 5´ illumina adaptor (5´-AATGATACGGCGACCACCGAGATCTACAC-3´), an index 
(5´-XXXXXXXX-3´), a forward primer pad (5´-TATGGTAATT-3´), a linker (5´-GT-3´) and a 16S 
rRNA specific primer (5´- GTGCCAGCMGCCGCGGTAA-3´). The reverse primer included the 
reverse complement of the 3´ illumina adaptor (5´-CAAGCAGAAGACGGCATACGAGAT-3´), an 
index (5´-XXXXXXXXXXXX-3´), a reverse primer pad (5´-AGTCAGTCAG-3´), a linker (5-´CC-3´) 
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and the 16S rRNA specific reverse primer (5´-GGACTACHVGGGTWTCTAAT-3´). Amplification 
was performed in duplicates with the Phusion HotStart Flex 2 Master Mix (New England 
Biolabs GmbH, Frankfurt a.M., Germany) using the cycling conditions listed in Table 3 in a 
GeneAmp PCR System 9700 (Applied Biosystems, Darmstadt, Germany).  
 
TABLE 3:  PCR  PROGRAM FOR THE AMPLIFICATION OF THE VARIABLE REGIONS V3 AND V4 OF THE 16S  RRNA  GENE  
Step Temperature  Duration Cycles 












Extension 72 °C 10 min 1 
 
PCR products were run on a 2 % agarose gel to assess the amplicon size and amplification 
performance. Quantities of the amplicons were normalized with the SequalPrep™ 
Normalization Plate Kit (Invitrogen, Darmstadt, Germany). Purification of the specific 
amplicon bands was performed using the QIAquick Gel Extraction Kit (Qiagen, Hilden, 
Germany) and concentration of the purified PCR products was measured with the Quant-iT™ 
PicoGreen® dsDNA Assay Kit (Invitrogen). Equal amount of the PCR products was mixed in a 
single tube and sequenced using the MiSeq sequencer (Illumina, San Diego, USA) and the 
MiSeq Reagent Kit v3 (Illumina, San Diego, USA) for 2 x 300 bp, which allowed the generation 
of paired end reads with overlapping regions. 
 
3.2.7 SE QUE NC E ANA L Y SI S  FOR  TA XON O MI C C LA S SI FI CA T ION  O F I DENT I FI ED  
BACT ERIA  
 
Sequence analysis was kindly performed by Dr. Ateequr Rehman. In brief, sequenced reads 
were primarily processed for quality control using the software MOTHUR 
(http://www.mothur.org/wiki/Download_mothur, version 1.32.1). Forward and reverse 
reads were assembled to form contigs. In the present study, sequences with more than 450 
bases in length as well as sequences having any ambiguous base or more than six 
homopolymers were excluded from the downstream analysis. Sequences passing these 
quality control parameters were subjected to the alignment against the 16S rRNA gene of the 
Silva reference data base [217] obtained from the MOTHUR website. Sequences, which were 
not aligned to the target region of the 16S rRNA gene, were discarded from the analysis. 
Furthermore, chimeric sequences were detected with the Uchime algorithm as implemented 
in MOTHUR and were removed from the analysis. Classification of the sequences was 
achieved using MOTHUR curated green genes training sets taxonomy database (release 
August 2013, containing 202,421 bacterial and archaeal sequences). Sequence classification 
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was performed in MOTHUR with the following parameters: method = Wang, k-mer size = 8, 
iteration = 100 and cutoff = 60. Sequences deemed to be originated from eukaryotes, 
chloroplasts or mitochondria were excluded from subsequent phylotype based analysis. Good 
quality classified bacterial sequences were binned in genus level phylotypes (label = 1). In 
order to display shared and unique phylotypes in samples and groups, MOTHUR based 
make.shared command was implemented to generate a count table. This table contained the 
number of sequences of each phylotype in a given sample. Diversity of the microbial 
populations was assessed using the non-parametric Shannon´s index. 
 
3.2.8 IS OL ATI ON A ND CU LTIV ATI ON O F C EL L S  
3.2.8.1 IS OL ATI ON  O F LA M INA  PROPRIA AN D INT E ST INA L EP IT HE L I AL FR AC TIO N S  
FRO M T HE S MA LL INT E S TIN E  
Lamina propria cells and intestinal epithelial cells were isolated using the Lamina Propria 
Dissociation Kit for mouse (Miltenyi BioTech, Bergisch Gladbach, Germany). Preparation of 
the small intestine and isolation of the two distinct cell fractions was performed according to 
the manufacturer´s protocol. In brief, intestinal epithelial cells were isolated by disruption of 
the structural integrity of the epithelium using ethylenediaminetetraacetic acid (EDTA) and 
dithiothreitol (DTT). Beside mechanical disruption the remaining lamina propria tissue was 
further enzymatically dissociated into a single cell suspension using collagenase. 
3.2.8.2 MAGN ET IC-ACT IV AT ED CE LL S ORTI N G (MACS)  FOR I SO LAT IO N O F CD11B +  
CE LL S D ERIV ED FRO M T HE LA M IN A PRO PRIA   
The positive selection of CD11b+ from the lamina propria fraction of the small intestine was 
performed using CD11b MicroBeads (human and mouse) from Miltenyi BioTec (Bergisch 
Gladbach, Germany). Briefly, the principle of this method relies on a specific separation of 
CD11b+ cells by magnetic beads labelled with antibodies against CD11b. By loading the cell 
suspension in a magnetic field, the magnetically labeled CD11b+ cells were retained in the 
magnetic column and can be separately eluted. In this study, a total number of 0.4-1 x 106 
cells were used for the isolation of CD11b+ cells using a 30 µm pre-separation filter followed 
by a magnetic MS column. To increase the purity of isolated CD11b+ cells the labeled fraction 
was again passed over a second magnetic MS column. Purity of isolated CD11b+ cells was 







3.2.8.3 IS OL ATI ON AND D IF F ERE N TI ATI ON O F  BON E MAR R OW-D ERIV ED 
MACR OP HA GE S  
All ex vivo experiments were performed with littermates at the age of 7-26 weeks. Mice were 
sacrificed by cervical dislocation. Femur and tibia were removed and temporarily stored in 
ice-cold DMEM medium (Invitrogen, Darmstadt, Germany). Bones were opened under sterile 
conditions. Bone marrow was flushed out with ice-cold BMDM medium (see chapter 8.1) 
using a syringe and a 26G needle. After disaggregation of the cells by gently pipetting several 
times within a 50 mL tube, cells were additionally passed through a 70 µm cell strainer. 
Finally, bone marrow cells were placed in a 15 cm petri dish in a total volume of 30 mL 
BMDM medium supplemented with 20 ng/mL macrophage colony-stimulating factor (mCSF) 
and cultured at 37 °C with 5 % (w/v) CO2 and 100 % (w/v) humidity for seven days. 
Additional 15 mL BMDM medium supplemented with 20 ng/mL mCSF were added on day 
four. As differentiated bone marrow-derived macrophages (BMDMs) attach to the petri dish 
undifferentiated cells were gently removed with warm PBS (Gibco, Darmstadt, Germany) and 
further cultivated in a 10 mL petri dish in BMDM medium. On day seven, differentiated 
BMDMs were scraped off with ice-cold PBS and transferred into a 50 mL tube. After 
centrifugation at 300 x g for 10 min at 4 °C, the supernatant was discarded and cells were 
resuspended in 5 mL BMDM medium. Cells were counted using an automatic cell counter 
(Cellometer Auto T4 Plus, PeqLab, Erlangen, Germany) and plated on either 6-well plates 
(1 x 106 cells/well), 12-well plates (0.5 x 106 cells/well), 96-well flat-bottom plates 
(2.5-4 x 104 cells/well) or 10 mL petri dishes (3-5 x 106 cells/well). 
3.2.8.4 MACS  FOR IS O LAT ION OF H E M AT OP OI ET IC ST E M C EL L S FR O M S PL E EN  
Spleens of Atg16l1fl/fl and Atg16l1LysM mice (n=5) were collected and temporarily stored in 
DMEM medium (Invitrogen, Darmstadt, Germany) on ice. To obtain cell suspensions each 
spleen was carefully grinded through a 40 µm cell strainer and splenocytes were counted as 
described in chapter 3.2.8.3. Differentiated splenocytes were removed using the Lineage Cell 
Depletion kit for mouse (Miltenyi BioTec, Bergisch Gladbach, Germany). Lineage negative 
(lin-) cells were stained for specific stem cell markers and analyzed by flow cytometry (see 
3.2.19). 
 
3.2.9 PROT E IN E XTR ACT ION AN D PRO TE IN A S SA Y  
 
0.5-1 x 106 BMDMs were washed once with PBS (Gibco, Darmstadt, Germany) and lyzed with 
30-40 µL 1 x denaturing lysis buffer (DLB) freshly supplemented with protease and 
phosphatase inhibitor (Thermo Scientific, Darmstadt, Germany). Cell lysis was performed by 
heating the samples at 95 °C for 5 min followed by sonication for 5 sec. Lysates were 
centrifuged at 16,000 x g for 10 min at 4 °C and the protein containing supernatant was 
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transferred into a new 1.5 mL tube. Protein concentrations were determined using DCTM 
Protein Assay (Bio-Rad, Munich, Germany) according to the manufacturer´s protocol. Briefly, 
the colorimetric assay is based on the Lowry method [218]. Hereby, proteins first react with 
copper in an alkaline medium following an immediate reduction by Folin reagent by the 
copper-treated-proteins. Absorbance was measured at 750 nm using the microplate reader 
Infinite M200 Pro (Tecan, Männedorf, Switzerland) and the associated software i-controlTM 
1.9 (Tecan, Männedorf, Switzerland). Protein lysates were stored at -80 °C.  
 
3.2.10 SOD IUM DOD EC YL SU L F AT E P O LYA CRY LA M IDE GE L E L EC TROP HOR E SI S   
 
For protein analysis, 10 - 15 µg of total protein was used. Lysates were supplemented with 
5 X SDS loading dye and heated at 95 °C for 5 min. Proteins were separated using a 3 % 
stacking gel and a 10 %, 12 % or 15 % separation gel (Table 4). Electrophoresis was 
performed in 1 x Tris/Glycine/SDS (TGS) buffer and carried out at 15 mA for 30 min and at 
30 mA for additional 60 min.  
 

















Distilled water 4.15 mL 3.5 mL 2.5 mL Distilled water 1.95 mL 
Separation 
buffer 












TEMED 10 µL TEMED 3 µL 
10 % (w/v) 
APS 
100 µL 





3.2.11 WE ST ERN B LO T AND PR OT E IN D ET ECT I ON  
 
For further analysis, separated proteins were transferred onto a polyvinylidene difluoride 
(PVDF) membrane using a semi-dry immunoblotting technique with a discontinuous buffer 
system of one cathode buffer and two anode buffers at 0.1 A for 45 min. After blocking the 
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membrane for 1 h at room temperature with 5 % (w/v) blotting grade blocker (non-fat dry 
milk) from Bio-Rad (Munich, Germany) or bovine serum albumin (BSA) in 1 X Tris-buffered 
saline (TBS) supplemented with 0.1 % (v/v) Tween 20 (TTBS), membranes were incubated 
with specific primary antibodies over night at 4 °C (Table 5).  
 









A20 rabbit  1:500 
Cell Signaling Technology 
(Leiden, The Netherlands) 
#5630 
ATG16L1 mouse  1:500 
MBL International (Woburn, 
USA) 
M150-3 
CYLD rabbit  1:500 
Cell Signaling Technology 
(Leiden, The Netherlands) 
#8462 
LC3BI/II rabbit  1:1,000 




MSR1 goat  1:1,000 
R&D Systems (Abingdon, United 
Kingdom) 
AF1797 
MyD88 rabbit  1:500 
Cell Signaling Technology 
(Leiden, The Netherlands) 
#4283 
p38 rabbit  1:1,000 
Cell Signaling Technology 
(Leiden, The Netherlands) 
#9212 
p65 rabbit  1:1,000 
Cell Signaling Technology 
(Leiden, The Netherlands) 
#3031 
p62 guinea pig  1:1,000 
Progen Biotechnik (Heidelberg, 
Germany) 
GP62-C 
phospho-ERK1/2 rabbit  1:1,000 
Cell Signaling Technology 
(Leiden, The Netherlands) 
#4370 
phospho-IκBα rabbit  1:500 
Cell Signaling Technology 
(Leiden, The Netherlands) 
#2859 
phospho-p38 rabbit  1:1,000 
Cell Signaling Technology 
(Leiden, The Netherlands) 
#9211 
phosho-p65 rabbit  1:1,000 
Cell Signaling Technology 
(Leiden, The Netherlands) 
#3031 
pro-IL1β goat  1:500 
R&D Systems (Abingdon, United 
Kingdom) 
AF401-NA 
RIP1 rabbit  1:1,000 
Cell Signaling Technology 
(Leiden, The Netherlands) 
#3493  
TLR4 mouse 1:250 




TRAF6 rabbit  1:500 













TRIF rabbit  1:500 
Abcam (Cambridge, United 
Kingdom) 
ab13810 
β-Actin mouse  1:10,000 Sigma (Munich, Germany) A-5441 
 
Membranes were washed with TTBS and probed with appropriate horseradish peroxidase 
(HRP)-conjugated secondary antibodies for 1 h at room temperature (Table 6).  
 











Goat-HRP donkey  1:3,000 
Abcam (Cambridge, United 
Kingdom) 
ab6884 
Guinea pig-HRP rabbit  1:3,000 
Abcam (Cambridge, United 
Kingdom) 
ab 6771 
Mouse-HRP sheep  1:3,000 
GE Healthcare (Hamburg, 
Germany) 
 NA931V 
Rabbit-HRP sheep  1:3,000 




Following additional washing steps with TTBS, protein bands were visualized by 
chemiluminescence with ECLTM Western Blotting Detection Reagents (GE Healthcare, 
Hamburg, Germany) or Pierce ECLTM Plus Western Blotting Substrate (Thermo Scientific, 
Darmstadt, Germany) and X-Ray films (GE Healthcare, Hamburg, Germany). Films were 
developed using the automatic developer machine Curix 60 (Agfa, Mortsel, Belgium). 
Stripping was performed in 50 mL stripping buffer supplemented with 0.6 % (v/v) 
β-mercaptoethanol for 20-30 min at 55 °C. Alternatively, HRP inactivation was achieved by 
incubation with 15 % H2O2 for 1 h at room temperature. 
 
3.2.12 TOTA L RNA  I S OL AT ION  
 
RNA extracts of tissues and BMDMs were prepared using the RNeasy kit (Qiagen, Hilden, 
Germany) following manufacturer´s instructions. Liquid nitrogen frozen tissues were first 
pulverized with a mortar and approximately 50 mg of the particular tissues were lyzed in 
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350 µL RLT buffer. Alternatively, BMDMs were washed once with warm PBS (Gibco, 
Darmstadt, Germany) and directly lyzed in RLT buffer (Qiagen, Hilden, Germany). 
Homogenization of lysates was performed using the QIAshredder system (Qiagen, Hilden, 
Germany). RNA concentrations were measured using the NanoDrop spectrometer ND1000 
(PeqLab, Erlangen, Germany).  
 
3.2.13 REV ER S E TRAN SC R IP TI ON (RT)-PCR 
 
For further analysis, 200 – 1000 ng total RNA was transcribed into complementary DNA 
(cDNA) by reverse transcription. Therefore, the Maxima H Minus First Strand cDNA Synthesis 
kit (Thermo Scientific, Darmstadt, Germany) was used according to the manufacturer´s 
protocol. 
 
3.2.14 SE MI-QUA NT ITAT IV E E ND-P OIN T PCR 
 
Amplification of the targeted cDNA was performed by semi-quantitative endpoint PCR. A 
standard PCR reaction was set up in a final volume of 20 μl. Table 7contains the pipetting 
scheme for the reaction. 
 
TABLE 7:  PIPETTING SCHEME FOR STANDARD PCR  REACTION  
 µL 
PCR H2O 12.5 
5 x GoTaq Puffer 4.0 
dNTPs (10 µM each) 0.5 
GoTaq Polymerase 0.5 
Primer-Mix (10 µM each) 0.5 
cDNA 2.0 
 
Exon-exon spanning primer pairs were designed to prevent amplification of genomic DNA. 
The following primer pairs were used for semi-quantitative end-point PCR (Table 8). 
 
TABLE 8:  LIST OF PRIMERS USED FOR THE SEMI-QUANTITATIVE END-POINT PCR 
Gene Primer sequence forward (5´→ 3´) Primer sequence reverse (5´→ 3´) 
Gapdh CCGGGGCTGGCATTGCTCTCA CTTGCTCAGTGTCCTTGCTGGGG 
iNOS GTCAACTGCAAGAGAACGGA GCCCCAGTTTTTGATCCTCA 
 
The used standard PCR program is shown in Table 9. In case of iNOS amplification a 









3.2.15 QUANTI TAT IV E R EA L-T I ME PCR  (QPCR) 
 
Amplification and simultaneous quantification of the targeted cDNA was achieved by 
quantitative real-time PCR (qPCR). Specific exon-exon spanning primers were designed based 
on transcript models of the NCBI database (http://www.ncbi.nlm.nih.gov/nuccore/, July 
2014) with a length of 20-25 bases, an optimal annealing temperature of 60 °C and an 
amplicon size of 200-400 bp (Table 11). Primers were synthesized by Microsynth (Lindau, 
Germany). 
 
TABLE 11:  LIST OF PRIMERS USED FOR THE QUANTITATIVE REAL-TIME PCR 
Gene Primer sequence forward (5´→ 3´) Primer sequence reverse (5´→ 3´) 
A20 CGATACACGCTGGAGATGTT CTGATGCCATTTTGACCAAG 
Asc AACTGCGAGAAGGCTATGGG TGGTCCACAAAGTGTCCTGT 
Cd11b GTTTCTACTGTCCCCCAGCA TTTTTGTCCTCCCATTCAGC 
Cd11c GTCTCCAAGTTGCTCAGAGCCTGCT TGGTGGCATCTTGCCGAGCTC 
Cd19 ACCAGTTGGCAGGATGATGG CCCATGCTGGTTCTAGGTCG 
Cd3e AAGTAATGAGCTGGCTGCGT  TCGTCACTGTCTAGAGGGCA  
Cd4 CGTGCTGGGTGGCTCCTTCG AGAGCAGAAGGCCGGAGGCA 
Cxcl1 GCTGGGATTCACCTCAAGAA TGGGGACACCTT TTAGCA TC 
Gapdh CCGGGGCTGGCATTGCTCTCA CTTGCTCAGTGTCCTTGCTGGGG 
Ifng ACTGGCAAAAGGATGGTGACA TCATTGAATGCTTGGCGCTG 
Il10 TGCTATGCTGCCTGCTCTTA TTTTCACAGGGGAGAAATCG 
Il1a CGCTTGAGTCGGCAAAGAAAT AAGGTGCTGATCTGGGTTGG 
Il1b GGCTGTCCTGATGAGAGCAT TGTTCATCTCGGAGCCTGTA 
Il2 GGAACCTGAAACTCCCCAGG TGTGTTGTCAGAGCCCTTTAGT 
Il4 TCACTGACGGCACAGAGCTA CTGTGGTGTTCTTCGTTGCTG 
Il6 GAC AAC TTT GGC ATT GTG G ATG CAG GGA TGA TGT TCT G 
Nlrp3 AGCCAGAGTGGAATGACACG CGTGTAGCGACTGTTGAGGT 
pro-Casp1 AGAAACGCCATGGCTGACAA TCCTGCCAGGTAGCAGTCTT 
Cycles Time Temp [°C] 
1 4 min 95 
30 
30 sec 95 
30 sec 54 
45 sec 72 
1 5 min 72 
Cycles Time Temp [°C] 
1 4 min 95 
10 
30 sec 95 
30 sec 65-55 (reduce 1 °C each cycle) 
30 sec 72 
35 
30 sec 95 
30 sec 55 
30 sec 72 
1 5 min 72 
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Gene Primer sequence forward (5´→ 3´) Primer sequence reverse (5´→ 3´) 
S100a8 GTCCTCAGTTTGTGCAGAATATAAA GCCAGAAGCTCTGCTACTCC 
S100a9 CTGTGACTCTTTAGCCTTGAGCA GTTGCCAACTGTGCTTCCAC 
Tnfa TCACACTCAGATCATCTTCTC  AGACTCCTCCCAGGTATATG  
 
All qPCR experiments were carried out on the 7900HT Fast Real Time PCR System (Applied 
Biosystems, Darmstadt, Germany). Samples were run in duplicates on 384-well plates. The 
PCR mixture contained 5-10 ng cDNA and 0.5 µL of specific primer pairs (5 µM each) or 
0.5 µL of the specific TaqMan® gene expression assay (Table 12). Standardized PCR program 
was performed according to the SYBR® Select Master Mix protocol (Applied Biosystems, 
Darmstadt, Germany) or TaqMan Gene Expression Master Mix protocol (Applied Biosystems, 
Darmstadt, Germany). Cycle threshold (Ct) values of the target genes were normalized to the 
respective gene expression of Gapdh or b-Actin. 
 
TABLE 12:  LIST OF TAQMAN ASSAYS USED FOR QUANTITATIVE REAL-TIME PCR 
Gene Company TaqMan Assay ID 
Actb Life Technologies (Darmstadt, Germany) 00607939 
Atg16l1 Life Technologies (Darmstadt, Germany) 00513085 
Gapdh Life Technologies (Darmstadt, Germany) 99999915 
Ifnb Life Technologies (Darmstadt, Germany) 439552 
Ifng Life Technologies (Darmstadt, Germany) 1168134 
Il1b Life Technologies (Darmstadt, Germany) 01336189 
Il18 Life Technologies (Darmstadt, Germany) 00434225 
Mpo Life Technologies (Darmstadt, Germany) 01298424 
 
For quantification of bacteria in murine tissues, detection and amplification of eukaryotic 
bacterial DNA was performed by a designed TaqMan Assay listed in Table 13 . 
 
TABLE 13:  DESIGNED TAQMAN ASSAY USED FOR EUKARYOTIC BACTE RIAL DNA  QUANTIFICATION BY QUANTITATIVE 
REAL-TIME PCR 
Probe sequence 
Primer sequence for  
(5´→ 3´) 
Primer sequence rev  
(5´→ 3´) 









3.2.16 IM MUN OF LU ORE SC EN CE  
 
BMDMs were seeded on cover slips overnight. Following a washing step with PBS, cells were 
fixed in 4 % (w/v) paraformaldehyde for 30 min at room temperature. Cell were washed 
three times with PBS and permeabilized for 3 min at room temperature using 1 % (v/v) 
Trititon X-100 in PBS supplemented with 5 % (w/v) BSA. Unspecific binding sites were 
blocked with 5 % (v/v) goat serum for at least 60 min at room temperature. Incubation with 
the primary antibody against p62 (also see Table 5) was performed using a dilution of 1:500 
over night at 4 °C. Following three washing steps with PBS, incubation with the second 
antibody goat anti-guinea pig conjugated with Alexa Fluor-488 (Life Technologies, Darmstadt, 
Germany, #A-11073) for 45 min at room temperature. Cells were washed for three times 
with PBS following a washing step with aqua dest and subsequently embedded in mounting 
medium (Roth, Karlsruhe, Germany). Stainings were analyzed using the confocal laser 
scanning microscope TCS SP5 (Leica, Wetzlar, Germany) and the appropriate software Leica 
Application Suite Advanced Fluorescence (Leica, Wetzlar, Germany). 
 
3.2.17 IM MUN OH I STO CH E MI ST RY  
3.2.17.1 T IS SU E PR OC ES S IN G  
Murine tissues were directly fixed in 10 % (w/v) formalin for at least 24 h at 4 °C. In terms of 
bones a decalcification step was performed in cooperation with the Prof. Wolfram Klapper´s 
laboratory (Department of Pathology, Haematopathology Section and Lymph Node Registry, 
University Hospital Schleswig-Holstein, Campus Kiel, Germany). Dehydration was achieved 
by incubation in ascending ethanol and xylene series. Tissues were embedded in paraffin and 
dissected in 3.5 - 4.5 µm sections using the RM2255 microtome (Leica, Wetzlar, Germany).  
3.2.17.2 HE MAT O XY L IN AND EO S IN  (H&E)  STA IN IN G  
Samples were rehydrated in decreasing xylene and ethanol series following additional 
washing steps with distilled water. Slides were stained for 2 - 5 min in hematoxylin. Nuclei 
were blued-up by incubation for approximately 10 min under running water. Counterstaining 
of the cytoplasm was performed using 1 % (v/v) eosin solution for 2 min. For further 
analysis, slides were again dehydrated and embedded in Roti-Histokitt mounting medium 
(Roth, Karlsruhe, Germany). Slides were analyzed with a transmitted light microscope (Axio 







3.2.17.3  3,3´-D IA MI NOB EN Z IDI NE (DAB)  ST AIN IN G  
Rehydration of the slides and slide analysis was performed as described in chapter 3.2.17.2. 
Antigen retrieval was achieved by boiling slides for up to 20 min in citrate buffer (pH 6.0). 
Blocking of unspecific binding sites and inactivation of naturally occurring peroxidases was 
achieved using 5 % (v/v) goat serum in PBS and 3 % hydrogen peroxide treatment, 
respectively. Incubation times were individually adapted with respect to the primary 
antibody. Antibody incubation and DAB staining was performed according to the 
manufacturer´s protocol of the Vectastain Elite ABC Kit (Vector Labs, Peterborough, United 
Kingdom). In brief, primary antibody signaling was maximized by incubation with a 
biotinylated second antibody. Colorimetric reaction of 3,3´-Diaminobenzidine (DAB) was 
achieved by a second incubation step using a horseradish peroxidase-conjugated streptavidin 
antibody, which allows DAB to get oxidized and gives a dark-brown color. Used antibodies 
and working dilutions are listed in Table 14. 
 
TABLE 14:  LIST OF ANTIBODIES USED FOR IMMUNOHISTOCHEMISTRY 
Antibody  Working dilution Company Article number 





Abcam (Cambridge, United 
Kingdom) 
ab107159 






3.2.17.4  TERM INA L D EO XY NUC LE OT IDY L TRA NS F ERA S E D UTP  NIC K E ND LA BEL IN G  
(TUNEL) 
Slides were rehydrated as described in chapter 3.2.17.2. Apoptotic cells were stained using 
the ApopTag® Plus Peroxidase In Situ Apoptosis Detection Kit (Merck Millipore, Darmstadt, 
Germany) according to the manufacturer´s protocol. In brief, terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) is an enzymatic reaction to detect apoptotic cells 









3.2.18 IM MUN OA S SA YS  
3.2.18.1 ENZ Y M E L INK ED IM MU N OS ORB ENT  A S SA Y (ELISA) 
Detection of cytokine and chemokine levels in serum or cell culture supernatants was 
achieved with enzyme linked immunosorbent assays (ELISA). All ELISA used in this study 
were performed according to the manufacturer´s protocol (Table 15). Absorbance was 
measured using the microplate reader Infinite M200 Pro (Tecan, Männedorf, Switzerland) 
and the associated software i-controlTM 1.9 (Tecan, Männedorf, Switzerland).  
 
TABLE 15:  LIST OF ANTIBODY PAIRS USED FOR ENZYME LINKED IMMUNOSORBENT ASSAYS 
Cytokine Company Article number 
murine CXCL1 R&D Systems (Abingdon, United Kingdom) DY453 
murine IFNβ  PBL Assay Science (New Jersey, USA) #42400 
murine IL18 MBL International (Woburn, USA) CMC3013 
 
3.2.18.2  MULTI PL E X TE CH NO LO GY  
Similar to the ELISA technique the multiplex technology is an antibody-based detection 
method for cytokines, chemokines and other inflammatory mediators. In brief, specific 
capture antibodies are coupled to magnetic beads. Fluorochrome-labeled detection 
antibodies enable the analysis by flow cytometry. In this study, the Bio-Plex Pro™ Mouse 
Cytokine 23-plex Assay (Bio-Rad, Munich, Germany) was used and measurement was 
performed in cooperation with Bioglobe Service (Hamburg, Germany). Median of the 
particular cytokine and chemokine concentration was calculated and values were z-score 
normalized. Results were depicted in heat-maps using the software Spotfire Integromics 
Biomarker Discovery 5.5 (Tibco Software Inc., Palo Alto, USA).  
 
3.2.19 FLOW CY TO M ETRY  ANA LY S I S  
 
For all measurements, 10,000 cells were analyzed with a FACSCaliburTM (BD Biosciences, 
Heidelberg, Germany) and the associated software CellQuestTM Pro (Version 5.2, BD 
Biosciences, Heidelberg, Germany). In all experiments, dead cells and cell debris were 
excluded using by gating in forward scatter vs. sideward scatter dot plots (R1, see also Figure 
4-11). Used fluorochrome-conjugated antibodies and working dilutions as well as isotype 







TABLE 16:  LIST OF USED FLUOROCHROME-LABELED ANTIBODIES FOR FLOW CYTOMETRY ANALYSIS 






CD11b APC Rat IgG2b κ  1:100 
eBioscience 
(Frankfurt a. M., 
Gemany) 
17-0112 
CD11b PE Rat IgG2b  1:100 
eBioscience 





hamster IgG  
 1:8 
eBioscience 
(Frankfurt a. M., 
Gemany) 
17-0114 
CD14 FITC Rat IgG2a κ  1:5 
eBioscience 
(Frankfurt a. M., 
Gemany) 
11-0141 



























c-Kit FITC Rat IgG2b κ  1:10 
eBioscience 
(Frankfurt a. M., 
Gemany) 
11-1171 
Ly6G FITC Rat IgG2b κ  1:100 
eBioscience 
(Frankfurt a. M., 
Gemany) 
11-5931 
MHCII PE Rat IgG2b  1:100 
eBioscience 
(Frankfurt a. M., 
Gemany) 
12-5322 
Sca-1 PE Rat IgG2a κ  1:8 
eBioscience 




TABLE 17:  LIST OF ISOTYPE CONTROLS USED FOR FLOW CYTOMETRY A NALYSIS  













hamster IgG  
PE  1:50 
eBioscience (Frankfurt 
a. M., Gemany) 
12-4888 
























Rat IgG2b PE  1:100 
eBioscience (Frankfurt 
a. M., Gemany) 
12-4031 
Rat IgG2b κ APC  1:100 
eBioscience (Frankfurt 
a. M., Gemany) 
17-4031 
Rat IgG2b κ FITC  1:10 or 1:100 
eBioscience (Frankfurt 
a. M., Gemany) 
11-4031 
 
Used unconjugated primary antibodies and isotype controls as well as fluorochrome-labeled 
secondary antibodies are listed in Table 18 and Table 19, respectively. 
 





































3.2.19.1 FLOW CY TO M ETRY ANA LY S I S O F TI S SU E AND M ACROP H A G ES  
For flow cytometry analysis, 2.5 x 104 cells per well were seeded in a 96-well V-bottom plate, 
washed with FACS washing buffer (FWB) and centrifuged at 300 x g for 5 min at room 
temperature. The supernatant was discarded and in case of monocytes and macrophages an 
unspecific antibody binding was prevented by blocking the Fc-receptor with anti-CD16/32 
for 15 min on ice. Incubation with the fluorochrome-labeled antibodies (Table 16), 
unconjugated primary antibodies (Table 18) and particular isotype control combination 
(Table 17, Table 18) was performed at 4 °C for 1 h. In case of staining with unconjugated 
primary antibodies, following three additional washing steps incubation with 
fluorochrome-labeled secondary antibodies was performed for 30 min at 4 °C. Cells were 
washed two times with 100 µL FWB and afterwards resuspended in 80 µL FWB. 





3.2.19.2  FLOW C YT O ME TRY A NA LY S I S O F BL OOD  
Blood was stored in EDTA tubes at room temperature. A mixture of 7 µL of the indicated 
fluorochrome-labeled antibody combination as well as the particular isotype control was 
prepared in a 96-well V-bottom plate. Avoiding direct light, 15 µL of the collected blood was 
added and incubated for 10 min at room temperature. For lysis of the red blood cells, 200 µL 
1 x BD FACS Lysing Solution (BD Biosciences, Heidelberg, Germany) was added. Following a 
15 min incubation at room temperature, cells were centrifuged at 300 x g for 5 min. The 
washing step was performed in 150 µL FWB and followed by an additional centrifugation at 
300 x g for 5 min. Stained cells were resuspended in 80 µL FWB and directly analyzed by flow 
cytometry. 
3.2.19.3 FITC-DE XTRAN ENDO C YTO S I S  A SS AY  
Endocytosis assay was performed by incubating 2.5 x 104 cells per well seeded in a 12-well 
plate with 1 mg/mL FITC-Dextran (Sigma Aldrich, Munich, Germany) for 60 min by 37 °C. 
Following three washing steps with 1 mL ice-cold PBS (Gibco, Darmstadt, Germany), cells 
were finally resuspended in 100 µL FWB and analyzed by flow cytometry. 
3.2.19.4 REC EPT OR IN TER NAL I Z AT I ON A S SAY  
For internalization assays 2.5 x 104 cells per well were seeded in a 12-well plate and grown 
over night. Cells were stimulated with either 100 ng/mL LPS (E.coli F515) or 1 µg/mL CD95 
Ligand (BD Biosciences, Heidelberg, Germany) for the indicated time points. Receptor 
internalization was stopped by washing with 1 mL ice-cold PBS (Gibco, Darmstadt, Germany). 
Staining of the remaining receptors at the cell surface was performed as described in chapter 
3.2.19.1.  
 
3.2.20 STAT I STI CA L ANA LY S I S  
 
All data were analyzed with a two-tailed unpaired or paired Student´s t-test [219] using the 
software GraphPad Prism 5 (GraphPad Software). Data are shown as mean ± standard 
deviation (S.D.). Statistical significance of the survival analysis was performed by a log-rank 
test. A p-value of < 0.05 was considered as significant (*) whereas a p-value of < 0.01 was 
considered as strongly significant (**), a p-value of < 0.001 as highly significant (***) and a 










4.1 PROOF OF THE TISSUE-SPECIFIC ATG16L1  DELETION IN 
ATG16L1LYSM  MICE  
 
4.1.1 CD11B +  LA MI NA PRO P RIA C EL L S  
 
Deletion of floxed genes in the LysMcre mouse model is described to be exclusively restricted 
to myeloid cells [213]. Tissue-specificity in the Atg16l1LysM mouse model was determined by 
isolation of distinct cell populations of the small intestine utilizing the magnetic-activated cell 
sorting (MACS) technology (Figure 4-1). CD11b+ immune cells derived from the lamina 
propria served as a positive control for the specific Atg16l1 deletion in myeloid cells. Non-
CD11b cells derived from the lamina propria as well as intestinal epithelial cells (IECs) were 
used as negative controls representing two distinct non-myeloid cell populations.  
 
FIGURE 4-1:  TISSUE-SPECIFIC KNOCK-OUT OF ATG16L1  IN CD11B+  MYELOID CELLS  
Small intestine of Atg16l1fl/fl and Atg16l1LysM mice was dissociated in lamina propria cells and intestinal epithelial 
cells (IECs) using the Lamina Propria Dissociation Kit for mouse. Additionally, CD11b+ and CD11b- cell populations 
were isolated from the lamina propria fraction by magnetic-activated cell sorting (MACS). Protein levels of 
ATG16L1 were verified by immunoblot. Levels of β-Actin served as loading control. 
  
Atg16l1fl/fl mice showed a uniform protein expression of ATG16L1 in all three cell types. As 
expected, the same was observed for CD11b- and IEC populations of Atg16l1LysM mice. In 
contrast, ATG16L1 was completely absent in CD11b+ myeloid cells of Atg16l1LysM mice 
demonstrating a specific deletion of Atg16l1. 
 
4.1.2 BONE MARR OW-DER IV E D MACR OP HA GE S (BMDMS) 
 
Bone marrow-derived macrophages (BMDMs) were used as ex vivo model. Due to the fact 
that bone marrow is the major source of hematopoietic stem cells and therefore harbors all 
three classes of blood cells (leukocytes, erythrocytes and platelets), efficiency of 
mCSF-mediated BMDM differentiation was verified on day seven by flow cytometry (Figure 
4-2). In this study, differentiated BMDMs were defined by cell surface expression of CD11b. 










indicated by the sideward scatter (SSC) (Figure 4-2). Cell debris and dead cells were excluded 
from the analysis by gating (Figure 4-2, left panel, black frame). Independent of the genetic 
background mCSF-mediated differentiation of bone marrow cells revealed more than 95 % 
macrophages specified as CD11b+ cells (Figure 4-2, right panel) demonstrating an efficient 
and specific differentiation. 
 
 
FIGURE 4-2:  CD11B EXPRESSION ON EX VIVO  DIFFERENTIATED BMDMS OF ATG16L1FL/FL AND ATG16L1LYSM MICE  
Bone marrow cells of Atg16l1fl/fl and Atg16l1LysM mice were isolated under sterile conditions and differentiated 
for at least seven days in presence of 20 ng/mL mCSF into macrophages. Purity of the differentiated BMDMs was 
verified measuring the macrophage-specific cell surface expression of CD11b by flow cytometry. FSC: forward 
scatter; SSC: sideward scatter 
 
To verify the efficiency of the conditional knock-out in BMDMs of Atg16l1LysM mice 
expression of Atg16l1 on RNA (Figure 4-3 A) and protein level (Figure 4-3 B) was evaluated 
compared to the expression in BMDMs of Atg16l1fl/fl littermates. Atg16l1LysM BMDMs showed 
a significantly reduced expression of Atg16l1 on mRNA level. Similarly, an exceedingly 
decreased protein level of ATG16L1 was observed in Atg16l1LysM BMDMs. 
 
FIGURE 4-3:  SUCCESSFUL KNOCK-OUT OF ATG16L1  IN ATG16L1LYSM BMDMS  
RNA and proteins were extracted from untreated BMDMs of Atg16l1fl/fl and Atg16l1LysM mice (n=4). RNA was 
transcribed into cDNA and expression of Atg16l1 was determined using a TaqMan Assay for all murine isoforms of 
Atg16l1 (A). TaqMan data represent mean ± S.D. and statistical significance was evaluated by an unpaired 
Student´s t-test. **** p < 0.0001 Protein levels of ATG16L1 were analyzed by immunoblot with β-Actin serving as 











































4.2 LOSS OF ATG16L1  LEADS TO IMPAIRED AUTOPHAGY IN BONE 
MARROW-DERIVED MACROPHAGES  
 
ATG16L1 is described to promote the elongation of the autophagosomal isolation membrane 
and is an essential component within autophagosome formation in yeast and mammalian 
cells [12, 51]. For this reason, the autophagic flux was biochemically studied in Atg16l1-
deficient macrophages by determining the conversion of LC3BI to its 
phosphatidylethanolamine-conjugated form LC3BII (Figure 4-4) which is an established 
marker for autophagosome formation [220]. Besides investigating basal autophagy in 
untreated cells, autophagy was induced by nutrient starvation with Hank´s Balanced Salt 
Solution and chemically by stimulation with the mTOR inhibitor rapamycin. 
 
 
FIGURE 4-4:  IMPAIRED AUTOPHAGY 
IN ATG16L1LYSM  BMDMS  
Atg16l1fl/fl and Atg16l1LysM BMDMs 
were nutrient-starved with HBSS for 
3 h, stimulated with rapamycin (50 
µg/mL) for 20 min or were left 
unstimulated. Protein lysates were 
probed by immunoblot for levels of 
the indicated proteins. β-Actin served 
as a loading control. Immunoblot 
represents results of three 
independent experiments. HBSS: 
Hank´s Balanced Salt Solution, 
unstim: unstimulated 
 
Untreated Atg16l1fl/fl BMDMs showed both forms of LC3B indicating an intact basal 
autophagic activity. Induction of autophagy by both, starvation and rapamycin treatment, led 
to a subsequent decrease in LC3BI and a simultaneously increase in LCBII. However, in 
Atg16l1LysM BMDMs an accumulation of LC3BI was detected under all three conditions, 
whereas the lipidation of LC3BII did not occur. Further, lysosomal degradation of the 
autophagosomal content was monitored by degradation of the selective autophagy receptor 
sequestosome 1 (Sqstm1, also known as p62) (Figure 4-4). Starvation-induced as well as 
rapamycin-induced autophagy decreased the protein levels of p62 in Atg16l1fl/fl BMDMs. In 
contrast, already in unstimulated Atg16l1LysM macrophages p62 was remarkably 
accumulated compared to Atg16l1fl/fl BMDMs, while induction of autophagy even increased 




















4.3 CHARACTERIZATION OF T HE ATG16L1LYSM  MOUSE MODEL  
 
4.3.1 ATG16L1LY SM  MI CE D EV E LO P A M ULT I FAC ET E D SP ONTA NE OU S PH EN O TYP E  
 
After confirmation of the successful tissue-specific knock-out of Atg16l1, the basal phenotype 
of the Atg16l1LysM mouse model was studied.  
Atg16l1LysM mice were born viable and at the expected Mendelian 1:2:1 ratio (Table 1).  
 
TABLE 20:  NUMBER OF MICE OF VARIOUS GENOTYPES OBTAINED BY THE ATG16L1FL/LYSM  INTERCROSS  
 Atg16l1fl/fl Atg16l1fl/LysM Atg16l1LysM 
Observed number of mice 93 181 99 
Expected number of mice (ratio 1:2:1) 93.25 186.5 93.25 
 
Analysis of the body weight did not reveal differences between Atg16l1LysM and Atg16l1fl/fl 
littermates (Figure 4-5 A).  
 
FIGURE 4-5:  BASAL PHENOTYPE OF HE MATOPOIETIC ORGANS OF THE ATG16L1LYSM MOUSE MODEL 
Body weight (A, n=22), spleen weight (B, n=24-26), lymph node size (C), liver weight (D, n=7-8) and bones (E) of 
Atg16l1LysM mice at the age of 7-26 weeks were compared to Atg16l1fl/fl littermates. Data are shown as 
mean ± S.D. and statistical significance was evaluated with an unpaired Student´s t-test. ** p < 0.01, **** p < 0.0001 
 
In contrast, gross examination of the tissues of untreated Atg16l1LysM mice showed a 
spontaneous increase in spleen (splenomegaly, Figure 4-5 B), lymph nodes 
(lymphadenopathy, Figure 4-5 C) and liver size (hepatomegaly, Figure 4-5 D). Further, the 
bones were characteristically brighter in Atg16l1LysM mice than in Atg16l1fl/fl animals 
(Figure 4-5 E). Quantification of the gastrointestinal tract revealed a significant elongation of 
the small intestine (Figure 4-6 A) whereas colon length and caecum weight were unaltered 
(Figure 4-6 B and C). 





































































































FIGURE 4-6:  BASAL PHENOTYPE OF THE GASTROINTESTINAL TRACT IN THE ATG16L1LYSM MICE 
The gastrointestinal tract of Atg16l1fl/fl and Atg16l1LysM littermates (n=5) was investigated. Length of small 
intestine (A) and colon (C) as well as caecum weight (B) are graphically depicted. Statistical significance was 
tested by an unpaired Student´s t-test. * p < 0.05 
 
Next, the affected tissues of Atg16l1LysM mice were analyzed by histology. Liver and lung 
showed a spontaneous infiltration of immune cells (Figure 4-5). Spleen and mesenteric lymph 
nodes (MLNs) displayed a disordered architectural structure, which was characterized by the 
loss of a clear differentiation between the red and white pulp as well as the germinal center 
(gc) and corona (c) (Figure 4-5). Dissection of the small intestine revealed an augmented size 
and number of aggregated lymphoid nodules, called Peyer´s patches (pp), in the submucosa 
of Atg16l1LysM mice compared to Atg16l1fl/fl mice (Figure 4-5 ileum). No obvious 
abnormalities were seen in the morphology of the colon (data not shown). 
In summary, the basal phenotype of Atg16l1LysM mice is characterized by the development of 
a spontaneous hepatosplenomegaly, lymphadenopathy and elongated small intestine 
accompanied by a massive immune cell infiltration in distinct tissues like spleen, lymph 
nodes, liver and lung compared to Atg16l1fl/fl littermates. 
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FIGURE 4-7:  SPONTANEOUS IMMUNE CE LL INFILTRATION IN VARIOUS TISSUES OF ATG16L1LYSM  MICE 
Formalin-fixed and paraffin-embedded tissues were dissected in 3.5 – 4.5µm sections and stained with H&E. 
Indicated tissues were analyzed by transmission light microscopy. Scale bars represent 100 µm. Images are 
representative for at least three mice. MLN: mesenteric lymph node, red: red pulp, white: white pulp, gc: germinal 




























4.3.2 INCR EA SE D EX TRA ME DUL L ARY H E MAT OP OI ES I S IN  T HE SP LE EN O F  
ATG16L1LYS M  M IC E  
 
To analyze the splenomegaly in Atg16l1LysM animals in more detail the number of 
hematopoietic stem cells (HSCs) within the spleen was analyzed (Figure 4-8). Differentiated 
splenocytes were depleted by cell type-specific lineage antigens. Remaining lineage negative 
cells (lin-) were stained for the HSC markers stem cell antigen-1 (Sca-1) and proto-oncogene 
c-Kit (c-Kit) (Figure 4-8 A, fourth panel). To verify the purity of depletion remaining 
differentiated splenocytes were analyzed by flow cytometry (Figure 4-8 A, second and third 
panel). After lineage depletion slight contaminations of 5.85 % ± 1.13 of CD3+ and 
8.1 % ± 2.14 of CD19+ cells were detected. Staining of CD11b+ cells revealed 7.58 % ± 1.5 in 
the lin- population (Figure 4-8 A, third panel). Since these contaminations were detected in 
lin- splenic cells of Atg16l1fl/fl and Atg16l1LysM mice, analysis of HSC markers was still 
comparable between both genotypes.  
 
FIGURE 4-8:  INCREASED NUMBER OF HEMATOPOIETIC STEM CELLS IN THE SPLEEN OF ATG16L1LYSM MICE  
Cell type-specific lineage depletion of splenocytes was performed using the Lineage Cell Depletion kit for mouse. 
Splenic lin- cells of Atg16l1fl/fl and Atg16l1LysM mice (n=4) were stained for cell type-specific antigens and HSC 
markers and were analyzed by flow cytometry. The gating strategy is shown by dot plots (A). R1 – gate on living 
cells, R2 – gate on CD3+ cells, R3 – gate on CD19+ cells. Percentage of Sca-1+/c-Kit+ cells were corrected for the 
isotype controls and are graphically displayed (B). Data are shown as mean ± S.D. Statistical significance was 
calculated by an unpaired Student´s t-test. * p < 0.05 Formalin-fixed and paraffin-embedded histological sections 
of the spleen were stained for the proliferation marker Ki67(brown) (C). Images were analyzed by transmission 
light microcopy and are representative for three mice. Scale bars represent 100 µm. FSC: forward scatter, SSC: 
sideward scatter 
 












































































After gating on living cells (R1), analysis of HSCs showed a significant increase in 
Sca-1+/c-Kit+ cells in the spleen of Atg16l1LysM mice compared to Atg16l1fl/fl mice (Figure 
4-8 B). Histological staining of the proliferation marker Ki67 revealed an augmented number 
of proliferative cells in the spleen of Atg16l1LysM mice (Figure 4-8 C). 
To investigate whether the increased proliferation rate also resulted in an increased 
turnover, apoptotic cells were immunohistochemically analyzed (Figure 4-9). Microscopic 
analysis of TUNEL+ cells revealed no differences in the number of apoptotic splenic cells 
between both, Atg16l1fl/fl and Atg16l1LysM animals. 
 
FIGURE 4-9:  EQUAL NUMBERS OF APOPTOTIC TUNEL+  CELLS IN THE SPLEEN OF ATG16L1FL/FL  AND ATG16L1LYSM 
MICE  
Formalin-fixed and paraffin-embedded splenic sections of Atg16l1fl/fl and Atg16l1LysM littermates (n=3) were 
stained for apoptotic cells with ApopTag® Plus Peroxidase In Situ Apoptosis Detection Kit (Merck Millipore, 
Darmstadt, Germany) (A). Scale bars represent 100 µm. Images were analyzed by transmission light microcopy. 
Counting of TUNEL+ cells (brown) was performed in a blinded fashion with 5 images per mouse. Mean ± S.D. of 
TUNEL positive cells is graphically depicted (B). Statistical significance was calculated using an unpaired Student´s 
t-test. 
 
Bone marrow was microscopically analyzed, because Atg16l1LysM mice showed a splenic 
expansion of extramedullary hematopoiesis which is characterized by an increased number 
of HSCs and proliferative cells. In contrast, bone marrow of Atg16l1LysM mice was slightly 
hyperplastic compared to C57BL/6J wild type mice but did not show any indications for a 










FIGURE 4-10:  INTACT HEMATOPOIESIS IN BONE MARROW 
OF  ATG16L1LYSM MICE  
Formalin-fixed bones of Atg16l1LysM and C57BL/6J wild 
type mice (n=2) were decalcified and afterwards 
paraffin-embedded. Sections were stained for H&E and 
analyzed by transmission light microscopy. Scale bars 






























4.3.3 LOS S O F AT G16L1  IN  M YE LO ID C E LL S A LT ER S C OM PO S ITI ON O F SP LE N O CYT E S  
 
Since the spleen was the most affected organ in Atg16l1LysM mice this study first focused on 
the splenic immune cell composition. Flow cytometry analysis included stainings for CD3+ 
T cells, CD19+ B cells, CD11c+ dendritic cells, CD11b+ macrophages as well as CD11b+/Ly6G+ 

































FIGURE 4-11:  GATING STRATEGY OF 
IMMUNE CELL POPULATIONS IN THE 
SPLEEN OF ATG16L1LYSM MICE 
Dot plots depicting forward scatter 
(FSC) and sideward scatter (SSC) were 
used to exclude dead cells and 
erythrocytes by gating. Analysis of CD3+ 
T cells (R2), CD19+ B cells (R3), 
CD11b+/Ly6G+ neutrophils (R4), 
CD11b+ macrophages (R5) and CD11c+ 
dendritic cells (R6) are exemplarily 































FIGURE 4-12:  ALTERED IMMUNE CELL COMPOSITION IN THE SPLEEN OF ATG16L1LYSM MICE 
Splenocytes were isolated from Atg16l1fl/fl and Atg16l1LysM littermates (n=3) and stained for the indicated cell 
type-specific antigens and the particular isotype control combinations and analyzed by flow cytometry. 
Percentage of the individual cell population was corrected for the particular isotype control. Data are shown as 
mean ± S.D. Statistical significance was calculated by an unpaired Student´s t-test. * p < 0.05 
 
Dead cells, cell debris and red blood cells were excluded from further analysis by gating 
(Figure 4-11, R1). Atg16l1LysM mice showed a significantly decreased number of CD3+ T cells 
whereas CD11b+/Ly6G+ neutrophils where significantly elevated compared to Atg16l1fl/fl 
animals (Figure 4-12). CD19+ B cells were slightly decreased whereas the number of CD11c+ 
dendritic cells was markedly upregulated. CD11b+ macrophages were only slightly increased 
in the spleen of Atg16l1LysM mice. In line, expression analysis of cell type-specific antigens in 
the spleen of Atg16l1LysM and Atg16l1fl/fl mice showed significantly diminished mRNA 
expression of Cd3e and Cd4 for T cells as well as Cd19 for B cells (Figure 4-13) which further 
strengthened the observed reduction of adaptive immune cells within the spleen of 
Atg16l1LysM mice compared to Atg16l1fl/fl animals (Figure 4-12). Moreover, flow cytometry 
analysis detected upregulation of CD11b+ splenocytes could be confirmed on mRNA 
expression level (Figure 4-13). Expression of Cd11c did not show differences between 
Atg16l1LysM and Atg16l1fl/fl mice (Figure 4-13).  
 
FIGURE 4-13:  CHANGED EXPRESSION OF CELL TYPE-SPECIFIC MARKERS IN THE SPLEEN OF ATG16L1LYSM MICE  
Spleens of Atg16l1fl/fl and Atg16l1LysM mice (n=5) were frozen in liquid nitrogen and mortared. RNA extracts were 
reverse transcribed into cDNA. Expression levels of the indicated cell-type specific genes were analyzed by SYBR® 
green qPCR and normalized to Gapdh. Data are shown as mean ± S.D. and statistical significance was calculated 











































































































Thus, splenomegaly in Atg16l1LysM mice was associated with an increased number of innate 
immune cells whereby adaptive immune cells are significantly downregulated. Next, the 
activation status of adaptive and innate immune cells was investigated by flow cytometry 
(Figure 4-14). 
 
FIGURE 4-14:  INCREASED NUMBER OF ACTIVATED  MYELOID CELLS BUT NOT T  CELLS IN ATG16L1LYSM SPLEEN 
Splenocytes were isolated from Atg16l1fl/fl and Atg16l1LysM littermates (n=3) and stained for the indicated 
antigen combinations or particular isotype controls and analyzed by flow cytometry. Percentage of activated 
T cells (A) or macrophages (B) was corrected for the particular isotype control. Data are shown as mean ± S.D. An 
unpaired Student´s t-test was performed to evaluate the statistical significance. ** p < 0.01 
 
Equal numbers of CD3+/CD25+ and CD4+/CD95+ T cells were observed in the spleen of 
Atg16l1LysM and Atg16l1fl/fl mice (Figure 4-14 A) whereas the number of activated CD11b+ 
myeloid cells characterized by MHCII, CD14 and CD95 was significantly higher in 
Atg16l1LysM animals compared to Atg16l1fl/fl littermates (Figure 4-14 B). 
 
4.3.4 MYE LO ID D ERIV ED -SU PPRE S SOR CE L L (MDSC)-LI K E PH EN OT YP E  IN TH E 
SP L EEN OF AT G16L1LY SM  MI CE  
 
Myeloid derived suppressor cells (MDSCs) are described to exert a high immunosuppressive 
function on T cell proliferation and response [221]. Thus, the spleen of Atg16l1fl/fl and 
Atg16l1LysM mice was analyzed for specific MDSC markers (Figure 4-15). Atg16l1LysM mice 
displayed a prominent expression of inducible nitric oxide synthase (iNOS), a hall mark of 
MDSC expansion [221], which was completely absent in the spleen of Atg16l1fl/fl mice (Figure 
4-15 A). Moreover, significantly increased mRNA expression levels of myeloperoxidase (Mpo), 
S100 calcium binding protein A8 (S100a8) and S100 calcium binding protein A9 (S100a9) were 
detected in spleens of Atg16l1LysM mice when compared to Atg16l1fl/fl mice (Figure 4-15B). 
In agreement with these results histological spleen sections of Atg16l1LysM mice, showed 
markedly elevated numbers of clustered MPO+ cells compared to Atg16l1fl/fl mice (Figure 
4-13 C) which further supports the findings of an increased CD11b+/Ly6G+ population 



































































FIGURE 4-15:  IDENTIFICATION OF MDSC  ATTRIBUTES IN THE SPLEEN OF ATG16L1LYSM MICE  
Snap frozen spleens of Atg16l1fl/fl and Atg16l1LysM mice were mortared and RNA was extracted. cDNA synthesis 
was performed. Splenic levels of iNOS were determined by end-point PCR in four littermate pairs (A). Gapdh level 
served as loading control. Splenic levels of Mpo as well as S100a8 and S100a9 were determined in five littermate 
pairs by TaqMan Assay and SYBR® green qPCR, respectively (B). Expression of the indicated targets was 
normalized to Gapdh. Formalin-fixed and paraffin-embedded splenic sections (n=3) were stained for MPO (brown) 
and analyzed by transmission light microcopy (C). Scale bars represent 100 µm. iNOS: inducible nitric oxide 
synthase, MPO: myeloperoxidase 
 
4.3.5 EXPR E S SI ON O F C YT OK I N E S IN  TH E  S PL E EN O F ATG16L1LYS M  M IC E  
 
To further investigate whether the observed increase in myeloid cells and their 
hyper-activation influences the cytokine profile in the spleen of Atg16l1LysM mice, mRNA 
expression analysis of distinct cytokines and chemokines was performed (Figure 4-16).  
Expression levels of the pro-inflammatory cytokines interleukin 1 beta (Il1b), Il6 and tumor 
necrosis factor alpha (Tnfa) as well as the anti-inflammatory cytokines Il10 and Il4 were 
equally determined in Atg16l1fl/fl and Atg16l1LysM mice. In contrast, the pro-inflammatory 
cytokines Il1a and interferon gamma (Ifng) revealed a slight upregulation on mRNA level in 
Atg16l1LysM mice. The pro-inflammatory neutrophil attracting chemokine (C-X-C motif) 
ligand 1 (Cxcl1) was significantly increased whereas expression of the pro-inflammatory 
cytokine Il18 and the autocrine T cell-mediated cytokine Il2 was significantly diminished.  
 


























































FIGURE 4-16:  ALTERED EXPRESSION OF MYELOID-  AND T  CELL-SPECIFIC CYTOKINES AND CHEMOKINES IN THE 
SPLEEN OF ATG16L1LYSM MICE 
Spleens of Atg16l1fl/fl and Atg16l1LysM mice (n=5) were snap frozen in liquid nitrogen. RNA extraction and cDNA 
synthesis were performed; expression of the indicated targets was analyzed by means of SYBR® green qPCR and 
normalized to Gapdh. Expression of Il1b and Il18 was analyzed by TaqMan Assay. Data show mean ± S.D. Statistical 
significance was calculated with an unpaired Student´s t-test. * p < 0.05 
 
Taken together, the cytokine profile in the spleen of Atg16l1LysM mice reflected in particular 
the naϊve status of T cells and the hyper-activation of myeloid cells.  
 
4.3.6 SPL EN IC PH EN OT YP E O F  AT G16L1LYSM  M IC E  I S  NO T DR IV EN  BY BA CTER IA L 
INV A SI ON  
 
Clearance of invading bacteria is one of the main functions of the spleen. Since the observed 
splenomegaly in Atg16l1LysM mice was accompanied by an increased number of hyper-
activated CD11b+ splenocytes, a putative barrier dysfunction was investigated by means of a 
PCR for eukaryotic bacteria (Figure 4-17).  
 
 
FIGURE 4-17:  NO BACTERIAL INVASION IN THE SPLEEN 
OF ATG16L1LYSM MICE  
Spleens of Atg16l1fl/fl and Atg16l1LysM mice (n=9) were 
directly frozen in liquid nitrogen and mortared. After 
DNA extraction, DNA of eukaryotic bacteria was detected 
using a specific TaqMan assay. Murine feces were used 
as positive control. Data are shown as mean ± S.D.  
 
However, bacterial DNA was neither observed in the spleen of Atg16l1fl/fl mice nor their 
Atg16l1LysM littermates. In conclusion, a bacterial invasion did not explain the observed 
hyper-activation of CD11b+ myeloid cells in the spleen of Atg16l1LysM mice. 
 











































































































































































n=9 of each genotype, mean +- S.D. of duplicates
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4.3.7 ENHA NC ED PR OT EIN  L E V EL O F PRO -IL1Β  BUT  NOT TLR4  C OM PON EN T S IN T HE 
SP L EEN OF AT G16L1LY SM  MI CE  
 
Recent studies have indicated a pivotal role for autophagy in IL1 cytokine production based 
on increased secretion of IL1β after activation of TLR4 signaling [22]. To analyze this 
phenomenon in Atg16l1fl/fl and Atg16l1LysM mice, protein levels of IL1β were determined in 
the spleen (Figure 4-18).  
 
FIGURE 4-18:  PRO-IL1Β BUT NOT TLR4  SIGNALING MOLECULES ACCUMULATE IN THE SPLEEN OF ATG16L1LYSM  
MICE 
Snap frozen spleens of Atg16l1fl/fl and Atg16l1LysM mice (n=5) were mortared. Proteins were extracted and 
lysates were probed by immunoblot for the indicated proteins with β-Actin serving as loading control.  
 
In four out of five littermate pairs the full-length inactive form of IL1β (pro-IL1β) was 
markedly enhanced in Atg16l1LysM mice compared to Atg16l1fl/fl mice. To determine if this 
observation is due to a defective degradation machinery of TLR4 signaling components, 
protein levels of MyD88, TRIF and TRAF6 were analyzed. However, none of the investigated 
proteins showed elevated levels when comparing both genotypes. 
 
4.3.8 EXPR E S SI ON  O F IN F LA MM A SO ME C O MP ON ENT S I N TH E SP L E EN  O F 
ATG16L1LYS M  M IC E  
 
Autophagy was further described to modulate IL1β production through regulation of the 
NOD-like receptor family, Pyrin domain containing 3 (NLRP3) inflammasome [222]. Thus, 
mRNA levels of inflammasome components were investigated (Figure 4-19). Activation of the 
inflammasome depends on the formation of a multimeric protein complex of the 
enzymatically inactive pro-Caspase-1 (pro-Casp1), Pyrin domain of apoptosis-associated 
speck-like protein containing a CARD (ASC) and the NOD-like receptor family, Pyrin domain 
containing protein 3 (NLRP3). Among both genotypes mRNA expression analysis of the three 















FIGURE 4-19:  UNALTERED EXPRESSION ON NLRP3  INFLAMMASOME COMPONENTS IN ATG16L1LYSM SPLEENS 
Spleens of Atg16l1fl/fl and Atg16l1LysM mice (n=5) were subsequently frozen in liquid nitrogen and mortared. 
Extracted RNA was reverse transcribed into cDNA and expression analysis was performed by means of SYBR® 
green qPCR. Expression levels of the indicated target genes were normalized to Gapdh. Data are shown as 
mean ± S.D. and the statistical significance was calculated using an unpaired Student´s t-test. 
 
Summing up, the detected accumulation of pro-IL1β in the spleens of Atg16l1LysM animals 
could be traced back neither to elevated protein levels of Toll-like receptor 4 signaling 
molecules nor to increased mRNA expression levels of NLRP3 inflammasome components. 
 
4.3.9 MYE LO ID C EL L  IN F ILTR ATI ON AF F ECT S  MU LT IP LE OR GA NS  BU T NOT TH E BRAI N  
OF AT G16L1LYS M  M IC E  
 
Given that innate immune cells, especially neutrophils, seem to play a crucial role in the 
splenic phenotype of Atg16l1LysM mice, additionally affected organs like mesenteric lymph 
nodes, liver and lung were analyzed by immunohistochemistry (Figure 4-20). Mesenteric 
lymph nodes (MLNs) of Atg16l1LysM mice showed cluster of MPO+ cells which was 
completely absent in MLNs of Atg16l1fl/fl mice. Similar results were observed for liver and 
lung of Atg16l1LysM mice when compared to their Atg16l1fl/fl littermates. However, not every 
cluster of infiltrated immune cells in the liver of Atg16l1LysM mice consisted of MPO+ cells 















































FIGURE 4-20:  INCREASED NUMBER OF MPO+  CELLS IN MLN, LIVER AND LUNG OF ATG16L1LYSM  MICE 
Tissues of Atg16l1fl/fl and Atg16l1LysM mice (n=3) were formalin-fixed and paraffin-embedded. Sections of MLN, 
liver and lung were stained for MPO (brown) and analyzed by transmission light microcopy. White arrows 
exemplarily indicate MPO+ cells. Scale bars represent 50 µm. MLN: mesenteric lymph node; MPO: myeloperoxidase 
 
In line, staining of macrophages using the pan-macrophage marker ionized calcium-binding 
adapter molecule 1 (IBA-1) [223] showed an increased infiltration of IBA-1+ macrophages in 
MLN and liver of Atg16l1LysM mice compared to their Atg16l1fl/fl littermates (Figure 4-21). 
Besides an elevated number, Atg16l1LysM mice revealed larger irregularly shaped IBA-1+ 
cells suggesting an increased pseudopodia formation and thus activation of IBA-1+ cells in the 
liver [224, 225]. In contrast, similar numbers of IBA-1+ microglia were observed in brain 
sections of Atg16l1LysM and Atg16l1fl/fl mice. IBA-1+ microglia exhibited the characteristic 
ramified shape pointing to quiescent microglia populations and thus an intact blood-brain 




















FIGURE 4-21:  ELEVATED INFILTRATION OF IBA-1+  MACROPHAGES IN MLN, LIVER AND BRAIN OF ATG16L1LYSM  
MICE 
MLN, liver and brain tissues of Atg16l1fl/fl and Atg16l1LysM mice (n=3) were formalin-fixed and paraffin-
embedded. Sections were stained for IBA-1 (brown) and analyzed by transmission light microcopy. Scale bars 
represent 50 µm. IBA-1: ionized calcium-binding adapter molecule 1; MLN: mesenteric lymph node 
 
4.3.10 NEU TROP HI L IA I N TH E B LO OD O F AT G16L1LYS M  M IC E  
 
In order to study whether the phenotype of CD11b+ cells is restricted to tissue-resident 
macrophages of the spleen, leukocyte populations in the blood of Atg16l1LysM mice were 
analyzed using flow cytometry (Figure 4-22).  
Dead cells and cell debris were excluded similarly as described for splenic cells (Figure 4-11, 
R1). No alterations were observed in the distribution of CD3+ and CD19+ immune cells, 
whereas CD11b+ and CD11c+ cells were slightly elevated in the blood of Atg16l1LysM mice 
compared to Atg16l1fl/fl littermates (Figure 4-22 A). Atg16l1LysM mice showed a significantly 



















analysis of the number of activated CD11b+ cells revealed a significant increase in the blood of 
Atg16l1LysM mice compared to Atg16l1fl/fl mice (Figure 4-22 B). In accordance with results 
seen in the spleen (see chapter 4.3.3) numbers of activated T cells in the blood of 
Atg16l1LysM mice were not altered. 
 
FIGURE 4-22:  PROPORTION OF LEUKOCYTES IN THE BLOOD OF ATG16L1LYSM MICE 
Blood of Atg16l1fl/fl and Atg16l1LysM littermates (n=3) was collected in EDTA tubes. After staining for the 
indicated antigens or particular isotype controls, red blood cells were lyzed with 1 x BD FACS Lysing Solution and 
remaining cells were analyzed by flow cytometry. Percentage of the indicated cell populations (A) as well as 
activated T cells (B) or macrophages (C) was corrected for the particular isotype control. Data are shown as mean 
± S.D. An unpaired Student´s t-test was performed to evaluate the statistical significance. * p < 0.05, *** p < 0.001 
 
4.3.11 CYTO KI NE LEV E LS IN U NTREA TE D ATG16L1LY SM  MI CE  
 
Since Atg16l1LysM mice showed a multifaceted inflammatory phenotype in various organs, 
serum cytokine and chemokine levels were analyzed in untreated Atg16l1fl/fl and Atg16l1LysM 
littermates (Figure 4-23). The multiplex-based screening revealed elevated cytokine levels 
under basal conditions in Atg16l1LysM mice compared to Atg16l1fl/fl animals. 
In detail, significant increase was observed for IL12p40 and p70, IL18, TNFα and IL10 as well 
as the myeloid-related chemokines macrophage inflammatory protein 1 alpha (MIP1α) and 
beta (MIP1β). No alterations were observed for IL1α and IL1β as well as for IL2, IL3, IL4, IL5, 
IL6, IL9, IL13, IL17, granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage 
stimulating factor (GM-CSF), IFNγ, monocyte chemotactic protein 1 (MCP1) and the 





































































































FIGURE 4-23:  INCREASED CYTOKINE AND 
CHEMOKINE LEVELS IN THE SERUM OF 
ATG16L1LYSM MICE 
Blood from Atg16l1fl/fl and Atg16l1LysM 
littermates (n=6) was collected in 
lithium-heparin tubes. Cytokine and 
chemokine levels in the serum were 
measured using the Bio-Plex Pro™ Mouse 
Cytokine 23-plex Assay (BioRad). Levels of 
IL18 were measured by ELISA. Results are 
displayed in a heat-map. For better 
readability, concentration values were z-




4.4 IMPACT OF IL1R  INHIBITION ON THE BASAL PHENOTYPE OF 
ATG16L1LYSM  MICE  
 
Recent studies implicated a role for autophagy in secretion of pro-inflammatory cytokines of 
the IL1-family [22, 46, 62, 227]. With regard to increased IL1 cytokines levels in spleen and 
serum of mice lacking Atg16l1 in the myeloid lineage, the in vivo role of IL1R signaling was 
studied. Atg16l1fl/fl and Atg16l1LysM mice were daily treated with 200 µg of the human 
interleukin-1 receptor (IL1R) antagonist Anakinra (Kineret®, Swedish Orphan Biovitrum AB) 
for a period of two weeks in order to inhibit IL1R signaling ([214], [228]).  
During this period of Anakinra treatment, body weight of Atg16l1fl/fl as well as Atg16l1LysM 
mice did not alter compared to sodium chloride (NaCl)-treated control mice (Figure 4-24 A). 
Analysis of the body weight revealed no effect of the IL1R antagonist on the spontaneous 
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FIGURE 4-24:  BODY AND ORGAN WEIGHT OF ATG16L1FL/FL AND ATG16L1LYSM MICE AFTER ANAKINRA THERAPY  
Atg16l1fl/fl and Atg16l1LysM mice were daily treated with 200 µg Anakinra (n=8) or 200 µL NaCL (n=4-5) for 14 d. 
Body weight loss was daily recorded (A). After a two week period of treatment, spleen (B) and liver weight (C) 
were assessed. Data represent mean ± S.D. and statistical significance was calculated with an unpaired Student´s 
t-test. ** p < 0.01 
 
Histological analysis of the spleen of Anakinra-treated Atg16l1fl/fl and Atg16l1LysM mice did 
not show differences in the morphology compared to appropriate NaCl-treated control mice 
(Figure 4-25). Thus, inhibition of IL1R signaling did not restore the architectural disorder in 







FIGURE 4-25:  HISTOLOGICAL ANALYSIS 
OF THE SPLENIC MORPH OLOGY IN 
ATG16L1LYSM MICE AFTER ANAKINRA 
TREATMENT 
After the two weeks treatment of 200 µg 
Anakinra (n=8) or 200 µL NaCl (n=4-5) 
per day, spleens of Atg16l1fl/fl and 
Atg16l1LysM mice were formalin-fixed 
and paraffin-embedded. Splenic sections 
were stained with H&E and analyzed by 
transmission light microscopy. Scale bars 
represent 100 µm. 
 























































































The impact of the IL1 cytokine family was further determined on cellular and molecular 
levels analyzing the cellular composition and activation status in the spleen of 
Anakinra-treated Atg16l1fl/fl and Atg16l1LysM mice (Figure 4-26).  
 
FIGURE 4-26:  INHIBITION OF IL1R  SIGNALING DID NOT RESCUE THE ALTERED LEUKOCYTE COMPOSITION IN THE 
SPLEEN OF ATG16L1LYSM MICE  
Atg16l1fl/fl and Atg16l1LysM mice (n=4) were daily administered with 200 µg Anakinra for 14 d. Splenocytes were 
stained with the indicated antibodies or appropriate isotype controls and analyzed by flow cytometry. Cellular 
composition (A) as well as numbers of activated T cells (B) and macrophages (C) were depicted as percentage of 
leukocytes corrected for the particular isotype control. Data are shown as mean ± S.D. Evaluation of statistical 
significance was performed with an unpaired Student´s t-test. * p < 0.05, ** p < 0.01 
 
 
After 14 d of Anakinra treatment, Atg16l1LysM mice still showed a significant decrease of 
CD3+ T cells and CD19+ B cells whereas CD11b+ macrophages and CD11b+/Ly6G+ neutrophils 
were significantly upregulated compared to Anakinra-treated Atg16l1fl/fl mice (Figure 
4-26 A). Splenic T cells of Atg16l1LysM mice demonstrated a diminished cell surface 
expression of CD25 and CD95 compared to Atg16l1fl/fl mice (Figure 4-26 B). As expected from 
these results, CD11b+ splenocytes of Anakinra-treated Atg16l1LysM mice still displayed an 
enhanced cell surface expression of the activation markers MHCII, CD14 and CD95 (Figure 
4-26 C). 
To determine whether IL1R inhibition has an influence on the altered cytokine expression in 
the spleen of Atg16l1LysM mice, mRNA expression analysis were performed (Figure 4-27). 
Inhibition of IL1R signaling did neither change expression of the IL1 family members Il1a and 
Il1b nor Tnfa, Il10 and Il6. In contrast, a slight decrease in Il18 expression was seen in 
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control mice. Significantly enhanced mRNA expression of Cxcl1 in Atg16l1LysM mice persisted 
after treatment with Anakinra indicating an IL1R signaling independent mechanism. 
 
FIGURE 4-27:  ANAKINRA TREATMENT DID NOT ALTER DIFFERENCES IN CYTOKINE EXPRESSION OF  ATG16L1FL/FL AND 
ATG16L1LYSM MICE 
Atg16l1fl/fl and Atg16l1LysM mice received a daily intraperitoneal injection of 200 µg Anakinra (n=8) or 200µL 
NaCl (n=4-5) as control. RNA from liquid nitrogen frozen spleens was extracted and transcribed into cDNA. 
Expression levels of the indicated chemokines and cytokines were measured by SYBR® green qPCR and 
normalized to Gapdh. Data represent mean ± S.D. and statistical analysis was performed with an unpaired 
Student´s t-test. ** p < 0.01, *** p < 0.001 
 
For verification of unaffected cytokine levels, serum cytokine and chemokine levels of 
Anakinra-treated Atg16l1fl/fl and Atg16l1LysM mice were measured (Figure 4-28). Inhibition 
of IL1R signaling did not result in alterations of one of the 24 investigated cytokines which is 
exemplarily shown for IL18 and IL12p40 in Figure 4-28. 
 
FIGURE 4-28:  UNALTERED CYTOKINE CONCENTRATIONS IN THE SERUM AFTER ANAKINRA TREATMENT  
Blood from Atg16l1fl/fl and Atg16l1LysM mice was collected in lithium-heparin tubes after a two-week period of 
Anakinra treatment (200µg/day, n=8) or NaCl (200µL/day) n=4-5) as control. Concentrations of IL18 were 
measured by ELISA. IL12p40 levels were analyzed using the Bio-Plex Pro™ Mouse Cytokine 23-plex Assay 
(BioRad). Data are represented as mean ± S.D. and statistical significance was evaluated by an unpaired Student´s 





































































































































_______* _______p = 0.0613
 
69 
Taken together, the observed phenotype of Atg16l1LysM mice could not be reverted by 
pharmacological IL1R signaling inhibition suggesting that IL1R signaling and the IL1 cytokine 
family does not mediate the complex inflammatory phenotype of the conditional Atg16l1LysM 
knock-out mouse model. 
 
4.5 ROLE OF ATG16L1  IN TLR4  SIGNALING  
 
4.5.1 HY PER-S ECR ET ION O F C YTO KI N E S I S TRAN SCR I PTI ONA LL Y  RE GU LAT ED  IN LPS-
ST IM ULA TE D ATG16L1LYSM  BMDMS  
 
To investigate the hyper-activation of Atg16l1-deficient CD11b+ cells in more detail, the 
functional role of ATG16L1 was further analyzed using bone marrow-derived macrophages 
(BMDMs) as ex vivo model. Since recently published studies implicated a role for autophagy 
and ATG16L1 in cytokine [22, 62, 227] and hormone secretion [229], the functional impact of 
ATG16L1 on exocytotic secretory pathways was studied. In a preliminary experiment, 
secretion of CXCL1 upon stimulation with several bacterial and viral stimuli was screened in 
Atg16l1LysM and Atg16l1fl/fl BMDMs (Figure 4-29).  
 
 
FIGURE 4-29:  INCREASED CXCL1  SECRETION IN ATG16L1LYSM BMDMS UPON TLR4 STIMULATION  
Atg16l1fl/fl and Atg16l1LysM BMDMs (n=1) were either left unstimulated or stimulated with 100 ng/mL LPS (E. coli 
F515), 1 µg/mL Poly I:C, 1 µg/mL ssRNA40 (ssRNA), 100 ng/mL Pam3CSK4 (Pam3), 100 ng/mL FSL-1, 
100 bacteria/cell heat-killed Listeria monocytogenes (HKLM), 25 ng/mL TNFα, 25 ng/mL IFNγ or 10 ng/mL MDP 
for 24 h. Cell culture supernatants were collected and concentrations of CXCL1 were measured by ELISA. Data are 
shown as mean of the measured triplicates ± S.D. 
 
Already untreated Atg16l1LysM BMDMs showed a slightly increased CXCL1 secretion 
compared to Atg16l1fl/fl BMDMs. Stimulation with lipopolysaccharide (LPS), 
polyinosinic:polycytidylic acid (Poly I:C), single-stranded RNA (ssRNA), TNFα or muramyl 
dipeptide (MDP) even resulted in a much stronger increase of CXCL1 release of Atg16l1LysM 
BMDMs whereas LPS treatment by far showed the strongest difference. Only slight 
differences were detected upon stimulation with the synthetic lipoproteins Pam3CSK4 and 
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70 
FSL-1 as well as upon stimulation with heat-killed Listeria monocytogenes (HKLM) and IFNγ. 
For this reason, the present study and any further experiments focused on the role of 
ATG16L1 in TLR4 signaling. 
To address if the observed results represent a general effect of ATG16L1 on cytokine 
secretion, supernatants of untreated and LPS-treated BMDMs were analyzed for several 
cytokines and chemokines. No differences were observed between Atg16l1LysM and 
Atg16l1fl/fl BMDMs under basal conditions (data not shown) whereas stimulation with LPS 
induced cytokine and chemokine secretion in both genotypes (Figure 4-30). However, 
Atg16l1LysM macrophages showed an augmented LPS-induced cytokine production 
compared to LPS-treated Atg16l1fl/fl BMDMs. Out of the 23 studied cytokines and chemokines 
IL1α and CXCL1 were significantly upregulated in Atg16l1LysM BMDMs. No changes were 








FIGURE 4-30:  TLR4-MEDIATED 
HYPER-SECRETION OF CYTOKINES AND 
CHEMOKINES IN ATG16L1LYSM BMDMS  
Atg16l1fl/fl and Atg16l1LysM BMDMs (n=5) 
were stimulated with 25 ng/mL LPS (E. coli 
F515) for 24 h. Cell culture supernatants 
were collected and concentrations of 
cytokines and chemokines were measured 
in duplicates using the Bio-Plex Pro™ 
Mouse Cytokine 23-plex Assay (BioRad) or 
ELISA. For better readability, concentration 
values were z-score normalized. 
 
 
To define whether the loss of Atg16l1 affects cytokine secretion directly by influencing the 
release or indirectly by regulating the expression, mRNA expression levels of pro- and anti-
inflammatory cytokines and chemokines were determined (Figure 4-31). Although untreated 
Atg16l1-deficient BMDMs did not show altered cytokine levels in the supernatant (data not 
shown), mRNA expression analysis revealed significantly upregulated expression of Cxcl1 and 
Ifng as well as significantly diminished expression of interleukin-18 (Il18) compared to 
Atg16l1fl/fl macrophages. Stimulation with LPS for 24 h resulted in significantly increased 
mRNA expression levels of Il1a, Il1b and Cxcl1 validating the observed significant differences 
in IL1α and CXCL1 secretion after LPS treatment (Figure 4-30). LPS-treated Atg16l1LysM 
BMDMs also exhibited significantly increased expression of Ifng in response to LPS. No 
alterations were observed for Il6 and Il10 as well as the type I interferon Ifnb, whereas 
expression of Tnfa and Il18 was slightly reduced in Atg16l1LysM macrophages compared to 





























FIGURE 4-31:  ATG16L1-DEFICIENCY LEADS TO AN ALTERED GENE EXPRESSION OF CYTOKINES AND CHEMOKINES 
AFTER LPS STIMULATION  
In three independent experiments Atg16l1fl/fl and Atg16l1LysM BMDMs (n=4) were stimulated with 25 ng/mL LPS 
(E. coli F515) for 24 h or left unstimulated. Expression levels of Il1a, Il6, Il10, Cxcl1 and Tnfa were analyzed by 
SYBR green qPCR. Il1b, Il18, Ifng and Ifnb expression analysis were performed using TaqMan assays. Expression 
levels of the indicated targets were normalized to Gapdh or β-Actin. Data are shown as mean ± S.D. and were tested 
for statistical significance using an unpaired Student´s t-test.* p < 0.05, ** p < 0.01 
 
4.5.2 CYTO KI NE E XPR E S SI ON  AND SECR ET IO N IS MOD ULA TE D BY CON S TITUT IV E 
NF-ΚB  A ND P 38  MAPK  ACTIV A TI ON I N ATG16 L1LYSM  BMDMS  
 
LPS-triggered TLR4 activation results in various signaling cascades initiating the activation of 
transcription factors like NF-κB, AP-1 and IRFs, which in turn leads to expression of cytokines 
and chemokines. In this scenario, NF-κB controls expression of pro- and anti-inflammatory 
cytokines whereas IRFs specifically induce expression of type I interferons like IFNβ. Given 
that expression of the upregulated cytokines Il1a, Il1b, Cxcl1 and Ifng is mainly controlled by 
NF-κB [230-234], phosphorylation of the NF-κB subunit p65 at Ser536 was investigated in a 
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FIGURE 4-32:  INCREASED AND PROLONGED PHOSPHORYLATION OF CANONICAL P65 AND P38 MAPK  SIGNALING IN 
ATG16L1LYSM MACROPHAGES UPON LPS STIMULATION 
Atg16l1fl/fl and Atg16l1LysM BMDMs were stimulated with 25 ng/mL LPS (E. coli F515) for the indicated time 
points or left unstimulated. Proteins were extracted and immunoblotted. Protein levels were evaluated using the 
indicated antibodies. Unphosphorylated proteins served as loading control. One representative immunoblot out of 
at least three individual experiments is shown. 
 
Loss of Atg16l1 resulted in an earlier and stronger activation of canonical NF-κB signaling by 
showing increased phosphorylation of the NF-κB subunit p65 and IκBα already after 30 min 
and 5 min of LPS stimulation, respectively (Figure 4-32). As expected, the augmented IκBα 
phosphorylation subsequently resulted in increased degradation of IκBα in Atg16l1LysM 
BMDMs in response to LPS. Further, p65 activation was prolonged for up to 24 h in Atg16l1-
deficient macrophages when compared to Atg16l1fl/fl littermate BMDMs. Similar results were 
observed for the canonical p38 MAPK signaling [235]. Phosphorylation and thus activation of 
MKK3/6 was stronger induced in Atg16l1LysM BMDMs already 10 min after LPS treatment. 
As canonical downstream targets, MKK3/6 phosphorylation mediated an earlier and stronger 
phosphorylation of p38 MAPK directly initiating the phosphorylation of MK2. In line with the 
canonical NF-κB signaling, MKK3/6, p38 and MK2 as components of the canonical p38 MAPK 
pathway demonstrated an enhanced and sustained activation for up to 24 h after LPS 
treatment. None of the indicated signaling molecules showed an accumulation of its basal 
unphosphorylated protein levels excluding a deregulated protein homeostasis of these 


































Beside canonical NF-κB activation via phosphorylation of IκBα and its subsequent 
proteasomal degradation [236] several studies reported a substantial role for p38 MAPK in 
NF-κB activation [237, 238]. To investigate a putative crosstalk between p38 MAPK signaling 
and the canonical NF-κB pathway BMDMs derived from Atg16l1fl/fl and Atg16l1LysM mice 
were challenged with either LPS or the selective p38 activity inhibitor SB202190 (ip38) alone 
or a combination of both stimuli (Figure 4-33).  
 
FIGURE 4-33:  CONSTITUTIVE ACTIVATION OF P65 OCCURRED INDEPENDENT OF P38 MAPK  ACTIVITY 
Atg16l1fl/fl and Atg16l1LysM BMDMs were stimulated for 6 h with DMSO as control or 25 ng/mL LPS (E.coli F515) 
in absence or presence of 10 µM p38 activity inhibitor SB202190 (ip38). Stimulation with ip38 was performed 1 h 
prior to DMSO or LPS. Protein lysates were immunoblotted and protein levels were analyzed using the indicated 
antibodies (A). β-Actin and unphosphorylated proteins served as loading controls. One representative 
immunoblot out of 3 individual experiments is shown. CXCL1 concentrations were determined in the appropriate 
supernatant by ELISA (B). ELISA results are representatives for at least three independent experiments. Data 
represent mean ± S.D. of technical duplicates. 
 
Stimulation with ip38 alone resulted in elevated phospho-p38 levels compared to the 
appropriate DMSO-treated controls but had no effect on phospho-IκBα or phospho-p65 levels 
in BMDMs of both genotypes. In addition, blocked p38 activity during LPS treatment further 
increased phospho-p38 but hardly reduced phospho-IκBα and phospho-p65 levels and did 
not diminish the observed differences in LPS-treated Atg16l1LysM BMDMs compared to 
Atg16l1fl/fl BMDMs. Following downstream events of NF-κB activation, CXCL1 secretion was 
analyzed as a hallmark of the ex vivo phenotype in Atg16l1-deficient macrophages (Figure 
4-33 B). Inhibition of p38 activity combined with LPS treatment led to a decrease in CXCL1 
secretion. However, the relative differences between Atg16l1LysM and Atg16l1fl/fl BMDMs 



































4.5.3 IM PAIR ED AU TO PHA G Y  DOE S NOT R E SU LT  IN AC CU MUL ATI ON OF  TLR4  
SI GN AL IN G C OM PO NE NT S  BUT P 62 
 
Recent studies implicated a role for autophagy in regulation of TLR4 signaling by degrading 
TLR4 components and complexes [239, 240]. For this reason, protein levels of TLR4 signaling 



















FIGURE 4-34:  PROTEIN LEVELS OF TLR4  
SIGNALING MOLECULES IN ABSENCE AND 
PRESENCE OF LPS 
Atg16l1fl/fl and Atg16l1LysM BMDMs were left 
unstimulated or stimulated with 25 ng/mL LPS 
(E.coli F515) for 24 h. Proteins were extracted 
and immunoblotted. Protein levels were 
analyzed using the indicated antibodies. 
β-Actin and unphosphorylated proteins served 
as loading controls.  
 
 
Atg16l1fl/fl and Atg16l1LysM BMDMs showed similar levels of the TLR4 receptor and its 
adaptor molecules MyD88, TRIF and receptor-interacting serine/threonine-protein kinase 1 
(RIP1) in presence and absence of LPS. In contrast, p62 levels increased in BMDMs of both 
genotypes in response to LPS. The observed relative differences seen in unstimulated cells 
persisted after LPS stimulation in Atg16l1LysM BMDMs. Coinciding with the immunoblot 
results, immunofluorescence analysis determined increased cytoplasmic level of p62 in 
untreated Atg16l1LysM BMDMs compared to Atg16l1fl/fl macrophages (Figure 4-35 A). 
Whereas Atg16l1fl/fl BMDMs demonstrated a uniform cytosolic distribution of p62, 
endogenous p62 in Atg16l1-deficient BMDMs was primarily localized in cytosolic aggregates. 
This phenomenon was also observed in cells of the red pulp in the spleen of Atg16l1LysM 
mice under basal conditions whereas it was completely absent in Atg16l1fl/fl mice (Figure 


























Atg16l1fl/fl BMDMs while a further accumulation of p62 was observed in Atg16l1LysM 
macrophages compared to the appropriate untreated cells (Figure 4-35 A). The initially 
detected differences in p62 levels of untreated Atg16l1fl/fl and Atg16l1LysM macrophages 
were preserved in presence of LPS supporting the findings on protein levels determined by 
immunoblot (Figure 4-34) which might point to a physiological role of p62 aggregate 
formation in response to LPS.  
 
 
FIGURE 4-35:  IN VITRO  AND IN VIVO  AGGREGATES OF P62 IN ATG16L1-DEFICIENT MACROPHAGE S 
BMDMs derived from Atg16l1fl/fl and Atg16l1LysM mice were left unstimulated or treated with 25 ng/mL LPS 
(E.coli F515) for 24 h and stained for p62 (green) using the immunofluorescence technique (A). Scale bars 
represent 5 µm. Representative images from at least 3 independent experiments are shown. Splenic sections from 
Atg16l1fl/fl and Atg16l1LysM mice were immunohistochemically stained for p62 (brown) (B). Scale bars represent 


































4.5.4 ATG16L1-D EF IC IE NT MACR OP HA GE S D I SP LA Y AN INTA CT END O CYT OT IC 
MAC HI NER Y  
 
Since TLR4 internalization emerged as a crucial step in TRIF-dependent late NF-κB signaling 
[241] and Atg16l1-deficient BMDMs showed a LPS-induced prolonged NF-κB activation, 
endocytosis was next investigated. To first analyze a putative general effect of Atg16l1-
deficiency on the endocytotic machinery, pinocytosis was measured by FITC-Dextran uptake 




FIGURE 4-36:  INTACT PINOCYTOSIS IN ATG16L1-DEFICIENT BMDMS 
Atg16l1fl/fl and Atg16l1LysM BMDMs (n=3) were incubated with 1 mg/mL FITC-Dextran or left untreated for 
60 min. Fluorescence intensity was measured by flow cytometry and depicted as a representative histogram (A). 
Geometric means of fluorescence intensity (n=3) are displayed in a graph as mean ± S.D. and statistical 
significance was tested using an unpaired Student´s t-test (B). 
 
Atg16l1fl/fl and Atg16l1LysM BMDMs showed no differences in FITC-Dextran uptake. However, 
endocytosis is not exclusively subclassified in pinocytosis, phagocytosis and receptor-
mediated endocytosis by the up taken particles but also by their invagination mechanisms. 
A general defect in receptor internalization could explain the increased TLR4 signaling 
(Figure 4-32) as well as the upregulated activation markers on Atg16l1-deficient CD11b+ 
myeloid cells in vivo (Figure 4-14). Stimulation-induced receptor internalization of CD95, one 
of the significantly upregulated activation markers on CD11b+ cells in spleen and blood 



































FIGURE 4-37:  SIMILAR INTERNALIZATION CAPACITY OF CD95  ON ATG16L1FL/FL AND ATG16L1LYSM BMDMS  
Cell surface expression of CD95 was analyzed on untreated Atg16l1fl/fl and Atg16l1LysM BMDMs (n=4) by flow 
cytometry (A). Representative histogram of the fluorescence intensity is depicted. Internalization rate of CD95 
was analyzed in Atg16l1fl/fl and Atg16l1LysM BMDMs (n=4) after treatment with 1µg/mL CD95L for the indicated 
time points (B). Graph displays geometric means of the fluorescence intensity ± S.D. Statistical significance was 
evaluated using an unpaired Student´s t-test. CD95L: CD95 Ligand 
 
Although not expected from the in vivo results, similar cell surface expression of CD95 was 
determined on untreated Atg16l1fl/fl and Atg16l1LysM BMDMs (Figure 4-37 A). Following 
stimulation with anti-CD95 as ligand (CD95L) for up to 3 h, BMDMs of both genotypes 
showed a similar internalization capacity of the CD95 receptor (Figure 4-37 B). Moreover, 
neither TLR4 nor macrophage scavenger receptor 1 (MSR1) showed differences in cell 
surface expression and on protein levels, respectively (Figure 4-38). 
 
 
FIGURE 4-38:  EQUAL EXPRESSION OF LPS-BINDING RECEPTORS IN ATG16L1FL/FL AND ATG16L1LYSM BMDMS 
TLR4 surface expression was analyzed by flow cytometry on untreated Atg16l1fl/fl and Atg16l1LysM BMDMs (A). 
Histogram is representative for at least three independent experiments. Protein levels of MSR1 in untreated and 
LPS-stimulated (E.coli, F515) Atg16l1fl/fl and Atg16l1LysM BMDMs (n=2) were analyzed by immunoblot. β-Actin 
served as loading control. MSR1: macrophage scavenger receptor 1 
 
Summing up, Atg16l1 deficiency did not result in a general endocytotic dysfunction as 



















































4.5.5 ATG16L1  D EF IC IE NC Y I NF LUE NC ES  PRO TE IN L EV E L S O F T HE  TLR4  N EG AT IV E  
REG ULA TOR A20  BU T N OT CYLD  UPON LPS  S TI MU LAT ION  
 
Protein levels of MyD88, TRIF and RIP1 were not affected and thus did not explain the 
prolonged activation of p38 and p65 in Atg16l1LysM BMDMs. Thus, the present study next 
focused on negative feedback loops as a regulatory mechanism of TLR4 signaling. 
NF-κB activation is controlled by a variety of negative feedback loops ensuring the 
downregulation of the TLR4 signaling cascade, e.g. tumor necrosis factor, alpha-induced 
protein 3 (Tnfaip3, also known as A20) and cylindromatosis (turban tumor syndrome) (Cyld) 
[242]. No alterations on protein levels of A20 and CYLD were observed in unstimulated 
Atg16l1LysM BMDMs when compared to Atg16l1fl/fl BMDMs (Figure 4-39). Challenging 
BMDMs for 6 h with LPS equally decreased the levels of CYLD in both, Atg16l1LysM and 
Atg16l1fl/fl macrophages. In contrast, protein levels of A20 were increased upon LPS 
stimulation in BMDMs of both genotypes. However, Atg16l1LysM macrophages showed a 
much stronger increase of A20 after LPS stimulation, which did not persist after inhibition of 
protein biosynthesis by cycloheximide (CHX). This result showed an LPS-mediated de novo 
synthesis of A20 which is amplified due to Atg16l1 deficiency. 
 
 
FIGURE 4-39:  ATG16L1  DEFICIENCY 
AFFECTS A20 BUT NOT CYLD  LEVELS 
Atg16l1fl/fl and Atg16l1LysM BMDMs 
were left unstimulated or stimulated for 
6 h with 25 ng/mL LPS (E.coli F515) in 
absence or presence of 1 µg/mL CHX 
(1 h prior to LPS). CHX or LPS alone 
served as controls. Protein extracts were 
immunoblotted. Using the indicated 
antibodies, proteins levels were 
detected. β-Actin served as loading 
control. CHX: cycloheximide 
 
To determine whether the elevated A20 levels directly resulted from the observed sustained 
p65 phosphorylation in Atg16l1LysM BMDMs mRNA expression levels of A20 were analyzed 
(Figure 4-40). In contrast to the detected differences in NF-κB-dependent cytokine 
expression (Figure 4-31), loss of Atg16l1 did not differentially modulate A20 expression 
compared to Atg16l1fl/fl BMDMs neither in absence nor in presence of LPS, which pointed to a 



















FIGURE 4-40:  SIMILAR MRNA  EXPRESSION OF A20 UPON 
LPS  STIMULATION IN ATG16L1LYSM  AND ATG16L1FL/FL  
MACROPHAGES  
Using SYBR green qPCR mRNA expression of A20/Tnfaip3 
was measured after RNA extraction of untreated or 
LPS-treated (25 ng/mL, E.coli F515) Atg16l1fl/fl and 
Atg16l1LysM BMDMs (n=4 per genotype). A20/Tnfaip3 
expression was normalized to Gapdh. Data represent mean 
± S.D. Statistical significance was evaluated using an 
unpaired Student´s t-test. 
 
This finding leads back to the hypothesis of a role for ATG16L1 in protein homeostasis. For 
this reason, protein degradation and trafficking was chemically inhibited during LPS 
stimulation in Atg16l1fl/fl and Atg16l1LysM macrophages (Figure 4-41 A). Inhibition of protein 
trafficking from the Golgi apparatus to the plasma membrane by Brefeldin A (BrefA) during 
LPS treatment did neither affect phosphorylation of p65 and p38 nor levels of A20. Inhibition 
of the proteasome using MG132 further increased LPS-induced phospho-p38 levels whereas 
phospho-p65 and A20 levels were only slightly enhanced compared to LPS-treated cells of 
both genotypes. In contrast, inhibition of lysosomal protein degradation means by treatment 
with Bafilomycin A (BafA) resulted in the opposite effect showing increased LPS-induced 
phospho-p65 and A20 levels but not phospho-p38 levels. Treatment with BafA and LPS 
further coincides with an increased CXCL1 secretion whereas LPS-induced CXCL1 secretion 
was slightly reduced by blocking proteasomal degradation (Figure 4-41 B).  
 
FIGURE 4-41:  INHIBITION OF LYSOSOMAL DEGRADATION DURING LPS STIMULATION LEADS TO A20  ACCUMULATION  
Atg16l1fl/fl and Atg16l1LysM BMDMs were stimulated for 8 h with DMSO as control, 25 ng/mL LPS (E.coli F515) 
alone or in combination with either 1 nM MG132, 100 nM BafA or 5 µg/mL BrefA 1h prior to LPS. Proteins were 
extracted and immunoblotted. Protein levels were detected using the indicated antibodies (A). β-Actin and 
unphosphorylated proteins served as loading controls. One representative immunoblot out of 3 individual 
experiments is shown. CXCL1 levels were determined in the appropriate supernatant by ELISA (B). ELISA results 
















































4.5.6 REACT IV E O X Y GE N SP EC I E S AM PL I FY  BUT  DO  NO T CAU S E LPS- INDUC ED  HY PER -
ACTIV ATI ON IN AT G16L1LYSM  BMDMS  
 
Recent studies suggested an immunoregulatory role for autophagy in NLRP3 activation via 
reactive oxygen species (ROS) due to impaired clearance of damaged mitochondria [22, 72, 
227]. For this reason, the impact of Atg16l1 deficiency in macrophages on ROS production 
and a putative role in the observed LPS-mediated hyper-activation was investigated.  
Analysis of Mitotracker staining using flow cytometry revealed a similar membrane potential 
of mitochondria in Atg16l1LysM BMDMs compared to Atg16l1fl/fl BMDMs (Figure 4-42 A). 
Similar results were also seen for ROS production under basal conditions (Figure 4-42 B). 
 
FIGURE 4-42:  ATG16L1  DEFICIENCY DOES NOT ALTER MITOCHONDRIAL MEMBRANE POTENTIAL AND ROS 
PRODUCTION IN MACROPHAGES  
Untreated Atg16l1fl/fl and Atg16l1LysM BMDMs were stained with either 1 µM Mitotracker Red (A) or 5 µM 
CellROX Deep Red (B) for 30 min at 37 °C and analyzed using flow cytometry. Representative histograms out of 
three independent experiments are displayed. 
 
To investigate whether increased ROS production might be responsible for the observed 
phenotype in macrophages lacking Atg16l1 BMDMs were stimulated with LPS alone or in 
combination with the ROS inhibitor diphenyleneiodonium (DPI) [243]. First, inhibitory 




FIGURE 4-43:  INHIBITION OF LPS-INDUCED PRODUCTION OF REACTIVE OXYGEN SPECIES IN BMDMS  
Atg16l1fl/fl and Atg16l1LysM BMDMs were treated for 24 h with 25 ng/mL LPS (E.coli F515) alone or in 
combination with 2 µM DPI that was administered 1 h prior to LPS. Cell were stained with 5 µM CellROX Deep Red 
for 30 min at 37°C and analyzed by flow cytometry. Representative histogram out of three independent 




























DPI specifically blocked LPS-induced ROS production in both, Atg16l1fl/fl and Atg16l1LysM 
BMDMs. Next, the functional impact of ROS within the LPS-mediated phenotype of 
Atg16l1LysM macrophages was analyzed on protein level (Figure 4-44 A). Stimulation with 
DPI alone does not result in altered protein levels. In contrast, inhibition of LPS-induced ROS 
production markedly decreased phosphorylation of p38 and p65 in Atg16l1fl/fl as well as 
Atg16l1LysM BMDMs. However, the observed differences in phospho-p38 and phospho-p65 
as well as on pro-IL1β levels persisted between Atg16l1LysM BMDMs compared to Atg16l1fl/fl 
cells suggesting an amplifying but not initial role for ROS within TLR4-mediated 
hyper-activation in Atg16l1LysM BMDMs. Interestingly, this phenomenon was not observed 
for A20 indicating a ROS-independent mechanism of regulating A20 levels. In agreement with 
the remaining differences in phosphorylation of p65, analysis of CXCL1 concentrations in the 
supernatant of BMDMs treated with LPS and DPI showed a diminished CXCL1 secretion 
compared to LPS-treated BMDMs with lasting differences between Atg16l1LysM and 
Atg16l1fl/fl BMDMs (Figure 4-44 B). 
 
 
FIGURE 4-44:  INHIBITION OF REACTIVE OXYGEN SPECIES AMELIORATES THE LPS-MEDIATED PHENOTYPE IN 
ATG16L1LYSM BMDMS 
Atg16l1fl/fl and Atg16l1LysM BMDMs were left unstimulated for 24 h or stimulated with either 25 ng/mL LPS 
(E.coli F515) or 2 µM DPI or in combination by administer DPI 1 h prior to LPS. Proteins were extracted; 
immunoblotted and indicated proteins were analyzed using the indicated antibodies (A). Unphosphorylated levels 
of the appropriate phosphorylated proteins as well as β-Actin served as loading controls. One representative 
immunoblot out of three independent experiments is displayed. CXCL1 concentrations were determined in the 
appropriate supernatant (n=3) by ELISA (B). Data represent mean ± S.D. and statistical significance was evaluated 













































4.5.7 CONS TI TUTIV E NF-ΚB  ACTIV ATI ON O CCUR S IN DEP END EN T OF IL1R  S I GNA L IN G 
IN AT G16L1LYSM  BMDMS  
 
Since pro-IL1β was stronger induced after LPS stimulation in Atg16l1LysM BMDMs compared 
to Atg16l1fl/fl BMDMs (Figure 4-44 A), a positive feedback loop of IL1β on long-term NF-κB 
activation was investigated using the IL1R antagonist Anakinra which was previously used in 
the in vivo study (Figure 4-45).  
 
 
FIGURE 4-45:  INHIBITION OF IL1R  SIGNALING DOES NOT AFFECT LPS-INDUCED NF-ΚB  ACTIVATION 
Atg16l1fl/fl and Atg16l1LysM BMDMs were left unstimulated for 24 h or stimulated with either 25 ng/mL LPS 
(E.coli F515) or 1 µg/mL Anakinra or in combination by administer Anakinra 1 h prior to LPS. Proteins were 
extracted; immunoblotted and indicated proteins were analyzed using the indicated antibodies (A). 
Unphosphorylated levels of p65 as well as β-Actin served as loading controls. One representative immunoblot out 
of three independent experiments is shown. CXCL1 concentrations were determined in the appropriate 
supernatant (n=3) by ELISA (B). Data represent mean ± S.D. and statistical significance was evaluated using an 
unpaired Student´s t-test. * p < 0.05, ** p < 0.01, Anak: Anakinra 
 
Anakinra treatment neither attenuated the basal nor the LPS-induced differences in p65 
phosphorylation and IκBα degradation between Atg16l1fl/fl and Atg16l1LysM BMDMs (Figure 
4-45 A). Corroborating these observations, augmented CXCL1 production of Atg16l1LysM 
BMDMs compared to Atg16l1fl/fl BMDMs persisted after treatment with the IL1R antagonist in 
presence and absence of LPS (Figure 4-45 B). Additionally, inhibition of IL1R signaling prior 
to LPS stimulation further increased the production of CXCL1.  
Taken together, these findings exclude a putative feedback loop of pro-IL1β on the 

















































4.6 ROLE OF ATG16L1  IN TLR4  SIGNALING IN VIVO  USING THE 
ENDOTOXIN SHOCK MODEL  
 
The in vivo impact of Atg16l1-deficiency on TLR4 signaling was further analyzed by 
challenging Atg16l1fl/fl and Atg16l1LysM mice with a sublethal dosage of LPS (E. coli KPM53) 
for 72 h. In this setting, four out of seven Atg16l1LysM mice died within the first 24 h of LPS 
treatment whereas all Atg16l1fl/fl mice survived (Figure 4-46). 
 
 
FIGURE 4-46:  SURVIVAL CURVE DURING 
SUBLETHAL ENDOTOXIN SHOCK  
Atg16l1fl/fl and Atg16l1LysM mice (n=7) 
received an intraperitoneal injection of 
5 mg/kg LPS (E.coli KPM53) or 5 µL/g 
PBS as control. Survival was monitored 
for 72 h and depicted in a Kaplan-Meier 
curve. Statistical significance was 
calculated using a log-rank test. 
* p < 0.05 
 
 
Validation of the organ weight after 72 h of LPS administration revealed a 
hepatosplenomegaly in Atg16l1fl/fl mice comparable to PBS- or LPS-treated Atg16l1LysM mice 
(Figure 4-47 A and B). Spleen and liver weight of Atg16l1LysM mice did not increase further 
by LPS treatment. 
 
FIGURE 4-47:  ORGAN WEIGHT AFTER 72 HOURS OF AN ENDOTOXIN-INDUCED SEPTIC SHOCK 
Spleen weight (A) and liver weight (B) of Atg16l1fl/fl and Atg16l1LysM mice (n=3-7) were assessed 72 h after an 
intraperitoneal injection of a sublethal dosis of 5 mg/kg LPS (E.coli KPM53) or 5 µL/g PBS as a control. Data 
represents mean ± S.D. and statistical significance was evaluated using an unpaired Student´s t-test. * p < 0.05, 
** p < 0.01, *** p < 0.001, **** p < 0.0001 
 
Analysis of the cytokine response within the first 6 h of LPS treatment showed markedly 
elevated levels of pro-inflammatory cytokines in the serum of Atg16l1LysM mice when 
compared to Atg16l1fl/fl mice (Figure 4-48).  







































































FIGURE 4-48:  CYTOKINE AND CHEMOKINE LEVELS DURING ENDOTOXIN-INDUCED SEPSIS  
Atg16l1fl/fl and Atg16l1LysM mice (n=4) were injected with a sublethal dosis of 5 mg/kg LPS (E.coli KPM53) for the 
indicated time points or with 5 µL/g PBS as control. Blood was collected in lithium-heparin tubes and serum was 
analyzed using the Bio-Plex Pro™ Mouse Cytokine 23-plex Assay (BioRad) or ELISA. Data are depicted as mean. 
Statistical significance was calculated using an unpaired Student´s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001 
 
Consistent with the mortality rate, approximately 50 % of Atg16l1LysM mice showed highly 
upregulated cytokines, e.g. IL1β, MIP1β, TNFα or IL18.  
These results provide in vivo evidence that Atg16l1 deletion in the myeloid lineage increases 
sensitivity and severity to a sublethal LPS-induced septic shock resulting in an elevated 
cytokine production of pro-inflammatory cytokines.  
 
4.7 IMPACT OF MICROBIOTA ON THE BASAL ATG16L1LYSM  PHENOTYPE  
 
To gain further insights into the in vivo relevance of the observed LPS hyper-sensitivity, the 
role of gut resident microbiota, as a natural source of endotoxin, was investigated with 
respect to the manifestation of the Atg16l1LysM phenotype. Adult Atg16l1fl/fl and Atg16l1LysM 
mice were treated with an antibiotic cocktail in order to deplete the intestinal microflora. 
Both, antibiotic-treated Atg16l1fl/fl and Atg16l1LysM mice, lost weight within the first week 









































































































FIGURE 4-49:  BODY WEIGHT LOSS DURING ANTIBIOTIC TREATMENT  
8-12 week-old Atg16l1fl/fl and Atg16l1LysM mice (n=5) were treated with an antibiotic cocktail administered via 
drinking water for 4 weeks. The control groups (n=3) received water without treatment. Neomycin was removed 
from the antibiotic cocktail at day 7. Body weight was monitored every day and is depicted in a graph as mean ± 
S.D. ABx: antibiotics 
 
Fecal microbial populations were analyzed using the non-parametric index of Shannon 
diversity that takes presence and absence as well as bacterial abundance into account (Figure 
4-50). Microbial populations were diminished from day 7 up to day 28 in the feces of both, 
Atg16l1fl/fl and Atg16l1LysM mice indicating a successful microbial depletion.  
 
FIGURE 4-50:  SUCCESSFUL MICROBIAL DEPLETION IN THE FECES OF ANTIBIOTIC-TREATED MICE  
An antibiotic cocktail was administered via drinking water to Atg16l1fl/fl and Atg16l1LysM mice (n=5) over a 
period of 4 weeks. Feces were collected every 7 days. Bacterial DNA was isolated and 16SrDNA sequencing was 
performed using the MiSeq sequencer (Illumina, San Diego, USA). Diversity of microbial populations in feces of 
Atg16l1fl/fl mice (A) and Atg16l1LysM mice (B) was assessed using the non-parametric Shannon's index. 
 
Organ weight of Atg16l1fl/fl and Atg16l1LysM mice was analyzed after 4 weeks of antibiotic 
treatment (Figure 4-51). As described, pathological indicators appear as a result of a 
diminished intestinal microbial community [244]. Thus, antibiotic treatment resulted in 
reduced spleen weight and enlarged ceca in mice of both genotypes (Figure 4-51 A and B).  


































































FIGURE 4-51:  SPLEEN AND CAECUM WEIGHT AFTER ANTIBIOTIC TREATMENT  
Spleen (A) and caecum weight (B) of adult Atg16l1fl/fl and Atg16l1LysM mice (n=1-5) were analyzed after 4 weeks 
of antibiotic treatment. Data are shown as mean ± S.D. and statistical significance was evaluated by an unpaired 
Student´s t-test. * p < 0.05, ** p < 0.01, ABx: antibiotics 
 
Whereas all Atg16l1fl/fl mice showed a reduced spleen weight, only three out of five 
Atg16l1LysM mice demonstrated a decrease in spleen weight after antibiotic treatment 
compared to untreated Atg16l1LysM mice (Figure 4-51 A). However, these two mice do not 
match with the once having a higher microbial diversity from day 21 on (Figure 4-50 B). 
Measurements of cytokine concentrations in serum revealed no changes in antibiotic-treated 
Atg16l1fl/fl mice compared to untreated mice (Figure 4-52). Atg16l1LysM mice showed 
significantly reduced IL18 levels after the antibiotic cocktail. IL12p40 was not affected and 
MIP1β was even increased. 
 
FIGURE 4-52:  CYTOKINE LEVELS IN SERUM OF ANTIBIOTIC-TREATED ATG16L1LYSM AND ATG16L1FL/FL  MICE 
Blood from untreated and antibiotic-treated Atg16l1fl/fl and Atg16l1LysM mice (n=3) was collected in lithium-
heparin tubes and analyzed using the Bio-Plex Pro™ Mouse Cytokine 23-plex Assay (BioRad) or ELISA. Data 
represent mean ± S.D. Results were tested for statistical significance using an unpaired Student´s t-test. * p < 0.05, 
** p < 0.01, *** p < 0.001, ABx: antibiotics 
 
Expression analysis of cell type-specific markers still displayed a reduced expression of Cd3e 
and Cd19 in the spleen of antibiotic-treated Atg16l1LysM mice compared to Atg16l1fl/fl mice 






























































































FIGURE 4-53:  EXPRESSION OF CELL TYPE SPECIFIC MARKERS IN THE SPLEEN AFTER ANTIBIOTIC TREATMENT  
Atg16l1fl/fl and Atg16l1LysM mice were left untreated (n=3) or treated for 4 weeks with an antibiotic cocktail 
(n=5). RNA from liquid nitrogen frozen spleens was extracted and transcribed into cDNA. Expression levels of the 
indicated cell type specific markers were measured by SYBR® green qPCR and normalized to Gapdh. Expression 
of Mpo was measured by TaqMan Assay. Data represent mean ± S.D. and statistical analysis was performed with 
an unpaired Student´s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001, ABx: antibiotics 
 
On the other hand, microbial depletion normalized Cd11b expression in Atg16l1LysM to 
expression levels in untreated as well as antibiotic-treated Atg16l1fl/fl mice. Antibiotic 
treatment resulted in diminished expression of the neutrophil marker Mpo in the spleens of 
both, Atg16l1fl/fl and Atg16l1LysM mice, which was further confirmed by 
immunohistochemistry (Figure 4-54). 
 





































































FIGURE 4-54:  MICROBIAL DEPLETION RESULTS IN REDUCED NUMBERS OF SPLENIC MPO+  CELLS IN ATG16L1LYSM 
MICE 
Atg16l1fl/fl and Atg16l1LysM mice were left untreated (n=3) or treated with an antibiotic cocktail for 4 weeks 
(n=5). Spleens were formalin-fixed and paraffin-embedded and stained for MPO+ cells. Representative images 
analyzed by transmission light microscopy are shown. Scale bars represent 50 µm. MPO: myeloperoxidase 
 
As the spleen weight of untreated Atg16l1LysM mice varied from two to ten times larger 
when compared to their Atg16l1fl/fl littermates (Figure 4-5 B), interpretation whether the 
spleen weight was specifically reduced based on the use of antibiotics remains speculative. 
Suggesting that adult Atg16l1LysM mice with an age of 8-12 weeks already developed a very 
prominent phenotype, a second preventive antibiotic treatment was performed starting 






















Gross examination of Atg16l1LysM mice at the age of 3 weeks showed neither an increased 
small intestine length nor liver weight compared to Atg16l1fl/fl mice (Figure 4-55). However, 
even at the age of 3 weeks Atg16l1LysM mice developed a significant splenomegaly, which 
was completely rescued by inhibition of the microbial colonization after birth. A successful 
microbial depletion was determined by the significantly increased caecum weight serving as 
a pathological indicator in antibiotic-treated mice [244].  
 
 
FIGURE 4-55:  ORGAN WEIGHT AND LENGTH AFTER PREVENTIVE ANTIBIOTIC TREATMENT  
Spleen (A), liver (B) and caecum weight (C) as well as small intestine length (D) were analyzed after control 
sucrose treatment (n=12-16) and preventive antibiotic treatment (n=3-8) of 3-week old Atg16l1fl/fl and 
Atg16l1LysM mice. Data are shown as mean ± S.D. and statistical significance was evaluated by an unpaired 
Student´s t-test. * p < 0.05, **** p < 0.0001, ABx: antibiotics, Ctrl: control 
 
Analysis of the splenic cell composition revealed an attenuated T cell population in 
Atg16l1LysM mice after preventive antibiotic treatment (Figure 4-56 A).  
 
FIGURE 4-56:  SPLENIC CELL COMPOSITION AFTER PREVENTIVE ANTIBIOTIC TREATMENT  
Splenic cell composition of 3 week old Atg16l1fl/fl and Atg16l1LysM mice preventively treated with an antibiotic 
cocktail (n=3-5) or 2 % sucrose (n=5) as control was analyzed by flow cytometry. Percentage of the individual 
adaptive (A) and innate (B) immune cell population was corrected for the particular isotype control. Data are 
shown as mean ± S.D. Statistical significance was calculated by an unpaired Student´s t-test. * p < 0.05, ** p < 0.01, 
ABx: antibiotics, Ctrl: control 
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Although increased populations of CD11b+ and CD11c+ cells persisted in Atg16l1LysM mice, 
the number of CD11b+/Ly6G+ cells was markedly decreased in both, antibiotic-treated 
Atg16l1fl/fl and Atg16l1LysM mice (Figure 4-56 B). A similar pattern was observed for the 
activation status of innate and adaptive immune cells (Figure 4-57). Whereas the decreased 
T cell activation was restored in Atg16l1LysM mice after microbial depletion (Figure 4-57 A), 
CD11b+ cells of Atg16l1LysM mice continuously expressed increased activation markers at 
their cell surface compared to antibiotic-treated Atg16l1fl/fl mice (Figure 4-57 B). 
 
FIGURE 4-57:  ACTIVATION STATUS OF SPLENIC IMMUNE CELLS AFTER PREVENTIVE ANTIBIOTIC TREATMENT  
Atg16l1fl/fl and Atg16l1LysM mice were preventively treated with an antibiotic cocktail (n=3-5) or 2 % sucrose 
(n=5) as control. Splenocytes were isolated and stained for the indicated antigen combinations or particular 
isotype controls and analyzed by flow cytometry. Percentage of the indicated T cell activation markers (A) or 
myeloid cell activation markers (B) was corrected for the particular isotype control. Data are shown as mean ± S.D. 
An unpaired Student´s t-test was performed to evaluate statistical significance. * p < 0.05, ** p < 0.01, 
ABx: antibiotics, Ctrl: control 
  
Since preventive antibiotic treatment ameliorated the suppressed T cell phenotype of 
Atg16l1LysM mice, expression of MDSC-associated genes was analyzed (Figure 4-58). 
Antibiotic-treated Atg16l1LysM mice demonstrated a significant reduction of Mpo, S100a8 
and S100a9 expression in the spleen compared to the appropriate control group. 
 






























































































































FIGURE 4-58:  ATTENUATED EXPRESSION OF MDSC-ASSOCIATED GENES IN THE SPLEEN OF  ATG16L1LYSM MICE 
AFTER PREVENTIVE ANTIBIOTIC TREATMENT  
Spleens of Atg16l1fl/fl and Atg16l1LysM mice preventively treated with an antibiotic cocktail (n=3-5) or 2 % 
sucrose as control were snap frozen and mortared. RNA extraction and cDNA synthesis were performed. 
Expression of the indicated targets was analyzed by SYBR® green qPCR and normalized to Gapdh. Expression of 
Mpo was analyzed by TaqMan Assay. Data show mean ± S.D. Statistical significance was calculated with an 
unpaired Student´s t-test. * p < 0.05, *** p < 0.001, ABx: antibiotics, Ctrl: control, Mpo: myeloperoxidase 
 
Taken together, inhibition of the colonization of the commensal microbial community in 
Atg16l1LysM mice partially attenuated the spontaneous phenotype by rescuing the 








































































5 DISCUSSION  
 
Autophagy plays a decisive role in maintaining the cellular homeostasis of eukaryotic cells 
through degradation and recycling of proteins and organelles [6]. Imbalance of this sensitive 
homeostasis as a result of genetic variants in autophagy-related genes is associated with 
numerous human diseases like inflammatory bowel disease [64], asthma [245] and various 
types of cancer [246-249]. For this reason, molecular functions of the individual autophagic 
components in inflammatory processes were intensively studied during the last years but 
still remain incompletely understood. Because macrophages represent the first line of 
defense in the immune response, the aim of the present study was to investigate the impact of 
ATG16L1 on inflammatory signaling pathways and cytokine production in myeloid cells. 
Using a myeloid-specific knock-out mouse model the results obtained in the study presented 
here combines for the first time in vivo as well as ex vivo data showing a vital role for 
ATG16L1 in immunoregulatory processes. 
 
5.1 CHARACTERIZATION OF T HE ATG16L1LYSM  MOUSE MODEL  
 
5.1.1 SPO NTAN EOU S S Y STE M I C IN FL AM MA TI ON I N AT G16L1LYSM  M IC E  
 
In contrast to Atg16l1 chimeric mice [22], the present study demonstrated that mice lacking 
Atg16l1 in the myeloid lineage develop a multifaceted spontaneous phenotype characterized 
by systemic inflammatory symptoms. Gross examination of Atg16l1LysM mice displayed a 
hepatosplenomegaly and lymphadenopathy. In detail, Atg16l1LysM mice showed an extensive 
extramedullary hematopoiesis in the spleen accompanied by increased numbers of myeloid 
cells in spleen, lymph nodes, liver and peripheral blood. Although these abnormalities at first 
sight resemble clinical symptoms of a chronic myeloid leukemia (CML) in humans [250], bone 
marrow of Atg16l1LysM mice did not reveal any histological anomalies in myeloid 
differentiation. These findings exclude CML as cause of the spontaneous phenotype seen in 
Atg16l1LysM mice. Similarly, an equal numbers of myeloid cells were detected in the bone 
marrow of Atg5LysM and Atg5fl/fl control mice [46]. However, Atg16l1LysM mice exhibited 
significantly elevated serum levels of pro-inflammatory cytokines and significantly 
upregulated numbers of activated CD11b+ myeloid cells in the peripheral blood and lymphoid 
organs.  
Surprisingly, the basal inflammatory phenotype of mice lacking other Atg genes in the 
myeloid lineage appears less prominent. Both, Atg5LysM and Atg7LysM mice solely develop a 
spontaneous inflammation in the lung [46, 251, 252]. Similar to the cytokine expression 
profile observed in the spleen of Atg16l1LysM mice, Atg5LysM and Atg7LysM mice show 
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increased pulmonary expression levels of various pro-inflammatory cytokines like Il1a and 
Tnfa. Further, increased mRNA levels of the neutrophil-attracting chemokine Cxcl1 coincides 
with a substantial infiltration of CD11b+/Ly6G+ neutrophils in the lung of Atg5LysM and 
Atg7LysM mice recapitulating the observed inflammatory characteristics in the spleen of 
Atg16l1LysM mice. In line with the presented findings in Atg16l1-deficient CD11b+ cells of the 
spleen, untreated Atg5-deficient alveolar macrophages demonstrated an inflammatory 
phenotype characterized by upregulation of activation markers like MHCII [46]. In contrast to 
Atg7-deficient macrophages showing an increased cell surface expression of inflammation 
inhibitory receptors such as macrophage scavenger receptor 1 (MSR1), protein levels of 
MSR1 were comparable between BMDMs of Atg16l1LysM and Atg16l1fl/fl mice. Bonilla and 
colleagues reported a less efficient depletion of Atg7 in splenic macrophages corresponding 
with a less prominent phenotype in Atg7LysM mice which could explain the distinct 
phenotypes in autophagy-deficient mouse models [47]. 
Summing up, loss of Atg16l1 in the myeloid lineage leads to a complex inflammatory 
phenotype in mice under physiological conditions whose individual aspects are discussed in 
more detail below. 
 
5.1.2 MYE LO ID-DER IV ED  S UPPRE S S OR C EL L-LI K E C E LL PO PUL ATI ON  IN  
ATG16L1LYS M  M IC E  
 
CD11b+/Ly6G+ cells account for less than 5 % in the spleen under healthy conditions and are 
absent in lymph nodes [253]. However, Atg16l1LysM mice showed significantly increased 
numbers of CD11b+/Ly6G+ myeloid cells in the spleen and the peripheral blood. Beside 
differentiated neutrophils, a second cell type, namely myeloid-derived suppressor cells 
(MDSCs), are described to co-express CD11b and Ly6G [254] and exhibit a potent 
immunosuppressive function on T cells [221]. MDSCs expand in blood, spleen and lymph 
nodes under pathological conditions, e.g. infections, inflammation and cancer [221]. Although 
myeloid cells of Atg16l1LysM mice demonstrated a strong inflammatory phenotype, the 
overall number of T cells was significantly diminished. In line with the proposed 
immunosuppressive function of CD11b+/Ly6G+ myeloid cells on T cells, the number of 
activated CD3+/CD25+ and CD4+/CD95+ T cells remained unaffected in Atg16l1LysM mice. 
The inhibitory capacity of MDSCs is mainly mediated by two mechanisms: (I) depletion of the 
conditionally essential amino acid L-arginine from the extracellular environment by 
arginase-1 and (II) production of nitric oxide (NO) and reactive oxygen species (ROS) by 
inducible nitric oxide synthase (iNOS) [221, 255]. Indeed, iNOS was strongly upregulated in 
the spleen of Atg16l1LysM mice suggesting that iNOS could contribute to T cell suppression in 
these mice. Increased MPO levels are another hallmark of MDSCs [256] but MPO is also stored 
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in large amounts in azurophilic granules of neutrophils that are released after neutrophil 
activation as part of the antimicrobial system [257]. Atg16l1LysM mice obtained increased 
numbers of MPO+ cells in spleen, lymph nodes, liver and lung determined by 
immunohistochemistry. However, it needs to be further investigated whether the differences 
in MPO observed in Atg16l1LysM mice results from increased numbers of neutrophils or the 
development of a MDSC-like cell population. Further, it has been reported that IL1β and the 
antimicrobial peptides S100A8/A9, both upregulated in the spleen of Atg16l1LysM mice, play 
an important role in activation and expansion of MDSCs promoting an autocrine feedback 
loop [258, 259]. Yet, it must be emphasized that so far unequivocal markers of MDSCs are not 
defined as most of the described principles are also hallmarks of inflammation. 
Taken together, CD11b+/Ly6G+ cell populations in lymphoid organs and the peripheral blood 
of Atg16l1LysM mice putatively represent a MDSC-like population that in turn may drive 
suppression of the T cell activation profile and expansion in these mice. However, a direct 
immunosuppressive capability of CD11b+/Ly6G+ cells of Atg16l1LysM mice on T cells needs to 
be demonstrated.  
 
5.1.3 A  PIV OT AL RO L E FOR T HE C OM M EN SA L M ICR O BIO TA IN T HE D EV E LO P ME NT O F 
THE IN FL AM MA TOR Y  AT G16L1LYS M  PH EN OT YP E  
 
Depletion of the intestinal microbiota using antibiotics was accompanied by a slightly 
ameliorated spleen size and a diminished infiltration of splenic MPO+ myeloid cells in adult 
Atg16l1LysM mice. These observations lead to the hypothesis of a decisive role for the 
commensal microbial community in the manifestation of the spontaneous Atg16l1LysM 
phenotype. This was even more pronounced by the inhibition of intestinal microbial 
colonization through a preventive administration of antibiotics which completely rescued the 
splenomegaly and significantly diminished the expression of Mpo as well as S100a8/9 in 
Atg16l1LysM mice. Coinciding with the normalization of these supposed MDSC-like 
characteristics, the diminished numbers of CD3+ T cells and CD4+/CD95+ activated T cells in 
the spleen was entirely restored. In a study investigating MDSC induction in tumor-bearing 
mice the phenomenon was also abrogated after depletion of commensal bacteria [260]. These 
findings point towards a regulatory function of the commensal microbiota on MDSC 














FIGURE 5-1:  PROPOSED MECHANISM FOR THE 
IMPACT OF THE COMMENSAL MICROBIOTA ON 
THE MANIFESTATION OF THE ATG16L1LYSM  
PHENOTYPE 
Loss of Atg16l1 in the myeloid lineage results in 
an inflammatory conditions partially mediated 
by the hyper-sensitivity to the commensal 
intestinal microbiota. Postnatal colonization of 
the commensal microbiota might be involved in 
the appearance and activation of a myeloid-
derived suppressor cell (MDSC)-like cell 
population. Subsequent MDSC-dependent 
cytokine production triggers the expansion and 
migration of MDSC-like cells into lymphoid 
organs and the peripheral blood and thus 
facilitates the T cell suppression via the 
expression of inducible nitric oxide synthase 
(iNOS).  
 
In line with findings in Atg16l1LysM mice presented here, a one-week intranasal antibiotic 
therapy of 2 week-old Atg7LysM mice reduced the levels of pro-inflammatory cytokines as 
well as neutrophil infiltration in the lung [251]. Moreover, preventive antibiotic treatment 
from prenatal stage to 3 weeks of age rescued the lung phenotype of Atg7LysM mice [251]. 
Thus, the postnatal microflora seems to act as crucial trigger for the spontaneous 
inflammation in mouse models lacking autophagy-related genes in the myeloid lineage. 
However, Atg5LysM and Atg7LysM mice as well as Atg16l1 chimeric mice demonstrated 
increased numbers of CD4+ T cells and regulatory T cells [22, 46, 251]. A conceivable 
explanation for the distinct phenotypes, might be the individual cellular functions of Atg 
proteins in various autophagy-independent processes like secretion of hormones and 
cytokines [261]. On the other hand, differences within microbial communities might give 
reason for dissimilarities in the presence of MDSC-like cell populations and T cell numbers in 
autophagy-deficient mouse models. Recent studies reported the capability of bacterial 
components, like the TLR-ligands LPS [262] and Flagellin [263], to elicit MDSCs. In this 
context, analysis of the microbial composition would enable the identification of specific 
MDSC-associated microbial communities. However, the research field of MDSC development, 
mobilization and expansion is still poorly understood and controversially discussed. Thus, 
further analysis is required and subject of ongoing studies. 
On the other hand, (activated) CD11b+ myeloid cells did not show reduced numbers after 
prenatal antibiotic treatment. Since antibiotic treatment strongly decreases but do not 
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completely abolish intestinal microbes, this phenomenon might reflect the hyper-sensitivity 
of CD11b+ myeloid cells towards the remaining microbes. Moreover, it is noteworthy that an 
effect of the antibiotics itself on the phenotype cannot be fully ruled out. Rederivation of the 
Atg16l1LysM mouse model into germ-free conditions could exclude antibiotics as an 
influencing factor and might probably normalize the hyper-activation state of CD11b+ 
myeloid cells. This might finally elucidate the role of the commensal microbiota in the 
manifestation of the systemic inflammatory phenotype in Atg16l1LysM mice. 
 
5.1.4 D IS PE NS AB LE R O LE F OR IL1  C YT OK IN ES  I N TH E D EV EL OP M ENT  OF  TH E  
IN FLA M MAT OR Y PH EN O TY P E I N ATG16L1LYSM  MI CE A ND BMDMS  
 
A noteworthy in vivo observation in Atg16l1LysM mice comprised an upregulation of 
interleukin-1 (IL1) family members. In line with this observation, untreated Atg5LysM mice 
and Atg7LysM mice also showed augmented pulmonary expression of Il1a and Il1b, 
respectively, suggesting a crucial role for IL1 cytokines in the development of inflammation in 
autophagy-deficient mice [46, 252]. Moreover, Atg16l1-deficient macrophages showed 
significantly upregulated Il1a and Il1b mRNA expression resulting in higher intracellular 
levels of pro-IL1β and significantly increased IL1α secretion in response to LPS compared to 
wild type BMDMs. Accordingly, previous studies implicated a role for autophagy and 
ATG16L1 as regulator of interleukin-1 receptor (IL1R) signaling [60] and effector of IL1 
cytokine production [22, 46, 72, 227]. 
However, the spontaneous inflammatory phenotype of Atg16l1LysM mice still persisted after 
a 2-week-treatment with the competitive IL1R inhibitor Anakinra. Interestingly, spontaneous 
inflammation in the lung of Atg7LysM mice did also not attenuate in response to 
subcutaneous Anakinra administration [252]. These results weaken the hypothesis of IL1α 
and IL1β as central mediators of the spontaneous inflammatory phenotype in autophagy-
deficient mice. Moreover, inhibition of IL1R signaling by Anakinra in ex vivo differentiated 
Atg16l1LysM BMDMs did neither diminish LPS-induced prolonged NF-κB signaling nor 
increased CXCL1 production. For this reason, TLR4-mediated IL1α/β production can be 
excluded as amplifying feedback loop in Atg16l1-deficient macrophages. 
Although several studies used a comparable experimental setup of a daily Anakinra injection 
[228, 252], it is worth mentioning that the terminal half-life of Anakinra ranges from 4 to 
6 hours [264]. This fact might speak against an efficient inhibition of IL1α and IL1β activity by 
a single daily dose. Contradicting this argument, pharmacokinetics of Anakinra in mice, 
receiving a single dosage regime comparable to the concentration used in the presented 
study, indeed showed a half-life of the IL1R antagonist of approximately 6 hours in serum but 
a prolonged accumulation for up to 12 hours in liver and kidney [214]. Moreover, a single 
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daily dose of Anakinra resulted in a less severe chemically-induced colitis after 5 days [265] 
indicative for a sufficient inhibition of IL1R signaling already after a short duration treatment.  
Maturation of the inactive IL1β precursor into its active form is restricted to proteolytic 
cleavage by caspase-1 [266]. As part of the inflammasome, caspase-1 activation is initiated 
through the formation of a multimeric complex consisting of an eponymous sensor molecule 
like NLRP3, the adaptor molecule ASC and the immature pro-form of caspase-1 [267]. The 
NLRP3 inflammasome is a well-characterized multiprotein complex and its activation can be 
triggered by mitochondrial ROS production [72]. However, under basal conditions, loss of 
Atg16l1 in macrophages neither affected mitochondrial membrane potential and thus 
mitochondrial homeostasis nor intracellular ROS production and pro-IL1β level in the 
presented study.  
With respect to the reported role of autophagy in IL1 cytokine production and/or secretion 
[22, 46, 72, 227], Atg16l1LysM BMDMs unexpectedly demonstrated similar ROS levels 
compared to Atg16l1fl/fl BMDMs in response to LPS. In contrast, a significant upregulation of 
Il1b on transcriptional levels was observed. These results corresponded with a stronger 
increase of pro-IL1β protein levels. Interestingly, the increased levels of pro-IL1β in 
Atg16l1LysM BMDMs correlated with increased phospho-p65 and phospho-p38 levels which 
are crucial signaling mediators of the IL1R/TLR superfamily [268]. In agreement with the 
described ex vivo data, spleens of Atg16l1LysM mice revealed elevated levels of pro-IL1β but 
not pro-Casp1, Nlrp3 or Asc, at least on transcriptional level. This finding suggests an 
NLRP3-independent regulation of pro-IL1β in the absence of Atg16l1. In contrast to the 
presented ex vivo findings, studies in Atg16l1-deficient fetal liver-derived macrophages 
showed an elevated ROS-dependent IL1β secretion but not transcription [22]. Additionally, 
Saitoh and colleagues did neither observe an increased activation of NF-κB nor IRF3 or p38 
MAPK implicating a regulatory role for ATG16L1 in IL1β secretion exclusively via the NLRP3 
inflammasome. The major reason for the different study outcomes might be the initial 
conditions. Whereas macrophages in Saitoh´s study were derived from the fetal liver of a 
phenotypically inconspicuous constitutive knock-out model of Atg16l1 [22], Atg16l1LysM 
macrophages originated from the bone marrow of tissue-specific knock-out mice already 
showing a very prominent inflammatory phenotype. In addition, differentiation of BMDMs in 
the presented study was achieved with mCSF treatment. In contrast, Atg16l1-deficient fetal 
liver-derived macrophages were ex vivo differentiated using the granulocyte macrophage 
colony-stimulating factor (gmCSF) which mainly facilitates the differentiation of dendritic 
cells [269]. Thus, different pathological conditions could also affect the ex vivo phenotype of 
Atg16l1-deficient macrophages in response to LPS.  
Inhibition of NAD(P)H oxidase-derived ROS using DPI [243] markedly reduced LPS-induced 
pro-IL1β levels in Atg16l1fl/fl and Atg16l1LysM BMDMs and was associated with decreased 
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levels of phosphorylated p65, IκBα and p38. Nevertheless the observed differences in 
phospho-p65, phospho-p38 and pro-IL1β persisted in Atg16l1LysM BMDMs coinciding with a 
lasting elevated CXCL1 secretion. Recent studies linked an impaired autophagic machinery to 
ROS-dependent inflammasome activation mediated by calpain activation, defective 
mitophagy and/or disrupted elimination of the inflammasome itself [46, 71, 72, 227]. 
However, the findings presented here point to mitochondrial ROS production as amplifier but 
not initiator of LPS-induced differences in NF-κB and MAPK activation as well as cytokine 
secretion in Atg16l1-deficient macrophages.  
Despite pro-IL1β in the spleen, untreated Atg16l1LysM mice showed significantly enhanced 
serum levels of the pro-inflammatory cytokine IL18, another component of the IL1 cytokine 
family. However, mRNA expression of Il18 was significantly diminished in the spleen of 
Atg16l1LysM mice. One might speculate that decreased Il18 mRNA expression reflects a 
compensatory effect of the hyper-inflammatory state in the spleen or that the loss of Atg16l1 
rather affects IL18 maturation and/or secretion than expression. Interestingly, maturation of 
IL1β and IL18 is equally processed by caspase-1 [266]. In contrast, IL1β- and IL18-initiated 
signaling is mediated by distinct receptors, namely IL1 receptor and IL18 receptor [270, 271]. 
This fact excludes IL18 as target for Anakinra [272]. Consistent with serum cytokine levels of 
untreated Atg16l1LysM mice, fetal liver-derived macrophages lacking Atg16l1 secreted higher 
amounts of IL18 in response to LPS [22]. In vivo neutralization of IL1β and IL18 using a 
combination of specific antibodies significantly ameliorated the severe dextran sodium 
sulfate (DSS)-induced colitis in Atg16l1 chimeric mice. In agreement with these results, IL18 
neutralizing antibodies prevented the spontaneous lung inflammation in adult Atg7LysM 
mice [252] pointing towards a role for IL1 cytokines in inflammatory processes of mice with 
defects in the autophagic machinery. 
However in conclusion, the obtained in vivo and ex vivo results suppose a dispensable role for 
IL1α and IL1β in the development of the inflammatory phenotype of Atg16l1LysM mice and 












5.2 AUTOPHAGY AS A NEGATIVE REGULATOR O F TLR4  SIGNALING  
 
5.2.1 LOS S O F AT G16L1  L EAD S TO IN CR EA S ED TLR4-ME DIA TE D NF-ΚB  S I GN ALI N G  
 
Studies in Atg16l1LysM BMDMs provided first evidence that ATG16L1 might act as crucial 
regulator in TLR4-mediated signaling. An earlier, stronger and prolonged activation of 
canonical NF-κB but also p38 MAPK signaling in response to LPS was observed. Specifically, 
differences in p65 and p38 MAPK activation at the early time points, in which no 
pro-inflammatory cytokines were yet produced, indicate that loss of Atg16l1 in macrophages 
directly modulates the TLR4 signaling cascade which in turn causes the significant increase in 
secretion of pro-inflammatory cytokines. In line with this observation, LPS-stimulated 
macrophages deficient for the autophagy-related gene Irgm1 display an elevated and 
prolonged p65 and p38 signaling coinciding with increased pro-inflammatory cytokine 
secretion [61] suggesting a general role for autophagy in the regulation of TLR4 signaling. 
The described inflammatory characteristics of untreated Atg16l1LysM mice phenocopy in 
large parts the pathologic phenotype of mice with defects in essential regulators of NF-κB 
signaling. Constitutive activation of NF-κB in IkBa-deficient mice resulted in extensive 
granulopoiesis and pro-inflammatory cytokine production [209]. Mice lacking the NF-κB 
negative feedback mediators Cyld or A20 developed exacerbated lymphoid organ 
abnormalities and abnormal B cell responses as well as multi-organ inflammation, cachexia 
and premature lethality, respectively [208, 273, 274]. Hence, the inflammatory symptoms of 
Atg16l1LysM mice are another indication for a putative regulatory function of ATG16L1 in 
NF-κB signaling. This presumption is further supported by the above discussed fact that 
Atg16l1LysM mice demonstrate a hyper-responsiveness towards the commensal microbiota 
which is a key player contributing to the host´s immune homeostasis [275]. Similarly, the 
severe phenotype of A20-deficient mice was caused by homeostatic MyD88-dependent NF-κB 
signaling triggered by the commensal microbiota [208]. It should be noted, however, that 
activation of NF-κB is induced by an exceptionally large number of more than 150 stimuli 
including pathogens but also stress conditions and pro-inflammatory cytokines [276]. This 
fact complicates the interpretation of a potential molecular mechanism in which ATG16L1 
might affect NF-κB signaling in vivo. 
However, in agreement with the ex vivo results presented in this thesis, Atg16l1LysM mice 
showed a severe susceptibility to a sublethal endotoxin-induced septic shock displaying more 
than 50 % mortality associated with remarkably increased serum levels of key acute phase 
cytokines like TNFα, IL1β and IL12. Contributing to these findings, a recently published study 
reported an association of the T300A polymorphism in the human ATG16L1 gene with septic 
shock in patients with ventilator-associated pneumonia [277]. Constitutive or tissue-specific 
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deletion of autophagy-related genes like Atg7 [252], Irgm1 [61], Map1lc3b and Becn1 [222] 
caused a comparable severe phenotype in response to LPS which confirms the idea that an 
intact autophagic machinery serves as a protective factor in sepsis development [278, 279].  
 
5.2.2 ATG16L1  OR CH ES TRA TE S  IN F IRS T LI NE MYD88-  BUT N OT TRIF-ME DIA TE D  
SI GN AL IN G  
 
Corresponding to the increased canonical NF-κB and p38 MAPK signaling detected in 
Atg16l1LysM BMDMs after LPS stimulation, the NF-κB targets IL1α and CXCL1 were 
significantly increased. Activation of transcription factors via TLR4-induced signaling is 
mediated by specific adaptor molecules. In contrast to NF-κB signaling, which is initiated by 
both TLR4 adaptor molecules, MyD88 and TRIF, expression of type I interferons is tightly 
regulated by a TRIF-dependent activation of the transcription factors IRF3 and IRF7 [187, 
280-282]. Precisely, internalization of the activated TLR4 complex to early endosomes 
represents an essential step which facilitates the recruitment of the TRIF-TRAM complex and 
results in the subsequent activation of IRF3/7 initiating the transcription of type I interferons 
like Ifnb [186, 283, 284]. Interestingly, mRNA and protein levels of IFNβ in Atg16l1LysM 
BMDMs were comparable to Atg16l1fl/fl control BMDMs in absence and presence of LPS. This 
leads to the hypothesis that ATG16L1 specifically regulates NF-κB-mediated signal 
transduction but is not capable of modulating the type I interferon signaling pathways. In 
addition, unchanged IFNβ levels also allow the conclusion to be drawn about a functional 
TLR4 internalization and ensuing endosomal TLR4 signaling which mediates a functional 
induction of the TRAM-TRIF pathway in absence of Atg16l1. Together with the observation 
that CD95 is functionally internalized in Atg16l1LysM BMDMs, the presented findings point to 
an intact TLR4 receptor internalization capacity in Atg16l1-deficient macrophages with only 
the MyD88-TRAF6 signaling downstream of the LPS-induced TLR4 activation being affected. 
It is known that TRIF-mediated signaling is able to orchestrate late NF-κB signaling [187]. 
However, hyper-activation of NF-κB and p38 MAPK signaling pathways occurred already 
within the first hour after TLR4 activation in Atg16l1LysM BMDMs. This finding indicates that 
loss of Atg16l1 primarily affects the early MyD88-dependend NF-κB response [285]. 
Peritoneal macrophages derived from Irgm1-deficient mice revealed a similar reaction 
pattern to LPS within the first 2 hours which was illustrated by elevated activation of NF-κB 
and p38 MAPK but not IRF3 [61]. Interestingly, murine embryonic fibroblasts (MEFs) lacking 
either Atg5 or Atg16l1 also demonstrated an hyper-activated NF-κB and MAPK signaling 
within the first 2 hours in response to IL1β [60]. As MyD88 has a common function in the 
modulation of IL1R/TLR-mediated responses [286], this might point to a general regulatory 
mechanism for autophagy in MyD88-dependent signaling. Moreover, this might provide a 
 
101 
molecular explanation for the faster responsiveness to LPS observed in Atg16l1LysM mice as 
well as Irgm1-deficient mice [61] as both mouse models develop extraordinarily pro-
inflammatory cytokine levels already one hour after injection.  
 
5.2.3 CROS STA L K BE TW EE N P 38  MAPK  AND NF-ΚB  SI GN AL IN G  
 
Since TLR4 was described to be the only TLR acting via both, MyD88 and TRIF [141], 
crosstalks within individually activated downstream pathways are even more complex [287]. 
Recent studies implicated a role for p38 downstream kinases in the modulation of 
phosphorylation but also long-term nuclear retention of the NF-κB subunit p65 at least in 
TNF and IL1 receptor signaling [288-290]. However, analysis of the crosstalk between 
TLR4-activated p38 MAPK and NF-κB cascades in Atg16l1LysM BMDMs demonstrated only a 
weak effect of p38 activity on canonical NF-κB signaling. In contrast, diminished p38 activity 
substantially reduced CXCL1 secretion in both, LPS-treated Atg16l1fl/fl and Atg16l1LysM 
macrophages, pointing to a general and indirect intervention of p38 MAPK in NF-κB signaling. 
Indeed, studies in the human monocyte cell line THP-1 as well as in the murine macrophage 
cell line RAW264.7 demonstrated a p38-dependent stabilization of LPS-induced transcripts 
containing adenylate/uridylate (AU)-rich elements like the human Il8 and the murine Cxcl1 
[291, 292] which would also elucidate the increased mRNA level of Cxcl1 in Atg16l1LysM 
macrophages. 
Concluding, in absence of Atg16l1, p38 MAPK signaling serves as amplification factor for p65 
phosphorylation and CXCL1 secretion. In this scenario, p38 might presumably enhance 
transcript stabilization but does not act as decisive initiator of NF-κB signaling. 
 
5.2.4 THE AUT OP HA GY R EC EPT O R  P62  A S A  PUT ATIV E CE NTRA L M ED I ATOR O F 
NF-ΚB  SI G NAL IN G  I N A UTOP HA GY -DE F IC IE NT CE LL S  
 
While Bihl and colleagues reported a positive correlation of Tlr4 expression levels and LPS 
responsiveness using a Tlr4 transgenic mouse model [293], Atg16l1LysM macrophages 
neither demonstrated augmented TLR4 protein levels nor cell surface expression. Similar 
observations were described for F4/80hi macrophages from the spleen, kidney, and 
peritoneal cavity derived from Atg7LysMcre/+ mice [48]. These findings exclude TLR4 as key 
driver for the increased pro-inflammatory signaling in Atg16l1LysM BMDMs. Besides TLR4, 
regulation of LPS-mediated NF-κB activation can be provided by a second cell surface 
receptor, namely MSR1. MSR1 competitively binds LPS [196] and/or directly inhibits TRAF6 
ubiquitination [294]. Thus, diminished levels of MSR1 would explain the hyper-activation 
seen in Atg16l1LysM BMDMs after LPS treatment. Disproving this suggestion, protein levels of 
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MSR1 were comparable between Atg16l1fl/fl and Atg16l1LysM BMDMs indicating a MSR1-
independent mechanism for ATG16L1 in the regulation of NF-κB activation pathways. In 
contrast, deletion of Atg3, Atg5 and Atg7 was described to increase nuclear factor (erythroid-
derived 2)-like 2 (NFE2L2)-dependent cell surface expression of MSR1 [47].  
MyD88 [285], TRIF [187] and RIP1 [295] are crucial mediators of TLR4-induced NF-κB 
activation and increased protein levels might elucidate the observed differences in 
LPS-mediated signaling [152]. However, loss of Atg16l1 did not affect one of the mentioned 
molecules. This might be indicative for a regulatory mechanism in TLR4 signaling beside an 
impaired autophagic degradation of classical TLR4 key components. 
Autophagy and innate immunity are strongly linked ancient processes, as TLR4-mediated 
signaling, is known to induce autophagy in a MyD88-dependent manner [31, 296]. Keeping 
this in mind, the observed LPS-induced levels of the autophagy receptor p62 in both, 
Atg16l1fl/fl and Atg16l1LysM BMDMs, might simply be interpreted as a result of autophagy 
induction which is transient under physiological conditions [23]. However, a striking 
hallmark of Atg16l1LysM BMDMs was the cytoplasmic formation of p62 aggregates under 
basal conditions which increased even more in the presence of LPS. Interestingly, 
over-expression studies in HeLa cells and MEFs identified p62 as an essential component of 
so called cytoplasmic inclusion bodies targeting ubiquitinated proteins for their autophagic 
degradation [27, 297]. These observations might be a reasonable explanation for the 
observed cytoplasmic p62 aggregates in Atg16l1LysM BMDMs. 
Ubiquitination is a decisive regulatory mechanism in NF-κB signaling [298]. In this context, 
recent studies implicated an essential role for multimeric complexes of p62 and sequestered 
Lys63 poly-ubiquitinated proteins in the activation of NF-κB serving as stabilizing platform 
[60, 299]. Indeed, p62 was originally described as a substantial modulator of NF-κB activity 
acting as a scaffolding protein [297, 300]. The recommended role of p62 as 
signaling-organizing node in NF-κB signaling relies on its multifunctional domains [301] 
which result in a variety of interactions with signaling modulators. Besides its 
autophagy-related LC3 interaction region [27], p62 harbors a N-terminal PB1 domain 
mediating the binding of atypical protein kinases C (aPKCs) [302]. In addition, the N-terminus 
encodes for a ZZ finger domain interacting with RIP1 [300] as well as for a TRAF6 binding 
site [303]. Since on the one hand oligomerized p62, putatively provoked by impaired 
autophagy, is proposed to bind Lys63 poly-ubiquitin chains with a higher affinity [304] and, on 
the other hand, TRAF6 and RIP1 are reported to undergo Lys63-ubiquitination as a crucial 
step in NF-κB activation [174, 295], this might lead to the idea of a p62 dose-dependent 
stabilization of TLR4-mediated signaling in Atg16l1-deficient macrophages. 
Corroborating this hypothesis, a common feature of the above mentioned p62 interaction 
partners is the recruitment and activation of TAK1 [305-307]. Because it is known to be a key 
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modulator of both, NF-κB and p38 signaling [175], TAK1 would be a promising candidate 
downstream of the observed p62 aggregates operating as key signal-transducer in TLR4-
induced hyper-activation of Atg16l1-deficient macrophages (Figure 5-2). 
 
 
FIGURE 5-2:  SUGGESTED EFFECT OF P62 AGGREGATES ON NF-ΚB  SIGNALING STABILIZATION IN 
ATG16L1-DEFICIENT BMDMS  
(A) TLR4 signaling is initiated by LPS-induced dimerization of the receptor. Engagement of adaptor molecules 
including MyD88 stimulates downstream signaling pathways that involve the interaction between the scaffolding 
protein p62 and atypical PKCs (aPKCs), TRAF6 and RIP1 which results in the activation of TAK1. Following this, 
TAK1 facilitates the phosphorylation of IκBα causing its subsequent degradation by the proteasome. These events 
allow for the phosphorylation of NF-κB and its translocation into the nucleus consequentially activating gene 
transcription. On the other hand, TAK1 stimulates the activation of the canonical p38 MAPK signaling. In this 
scenario, ATG16L1 mediates the degradation of p62 via the autophagosomal-lysosomal pathway. (B) Absence of 
ATG16L1 and thus autophagy provokes the accumulation and oligomerization of p62 which presumably promotes 
the sustained formation of a signaling platform. As a major consequence, homeostatic p62 signaling might 
constitutively stimulates, probably via TAK1, on the one hand increased and prolonged degradation of IκBα and 
thus NF-κB activation and NF-κB-dependent gene expression and on the other prolonged and increased p38 
MAPK signaling facilitating augmented stabilization of transcript containing AU-rich elements (ARE) (see also 
chapter 5.2.3 for more detail). 
 
On the other hand, the above mentioned model would also give an explanation for the 
increased number of activated CD11b+ macrophages in Atg16l1LysM mice. As seen in 
untreated Atg16l1LysM BMDMs, splenocytes of the red pulp, which mainly present myeloid 
cells [308], demonstrated large p62 accumulations in the cytoplasm. Similar observations 
were reported for hepatocytes and neurons of liver- and brain-specific Atg7 knock-out mice 
as well as for various organs of mice bearing a mosaic deletion of Atg5 [42, 309]. In addition, 
large p62 aggregates were determined in Irgm1-deficient MEFs [310]. Beside mammalians, 
Drosophila melanogaster deficient in atg8a, the homologue of the vertebrate LC3A, showed 
comparable accumulations of the p62 orthologue Ref(2)P in the brain [311]. These findings 
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point towards a general phenomenon of p62 aggregate formation in case of impaired 
autophagy. Comparable to Atg16l1LysM mice, loss of Atg7 in hepatocytes and neurons also 
resulted in hepatomegaly and fatal behavioral abnormalities, respectively [21, 44]. Thus, one 
might speculate about a pathophysiological association of p62 aggregates with the 
inflammatory phenotype of autophagy-deficient mice. In fact, deletion of p62 in liver-specific 
Atg7 knock-out mice rescued the liver injury [42]. However, the neuronal phenotype of mice 
bearing a brain-specific ablation of Atg7 was not attenuated after additional ablation of p62 
[42]. This paradoxical finding was interpreted to depend on distinct tissue-dependent 
autophagic activities supporting the above declared suggestion of a positive correlation 
between the magnitude of p62 aggregates and NF-κB signaling. For this reason, disrupted 
degradation of p62 multimeric complexes might already provoke a constitutive activation of 
NF-κB signaling and thus increased activation of Atg16l1-deficient CD11b+ macrophages that 
in turn leads to chronic inflammatory conditions. Thus, Atg16l1 and probably autophagy 
might represent crucial regulatory component for the temporal control of p62-mediated 
NF-κB signaling. 
Finally, it is worth mentioning that the initial stimulation experiment in the presented study 
also revealed increased CXCL1 production in response to Poly I:C, ssRNA, TNFα and MDP. 
Interactions of p62 with aPKCs, RIP1 and TRAF6 were originally identified in NF-κB 
regulatory processes of TNFR- and IL1R-mediated signaling pathways [300, 303]. Later on, 
p62 was reported as scaffolding protein in numerous NF-κB activating signaling cascades of 
cell surface receptors like TLR2/6 and TLR4 [32] but also receptor activator of nuclear factor 
κ B (RANK) [312]. Consequently, the in this study proposed regulatory function of p62 
multimeric complexes might not be completely restricted to TLR4-mediated NF-κB 
activation. In agreement with this suggestion, increased IL1β-induced NF-κB activation in 
Atg16l1-deficient MEFs was assumed to rely on a p62-promoted activation and 
oligomerization of TRAF6 [60]. Additionally, a recently published study identified p62 as 
positive regulator of NOD2-mediated NF-κB and p38 MAPK activity based on its direct 
interaction with NOD2 [313]. Park and colleagues assumed in their study a similar 
mechanism for p62 in the formation and stabilization of large p62-NOD2 complexes. Based 
on a genomic and functional approach, a similar model of selective degradation for TLR 
adaptors via NDP52, another autophagy cargo receptor, was recommended which indicates a 
general role for selective autophagy in the modulation of TLR signaling [314, 315]. Studies in 
human HEK293T cells suggested a similar working model for NDP52 to mediate aggregation 
of MyD88-TRAF6 and TRIF-TRAF6 which are eliminated via the autophagosomal-lysosomal 
pathway under certain conditions [240]. 
Accumulation of p62 was not only associated with inflammatory phenotypes of autophagy-
deficient mice but also with dysregulated protein levels in neurodegenerative disorders like 
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amyotrophic lateral sclerosis (ALS) [316] and huntingtin disease [297] as well as in 
tumorigenesis and tumor growth [317, 318]. Consequently, the results of the presented study 
might strengthen the focus on p62 and its targeted protein aggregates as new promising 
therapeutical targets in several human diseases. 
Although, the determined accumulation of p62 in Atg16l1-deficient cells might be a 
reasonable explanation for the observed in vivo and ex vivo inflammatory phenotype, a 
detailed characterization of the nature and function of p62 aggregates and putatively p62 
multimeric complexes in Atg16l1LysM BMDMs is necessary to advance the understanding of 
their presumable regulatory role in cellular pathology. This is subject of ongoing research. 
 
5.2.5 IM PAIR ED AUT OPH A G OS O M AL-L Y SO S OM AL DE GRADA TI O N OF A20  I S  
AS SO CIA TE D WI TH SU ST AIN ED NF-ΚB  SI GN AL IN G  
 
Supporting the hypothesis that an autophagy-driven impaired proteostasis specifically 
modulates the maintenance of TLR4 signaling, a second protein, namely A20, showed 
increased levels in Atg16l1LysM BMDMs in response to LPS. Similarly, Atg7-deficient 
F4/80hi-sorted macrophages showed elevated A20 levels in response to the TLR2 agonist 
Pam3CSK4 [48]. Contributing this idea, an additional treatment with BafA in LPS-stimulated 
Atg16l1fl/fl control BMDMs, inhibiting the acidification and protein degradation in 
(autophago-)lysosomes [319], reproduced the observed A20 accumulation seen in 
LPS-treated Atg16l1-deficient BMDMs. Paradoxically, A20 is a well described protein 
ensuring the intrinsic termination of TLR4-mediated NF-κB activity [201]. For this reason, 
decreased but not increased levels or an impaired functionality of the accumulated A20 
would elucidate the constitutively activated TLR4-mediated signaling in Atg16l1LysM 
BMDMs.  
Surprisingly, protein levels of CYLD, another protein belonging to the broad repertoire of 
NF-κB-regulating negative feedback loops [204], are not affected by the ablation of Atg16l1. 
This points to a specific autophagy-dependent mechanism in the regulation of LPS-mediated 
A20 levels. Inhibition of the protein biosynthesis using CHX demonstrated a LPS-induced 
de novo synthesis of A20 in Atg16l1LysM macrophages corresponding to an NF-κB-induced 
A20 synthesis after activation of the TNFR pathway [203]. As CYLD activity is not controlled 
by NF-κB activity but either by its subcellular localization in perinuclear regions or by its 
phosphorylation [205, 320], it would be conceivable that the observed differences in A20 
might occur from the increased activation of NF-κB. However, mRNA levels of A20 were 
neither increased in absence nor in presence of LPS in Atg16l1-deficient BMDMs which 
indicates a regulation of A20 on the post-translational level.  
 
106 
Besides A20, stimulation with LPS in combination with BafA also increased levels of 
phospho-p65 associated with an amplified secretion of CXCL1 in Atg16l1fl/fl control 
macrophages. This phenotype reflects the increased inflammatory state of solely LPS-treated 
Atg16l1LysM BMDMs. Consequently, it seems reasonable to assume that the augmented 
inflammatory NF-κB-mediated response in Atg16l1LysM BMDMs might occur independently 
of the magnitude of A20. With this is mind, a compromised functional activity of A20 would 
give a reason for the prolonged TLR4-mediated signaling in absence of Atg16l1.  
Although both, A20 and CYLD attenuate canonical NF-κB signaling by acting as 
deubiquitinase enzymes (DUBs), their molecular mechanisms depend on different domains. 
CYLD belongs to the DUB family of ubiquitin-specific proteases [321] whereas A20 harbors a 
deubiquitinating ovarian tumor (OTU) domain. Interestingly, the inhibitory capacity of A20 
on NF-κB was originally described to be mediated by its DUB activity on 
Lys63 poly-ubiquitinated signaling intermediaries like TRAF6, NEMO and RIP1 [200-202]. 
However, a recently published study in A20∆OTU transgenic mice, lacking the OTU domain of 
A20, implicated a dispensable role for its DUB activity in TNF-and LPS-mediated NF-κB 
activation [322]. Taking this into account, an NF-κB-terminating molecular mechanism for 
A20 apart from its DUB activity might explain the differences in A20 and CYLD levels due to 
the loss of autophagy.  
Unlike CYLD, A20 is able to add Lys48 poly-ubiquitin chains via its C-terminal zinc finger 
domains targeting substrates like RIP1 for their proteolytic degradation [200]. Because 
Atg16l1fl/fl and Atg16l1LysM BMDMs demonstrated comparable protein levels of RIP1 and the 
above mentioned mechanism was up to now only described in the TNFR pathway, an 
impaired E3 ubiquitin ligase activity is implausible. Accordingly, over-expression of A20 in 
aortic allografts showed stable protein levels of RIP1 and Enesa et al. consequentially 
suggested to uncouple the anti-inflammatory effects of A20 from its proposed role in RIP1 
destabilization [323]. 
Besides its function as a dual ubiquitin-modifying enzyme, several non-catalytic mechanisms 
were identified by which A20 is capable to interrupt NF-κB signaling and thus strictly 
controls inflammation. Inactivation of TRAF6 is achieved by an A20-dependent disruption of 
the TRAF6-Ubc13/UbcH5c interaction [324]. Inhibition of IKK phosphorylation is based on a 
poly-ubiquitin-dependent recruitment of A20 to NEMO [325]. Nevertheless, none of these 
functions gives reason for the contradictory finding of simultaneously augmented A20 levels 
and NF-κB signaling in absence of Atg16l1 and autophagosomal-lysosomal degradation. 
However, in line with the above mentioned observations in BMDMs showing a deficient or 
inhibited autophagosomal-lysosomal degradation, another catalytic-independent mechanism 
for A20 in the modulation of NF-κB signaling was described. Precisely, Li and colleagues 
discovered a membrane-associated localization of endogenous A20 in HeLa cells which was 
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even more apparent in response to TNFα [326]. Further studies elucidated an 
NF-κB-regulating function for lysosome-associated A20 by capturing signaling components 
like TRAF2 for their lysosomal degradation [327]. Similarly, a study in human umbilical vein 
endothelial cells (HUVECs) developed a model in which A20 abolishes NF-κB signaling by 
targeting Lys63 poly-ubiquitinated signaling proteins like RIP1 for their transport to 
aggresomes [323]. Interestingly, recruitment of A20 to TNFR signaling complexes strictly 
depends on its binding capacity to Lys63 poly-ubiquitin chains [328, 329]. Thus, an 
involvement of autophagosomal degradation might be possible. Supporting this hypothesis, a 
recently published study demonstrated a p62-mediated autophagic sequestration of A20 in 
cytoplasmic punctate structures [48]. However, in contrast to Atg16l1LysM BMDMs, loss of 
Atg7 in F4/80hi macrophages led to a reverse correlation between the amount of A20 and the 
activity of NF-κB, at least in response to Pam3CSK4. Whether the change in A20 levels and/or 
localization contributes to the observed phenotype of sustained NF-κB activation e.g. by 
sequestering A20 activity or whether A20 levels are simply overridden by other mechanisms 
























5.3 FUTURE PROSPECTS  
 
The presented work provides first insights into the sophisticated function of ATG16L1 in 
myeloid cells modulating tissue homeostasis and NF-κB-mediated inflammatory responses. 
Based on these findings, a number of unresolved issues as well as new questions raised and 
will be discussed below. 
 
Loss of Atg16l1 in the myeloid lineage of mice resulted in far-reaching impacts on the basal 
phenotype of Atg16l1LysM mice. In the present thesis, the particular research focus was set 
on the impaired tissue homeostasis in hematopoietic organs and the peripheral blood. 
Although several facts implicate a MDSC-like phenotype of CD11b+/Ly6G+ cells in 
Atg16l1LysM mice, one has to be aware that all splenic experiments were performed on 
whole tissues. Thus, a quantitative comparison of MDSC-characteristic genes between 
isolated CD11b+/Ly6G+ cells of both genotypes as well as ex vivo co-culture experiments 
might probably confirm the proposed hypothesis of an immunosuppressive capability of 
Atg16l1-deficient CD11b+/Ly6G+ cells on T cell proliferation and activation. 
Gross examination of the gastrointestinal tract further revealed an elongated small intestine 
in Atg16l1LysM mice. Thus, it would be interesting to investigate the morphology and cellular 
composition of the lamina propria in more detail. With regard to the described association of 
ATG16L1 with Crohn´s disease [64], the role of Atg16l1-deficient macrophages in the 
gastrointestinal tract under basal as well as challenging conditions like DSS need to be further 
elucidated. 
Further studies might also include the observed bone differences in Atg16l1LysM mice. As the 
autophagy receptor p62 is also known to play a pivotal role in murine osteoclastogenesis 
[312] and increased expression of p62, due to a genetic mutation in the UBA domain, is 
associated with disordered bone formation in Paget´s disease [330], it might be a conceivable 
explanation for the characteristically brighter bones of Atg16l1LysM mice. Histological 
examination of the bone formation as well as ex vivo differentiation experiments of 
osteoclasts might be a good starting point for the studies of osteogenesis in absence of 
Atg16l1. 
On the other hand, the physiological relevance of p62 aggregates observed in the spleen as 
well as in BMDMs of Atg16l1LysM mice is still unclear. As proposed by Komatsu et al., the 
impact of p62 inclusion bodies on the impaired tissue homeostasis and its related 
physiological abnormalities in autophagy-deficient mice seem to depend on the basal 
autophagic activity of the affected cell types [42]. For this reason, a double knock-out of 
Atg16l1 and p62 in myeloid cells could help to understand the suggested function of p62 
aggregates in inflammatory response of Atg16l1-deficient macrophages. On the molecular 
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level, it needs to be further addressed whether p62 indeed stabilizes TLR4-mediated NF-κB 
signaling and whether this occurs due to the interaction of one or more interaction partner. 
In this scenario, it would also be of interest to include autophagy inhibitors and other Atg 
knock out models to confirm a general role for autophagic degradation as NF-κB-regulating 
mechanism. Moreover, stimulation of other NF-κB-activating immune receptors like 
additional Toll-like receptors and NOD-like receptors but also the role of other autophagy 
receptors might facilitate the identification of common features and molecules, which might 
partially complete the yet insufficient understanding about the regulatory mechanisms by 
which ATG16L1 negatively controls immune responses. 
An impaired NF-κB-regulating function of A20 would explain the similar basal and 
LPS-induced phenotypes between Atg16l1LysM mice and A20-deficient mice [208, 331]. 
Similarly, it would be a possible exemplification of the controversial findings in Atg16l1LysM 
macrophages demonstrating simultaneously increased levels of phospho-p65 and its 
upstream negative regulator after TLR4 activation. However, a convincing proof is missing so 
far. This might be done by studying the localization of A20 as well as the binding capacity to 
its substrates/interaction partners like TRAF6. 
Last but not least, one has to keep in mind that all experiments presented in this work were 
performed in mice and murine primary cells. Thus, the transferability of the obtained 
knowledge into the human (cell) system and in the long term into a therapeutic approach in 
patients would be the next important steps to elucidate the molecular mechanisms by which 

















6 SUMMARY  
 
Eukaryotic cells adapt to changing nutrient conditions through an evolutionarily conserved 
catabolic mechanism called autophagy. During this “self-eating” process, cytoplasmic 
constituents and organelles are engulfed by a specialized double-membraned 
autophagosome, which delivers its cargo to degrading lysosomes. Recent studies also 
implicated a role for autophagy in immunological processes, such as the removal of 
intracellular pathogens and the secretion of cytokines. Contributing to these observations, 
impaired autophagy is associated with a wide range of human diseases like inflammatory 
bowel disease, asthma and cancer. Studies in mice and men demonstrated a multifunctional 
role of ATG16L1 not only as an essential component of the autophagic machinery but also as 
regulator of inflammatory signaling. However, the molecular mechanisms by which ATG16L1 
and probably autophagy modulate inflammatory processes remains poorly understood. Thus, 
the aim of the presented study was to get deeper insights in the impact of ATG16L1 on 
inflammatory signaling pathways and cytokine production in myeloid cells. 
 
The presented work shows for the first time that ablation of Atg16l1 in murine myeloid cells 
has far-reaching consequences for immune homeostasis. Mice lacking Atg16l1 specifically in 
myeloid cells (Atg16l1LysM) spontaneously develop a hepatosplenomegaly and lymph-
adenopathy associated with enhanced myeloproliferation in hematopoietic organs and the 
peripheral blood. Systemic inflammation in Atg16l1LysM mice is further typified by the 
upregulation of a variety of pro-inflammatory cytokines in spleen and serum coinciding with 
increased activation markers at the cell surface of CD11b+ macrophages. Despite increased 
numbers of CD11b+/Ly6G+ neutrophils in spleen and peripheral blood, diminished T cell 
numbers in Atg16l1LysM mice were observed. Molecular analysis of the spleen determined 
elevated markers of T cell-suppressing myeloid-derived suppressor cells (MDSCs), like the 
exclusive expression of iNOS, suggesting a MDSC-like phenotype of CD11b+/Ly6G+ cells in 
these mice. In addition, a recurring observation in Atg16l1LysM mice was the upregulation of 
interleukin-1 family members like pro-IL1β in the spleen and IL1α in the serum. 
Therapeutical treatment with Anakinra, a human interleukin-1 receptor (IL1R) antagonist, 
had no attenuating effect on the inflammatory symptoms of Atg16l1LysM mice indicating a 
dispensable role for IL1R signaling in the manifestation of the spontaneous phenotype. In 
contrast, prevention of the postnatal microbial colonization of the gastrointestinal tract using 
antibiotics restored the splenomegaly as well as the immunosuppressed T cell phenotype 




Detailed studies in Atg16l1LysM bone marrow-derived macrophages (BMDMs) revealed an 
earlier, increased and prolonged activation of IκBα-mediated NF-κB signaling as well as 
canonical p38 MAPK signaling in response to LPS. These findings corresponded with an 
increased NF-κB-dependent cytokine production suggesting a terminating role for ATG16L1 
in the temporal control of NF-κB signaling. Investigations of an impaired proteostasis due to 
the loss of autophagy determined the accumulation of p62 and A20. Whereas p62 acts as the 
autophagic cargo receptor and NF-κB signaling modulator, A20 is a well-known TLR4 
negative regulator. Whether the accumulation of p62 or A20 is causative for the increased 
TLR4-mediated signaling in Atg16l1-deficient macrophages needs to be further addressed.  
 
In conclusion, the presented work provides strong evidence for a crucial role of ATG16L1 in 
inflammatory processes of myeloid cells. By regulating the proteostasis of TLR4 signaling 
components, ATG16L1 and presumably autophagy represents an important control 
mechanism in the termination of TLR4-mediated signaling. Thus, the loss of Atg16l1 in the 























7 ZUSAMMENFASSUNG  
 
Eukaryotische Zellen besitzen einen evolutionär konservierten Mechanismus namens 
Autophagozytose, der es ermöglicht, sich an ändernde Nährstoffbedingungen anzupassen. 
Hierbei werden zytoplasmatische Bestandteile und Organellen von einer Doppelmembran 
umschlossen, die sich zu einem Autophagosom ausbildet, und ihren Inhalt anschließend für 
den Abbau zu Lysosomen transportiert. Neueste Studien implizieren jedoch auch einen 
Einfluss von Autophagie auf immunologischen Prozessen wie der Abwehr von intrazellulären 
Pathogenen und der Zytokinsekretion. Eine gestörte Autophagozytose ist mit einer Vielzahl 
humaner Krankheiten wie chronisch-entzündlichen Darmerkrankungen, Asthma und Krebs 
assoziiert. Humane und murine Studien konnten bereits eine multifunktionelle Rolle für das 
mit der Autophagozytose-assoziierte Protein ATG16L1 zeigen. Neben der essentiellen Rolle 
bei der Ausbildung des Autophagosomens, wird ATG16L1 auch mit der Regulation von 
inflammatorischen Signalkaskaden in Verbindung gebracht. Die molekularen Mechanismen 
sind dabei bisher nur unzulänglich aufgeklärt. Aus diesem Grund war das Ziel der 
vorliegenden Studie, detailliertere Erkenntnisse über den Einfluss von ATG16L1 auf 
inflammatorische Signalkaskaden und die Zytokinsekretion in myeloiden Zellen zu gewinnen. 
 
In der vorliegenden Arbeit konnte zum ersten Mal gezeigt werden, dass die Deletion von 
Atg16l1 in myeloiden Zellen weitreichende Konsequenzen für die Immunhomöostase hat. 
Mäuse mit einer gewebsspezifischen Deletion von Atg16l1 in den myeloiden Zellen 
(Atg16l1LysM) entwickeln eine vermehrte Myeloproliferation in hämatopoetischen Organen 
und dem peripheren Blut, die mit einer spontanen Hepatosplenomegalie sowie eine 
Lymphadenopathie assoziiert ist. Die systemische Entzündung in Atg16l1LysM Mäusen wird 
außerdem von erhöhten Zytokinleveln in Milz und Serum sowie der vermehrte Expression 
von Aktivierungsmarkern auf der Zelloberfläche von CD11b+ Makrophagen geprägt. Die 
erhöhte Anzahl an CD11b+/Ly6G+ Neutrophilen in der Milz und dem peripheren Blut ist mit 
einer verminderten Anzahl von T-Zellen assoziiert. Es konnte gezeigt werden, dass die Milz 
vermehrt Charakteristika von T-Zell-supprimierenden myeloiden Suppressorzellen aufweist. 
Zusätzlich konnte in Atg16l1LysM Mäusen ein erhöhtes Auftreten von Komponenten der 
Interleukin-1 Zytokinfamilie, wie zum Beispiel pro-IL1β in der Milz und IL1α im Serum, 
festgestellt werden. Eine Therapie mit Anakinra, einem humanen Interleukin 1 Rezeptor 
(IL1R) Antagonisten, zeigte keinen Effekt auf die inflammatorischen Symptome der 
Atg16l1LysM Mäuse, so dass eine wesentliche Beteiligung dieser Signalkaskade in der 
Ausprägung des spontanen Phänotyps auszuschließen ist. Im Gegensatz dazu, konnte die 
Prävention der postnatalen mikrobiellen Kolonisierung des gastrointestinalen Trakts durch 
die Gabe von Antibiotika sowohl die Ausbildung der Splenomegalie als auch des Phänotyps 
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der T-Zellen in Atg16l1LysM Mäusen verhindert werden. Dieser Befund weist auf eine 
erhöhte Sensitivität gegenüber der intestinalen kommensalen Mikroflora hin. Die vermehrte 
Anzahl sowie die erhöhten Aktivierungsmarker auf CD11b+ Makrophagen blieben jedoch 
auch nach der Depletion der intestinalen Mikrobiota bestehen. 
Detailliertere Studien in Atg16l1LysM Knochenmarksmakrophagen wiesen eine frühere, 
verstärkte und anhaltende Aktivierung des NF-κB und p38 MAPK Signalweges nach LPS 
Stimulation auf. Diese Ergebnisse korrelierten mit einer NF-κB-abhängigen 
Zytokinproduktion, was auf einen Einfluss von ATG16L1 auf die temporäre Kontrolle von NF-
κB Signalwegen deutet. Untersuchungen fehlregulierter Proteinlevel durch die gehemmte 
autophagosomale Degradation zeigten die Akkumulation von p62 und A20. Während p62 als 
Autophagie-Rezeptor sowie als Modulator von NF-κB Signalwegen fungiert, agiert A20 als 
Negativregulator des TLR4 Signalweges. Ob die Akkumulation von p62 oder A20 jedoch 
ursächlich für die vermehrte TLR4-vermittelte Entzündungsreaktion in Makrophagen ist, 
müssen weitere Untersuchungen zeigen. 
 
Zusammenfassend konnte in dieser Arbeit erstmals gezeigt werden, dass ATG16L1 eine 
entscheidende Rolle in entzündlichen Prozessen von myeloiden Zellen einnimmt. Durch die 
Regulation der Proteostase von Komponenten des TLR4 Signalweges, stellt ATG16L1 über die 
Autophagozytose einen wichtigen Kontrollmechanismus in der Terminierung des TLR4 
Signalweges dar. Dadurch führt der Verlust von Atg16l1 in myeloiden Zellen in vivo 

















8 APPENDIX  
 
8.1 BUFFERS AND MEDIA  
 
TABLE 21:  LIST OF USED BUFFERS AND APPROPRIATE COMP OSITION  
Buffer Composition Company 
10 x TAE buffer 0.4 M Tris-acetate, 0.1 M EDTA Roth (Karlsruhe, Germany) 
10 x TBS 200 mM Tris (pH 7.6), 1,37 M NaCl -  
10 x TGS buffer 25 mM Tris (pH 8.3), 192 mM glycine, 
0.1 % SDS 
BioRad (Munich, Germany) 
2 x DLB buffer 20 mM Tris (pH 7.4), 2 % (w/v) SDS -  
5 x SDS loading 
dye 
250 mM Tris (pH 6.8), 10 % (w/v) SDS, 
50 % (v/v) glycerol, 500 mM DTT 
-  
Anode buffer 1 30 mM Tris, 20 % (v/v) methanol -  
Anode buffer 2 300 mM Tris, 20 % (v/v) methanol -  
Cathode buffer 25 mM Tris , 40 mM 6-aminocaproic acid, 
20 % (v/v) methanol 
-  
Citrate buffer 11 mM Citric acid (pH 6.0) -  
EMSA buffer 1 10 mM HEPES (pH 7.9), 10 mM KCl, 0. mM 
EDTA, 1 mM DTT 
-  
EMSA buffer 2 20 mM HEPES (pH 7.9), 0.4 M NaCl, 0.2 








1 mM KH2PO4, 155 mM NaCl, 3 mM 
Na2HPO4-7H2O 
Gibco (Darmstadt, Germany) 
Separation 
buffer 
1.5 M Tris (pH 8.8), 0.4 % (w/v) SDS -  
Stacking buffer 0.5 M Tris (pH 6.8), 0.4 % (w/v)SDS -  
Stripping 
buffer 
2 % (w/v) SDS, 62.5 mM Tris (pH 6.8) -  








TABLE 22:  LIST OF USED MEDIA  
Media Company or composition 
BMDM medium DMEM and Macrophage SFM medium (1:1) 
supplemented with 10 % (v/v) FCS, 5 % (v/v) 
Penicillin/Streptomycin, 5 % (v/v) Fungizione 
DMEM cell culture medium Gibco (Darmstadt, Germany) 
Hank´s Balanced Salt Solution (HBSS) Gibco (Darmstadt, Germany) 
Macrophage SFM medium Gibco (Darmstadt, Germany) 
 
8.2 KITS  
 
TABLE 23:  LIST OF USED KITS  
Kit Company 
ApopTag® Plus Peroxidase In Situ 
Apoptosis Detection Kit 
Merck Millipore (Darmstadt, Germany) 
Bio-Plex Pro™ Mouse Cytokine 23-plex 
Assay 
Bio-Rad (Munich, Germany) 
DCTM Protein Assay Bio-Rad (Munich, Germany) 
Lamina Propria Dissociation Kit for 
mouse  
Miltenyi BioTec (Bergisch Gladbach, Germany) 
Lineage Cell Depletion kit for mouse Miltenyi BioTec (Bergisch Gladbach, Germany) 
Maxima H Minus First Strand cDNA 
Synthesis kit 
Thermo Scientific (Darmstadt, Germany) 
MiSeq Reagent Kit v3 (2 x 300 bp) Illumina (San Diego, USA) 
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PowerSoil® DNA Isolation Kit MoBio (Carlsbad, USA) 
QIAquick Gel Extraction Kit Qiagen (Hilden, Germany) 
Quant-iT™ PicoGreen® dsDNA Assay Kit Invitrogen (Darmstadt, Germany) 
RNeasy kit Qiagen (Hilden, Germany) 
SequalPrep™ Normalization Plate Kit 
 
Invitrogen (Darmstadt, Germany) 
Vectastain Elite ABC Kit Rabbit IgG Vector Labs (Peterborough, United Kingdom) 
 
8.3 REAGENTS  
 
TABLE 24:  LIST OF USED REAGENTS FOR ANIMAL EXPERIMENTS  
Reagents for animal experiments Company 
0.9 % (w/v) NaCl Fresenius Kabi Deutschland GmbH (Bad 
Homburg, Germany) 
Ampicillin  Sigma Aldrich (Munich, Germany) 
Anakinra (Kineret®) Swedish Orphan Biovitrum AB (Stockholm, 
Sweden) 
Ciprofloxacin Fresenius Kabi Deutschland GmbH (Bad 
Homburg, Germany) 
LPS (Escherichia coli, strain KPM53) generous gift by Dr. Nicolas Gisch (Research 
Center Borstel, Borstel, Germany) 
Metronidazole Sigma Aldrich (Munich, Germany) 
Neomycin Sigma Aldrich (Munich, Germany) 
Phosphat-buffered saline (PBS) Gibco (Darmstadt, Germany) 









TABLE 25:  LIST OF USED REAGENTS   
Reagents Company 
1 % Eosin solution Roth (Karlsruhe, Germany) 
10 % Formalin Sigma Aldrich (Munich, Germany) 
10 x BD FACS Lysing Solution BD Biosciences (Heidelberg, Germany) 
10 x SYBR® Safe DNA gel stain Life Technologies (Darmstadt, Germany) 
30 % Bis-acrylamide (37.5:1) Bio-Rad (Munich, Germany) 
30 % Hydrogen peroxide (H2O2) Sigma Aldrich (Munich, Germany) 
5 x Green GoTaq® Reaction Buffer Promega (Mannheim, Germany) 
6-aminocaproic acid Sigma Aldrich (Munich, Germany) 
Agarose Biozym (Hessisch Oldendorf, Germany) 
Ammonium persulfate (APS) Sigma Aldrich (Munich, Germany) 
Bafilomycin A Enzo Life Sciences GmbH (Lörrach, Germany) 
Blotting grade blocker (non-fat dry milk) Bio-Rad (Munich, Germany) 
Bovine serum albumin (BSA) Roth (Karlsruhe, Germany) 
Brefeldin A Sigma Aldrich (Munich, Germany) 
CD11b MicroBeads (human and mouse) Miltenyi BioTec (Bergisch Gladbach, Germany) 
CD95L ( Jo2) BD Biosciences (Heidelberg, Germany) 
CellROX Deep Red Life Technologies (Darmstadt, Germany) 
Citric acid Roth (Karlsruhe, Germany) 
Cycloheximide (CHX) Sigma Aldrich (Munich, Germany) 
Deoxynucleotide triphosphates (dNTPs) Thermo Scientific (Darmstadt, Germany) 
Dimethyl sulfoxide (DMSO) Sigma Aldrich (Munich, Germany) 
Diphenyleneiodonium (DPI) Sigma Aldrich (Munich, Germany) 
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Dithiothreitol (DTT) Sigma Aldrich (Munich, Germany) 
DreamTaq DNA Polymerase Thermo Scientific (Darmstadt, Germany) 
ECLTM Western Blotting Detection 
Reagents 
GE Healthcare (Hamburg, Germany) 
Ethanol Roth (Karlsruhe, Germany) 
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich (Munich, Germany) 
Fc-receptor block (anti-CD16/32 ) BD Biosciences (Heidelberg, Germany) 
Fetal calf serum (FCS) Merck Millipore (Darmstadt, Germany) 
FITC-Dextran Sigma Aldrich (Munich, Germany) 
FSL-1 (Pam2CGDPKHPKSF) Invivogen (Toulouse, France) 
Glycerol Roth (Karlsruhe, Germany) 
Heat-killed Listeria monocytogenes 
(HKLM) 
Invivogen (Toulouse, France) 
Hematoxylin solution Th Geyer (Renningen, Germany) 
HEPES Sigma Aldrich (Munich, Germany) 
Interferon γ (IFNγ) (recombinant mouse) Immunotools (Friesoythe, Germany) 
Interleukin 1 β (IL1β) (recombinant 
mouse) 
Peprotech (Hamburg, Germany) 
Lipopolysaccharid (Escherichia coli, 
F515) 
generous gift by Dr. Nicolas Gisch (Research 
Center Borstel, Borstel, Germany) 
Macrophage colony-stimulating factor 
(mCSF) 
Immunotools (Friesoythe, Germany) 
Methanol Roth (Karlsruhe, Germany) 
Mitotracker Red Life Technologies (Darmstadt, Germany) 
Muramyl dipepetide (MDP) Bachem (Bubendorf, Switzerland) 
N,N,N',N'-Tetramethylethylendiamin 
(TEMED) 
Sigma Aldrich (Munich, Germany) 
Nuclease-free water Qiagen (Hilden, Germany) 
Pam3CSK4 Invivogen (Toulouse, France) 
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Paraffin Thermo Scientific (Darmstadt, Germany) 
Penicillin-Streptomycin (10,000 U/mL) Life Technologies (Darmstadt, Germany) 
Phusion HotStart Flex 2 Master Mix New England Biolanbs GmbH (Frankfurt a.M., 
Germany) 
Pierce ECLTM Plus Western Blotting 
Substrate 
Thermo Scientific (Darmstadt, Germany) 
Polyinosinic:polycytidylic acid (Poly 
(I:C)) 
Invivogen (Toulouse, France) 
Protease and phosphatase inhibitor Thermo Scientific (Darmstadt, Germany) 
Proteinase K Thermo Scientific (Darmstadt, Germany) 
Rapamycin (Streptomyces 
hygroscopicus) 
Sigma Aldrich (Munich, Germany) 
Roti-Histokitt mounting medium Roth (Karlsruhe, Germany) 
SB-202190(ip38) Enzo Life Sciences GmbH (Lörrach, Germany) 
Sodium chloride (NaCl) Merck Millipore (Darmstadt, Germany) 
Sodium dodecyl sulfate (SDS) Roth (Karlsruhe, Germany) 
Sodium hydroxide (NaOH) Merck Millipore (Darmstadt, Germany) 
ssRNA 40 Invivogen (Toulouse, France) 
SYBR® Select Master Mix Applied Biosystems (Darmstadt, Germany) 
TaqMan Gene Expression Master Applied Biosystems (Darmstadt, Germany) 
Tris Merck Millipore (Darmstadt, Germany) 
Tumor necrosis factor α (TNFα) 
(recombinant mouse) 
Peprotech (Hamburg, Germany) 
Tween 20 Roth (Karlsruhe, Germany) 
Xylene Thermo Scientific (Darmstadt, Germany) 
Z-Leu-Leu-Leu-CHO (MG132) Enzo Life Sciences GmbH (Lörrach, Germany) 






8.4 DEVICES  
 
TABLE 26:  LIST OF USED DEVICES  
Devices Company 
100-1000 µL pipette  Eppendorf (Hamburg, Germany) 
10-100 µL pipette Eppendorf (Hamburg, Germany) 
10-200 µL multi-channel pipette Eppendorf (Hamburg, Germany) 
1-10 µL pipette Eppendorf (Hamburg, Germany) 
7900HT Fast Real Time PCR System  Applied Biosystems (Darmstadt, Germany) 
Agarose gel chamber wide mini sub-cell 
GT 
Bio-Rad (Munich, Germany) 
Automatic developer machine Curix 60 Agfa (Mortsel, Belgium) 
Axio Imager Z1 ZEISS (Oberkochen, Germany) 
Balance  PeqLab (Erlangen, Germany) 
Cell Counter (Cellometer Auto T4 Plus) Heraeus (Hanau, Germany) 
Centrifuge Fresco21 Centrifuge Heraeus (Hanau, Germany) 
Centrifuge Megafuge 16 Bio-Rad (Munich, Germany) 
ChemiDoc XRS Biometra (Göttingen, Germany) 
Confocal laser scanning microscope TCS 
SP5 
Leica (Wetzlar, Germany) 
Electrophoresis chamber Multigel G44 Tecan (Männedorf, Switzerland) 
ELISA plate shaker Thermo Scientific (Darmstadt, Germany) 
ELISA washer Columbus plus BD Biosciences (Heidelberg, Germany) 
Embedding station STP120  Applied Biosystems (Darmstadt, Germany) 
FACSCaliburTM BD Biosciences (Heidelberg, Germany) 
GeneAmp PCR System 9700 Sartorius (Göttingen, Germany) 
Incubator Tecan (Männedorf, Switzerland) 
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Magnetic stirring plate Severin (Sundern, Germany) 
Microplate reader Infinite M200 Pro Illumina (San Diego, USA) 
Microwave PeqLab (Erlangen, Germany) 
MiSeq sequencer  Miltenyi BioTec (Bergisch Gladbach, Germany) 
NanoDrop spectrometer ND1000  Biometra (Göttingen, Germany) 
OctoMACS Leica (Wetzlar, Germany) 
Power Supply PP 3000 Bandelin (Berlin, Germany) 
RM2255 microtome  Heraeus (Hanau, Germany) 
Sonificator Sonopuls Eppendorf (Hamburg, Germany) 
Sterile bench Herasafe KS12 Bio-Rad (Munich, Germany) 
Thermomixer compact ZEISS (Oberkochen, Germany) 
TransBlot Turbo Transfer System  Stuart Scientific (Chelmsford, United Kingdom) 
Tube rotator SRT6 GFL (Burgwedel, Germany) 
Vortex Genie 2 Scientific Industries (New York, USA) 
Water bath 1013 GFL (Burgwedel, Germany) 
 
 
8.5 CONSUMABLES  
 
TABLE 27:  LIST OF USED CONSUMABLES  
Consumables Company 
0.5 mL/1.5 mL/2.0 mL tubes Sarstedt (Nümbrecht, Germany) 
1.5 mL/2.0 mL safe seal tubes Sarstedt (Nümbrecht, Germany) 
10 mL syringe BD Biosciences (Heidelberg, Germany) 
1-10 µL/10-100 µL/100-1000 µL pipette 
(filter) tips 
Sarstedt (Nümbrecht, Germany) 
15 cm/10 mL petri dish Sarstedt (Nümbrecht, Germany) 
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15 mL/50 mL tubes Sarstedt (Nümbrecht, Germany) 
18G/20G/26G needles BD Biosciences (Heidelberg, Germany) 
1 mL syringe BD Biosciences (Heidelberg, Germany) 
384-well plates Life Technologies (Darmstadt, Germany) 
40 µm/70 µm cell strainer BD Biosciences (Heidelberg, Germany) 
5 mL/10 mL/25 mL pipettes Sarstedt (Nümbrecht, Germany) 
6-well/12-well/96-well plate (flat 
bottom) 
Sarstedt (Nümbrecht, Germany) 
96-well V-bottom plate BD Biosciences (Heidelberg, Germany) 
cell scraper Sarstedt (Nümbrecht, Germany) 
coversplips (24x50mm) Geyer (Renningen, Germany) 
FACS tubes Greiner (Frickenhausen, Germany) 
EDTA tubes Sarstedt (Nümbrecht, Germany) 
Lithium-heparin tubes Sarstedt (Nümbrecht, Germany) 
MACS MS columns Miltenyi BioTec (Bergisch Gladbach, Germany) 
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10 SUPPLEMENTS  
 
10.1 LIST OF ABBREVIATIONS  
 
(RT)-PCR Reverse transcription PCR 
ABx antibiotics 
ALS amyotrophic lateral sclerosis  
AP-1 activator protein-1  
aPKC atypical protein kinase C  
APS ammonium persulfate 
ARE AU-rich elements  
ASC 
pyrin domain of apoptosis-associated speck-like protein containing a 
CARD 
ATG autophagy-related 
ATG16L1 autophagy-related protein 16 like 1 (S. cerevisiae) 
AU adenylate/uridylate  
BafA Bafilomycin A 
BMDMs bone marrow-derived macrophages  
BrefA Brefeldin A 
BSA bovine serum albumin  
c corona 
CD cluster of differentiation 
CD95L anti-CD95 ligand  
cDNA complementary DNA  
CHX cycloheximide  
c-Kit proto-oncogene c-Kit 
CLP common lymphoid progenitor  
CMP common myeloid progenitor  
Ct cycle threshold  
CXCL1 (C-X-C motif) ligand 1  
CYLD cylindromatosis (turban tumor syndrome) 
DAB 3,3´-Diaminobenzidine  
DC dendritic cell 
DLB denaturing lysis buffer  
DNA deoxyribonucleic acid 
dNTPs deoxynucleotide triphosphates  
DPI diphenyleneiodonium  
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DSS dextran sodium sulfate  
DTT dithiothreitol 
DUB deubiquitinase enzyme 
EDTA ethylenediaminetetraacetic acid  
ELISA enzyme linked immunosorbent assay  
ER endoplasmic reticulum  
ERK extracellular signal-regulated protein kinase  
FACS  fluorescence-activated cell sorting 
FIP200 focal adhesion kinase-interacting protein of 200 kDa  
FITC Fluorescein isothiocyanate 
for forward 
FSC forward scatter  
FSL-1  synthetic diacylated lipoprotein (Pam2CGDPKHPKSF) 
FWB FACS washing buffer  
gc germinal center  
G-CSF granulocyte-colony stimulating factor  
GM-CSF granulocyte-macrophage stimulating factor 
H&E hematoxylin and eosin  
HKLM heat-killed Listeria monocytogenes  
HRP horseradish peroxidase  
Hsc70 heat shock-cognate protein of 70 kDa  
HSCs hematopoietic stem cells  
IBA-1 ionized calcium-binding adapter molecule 1 
IECs intestinal epithelial cells  
IFN interferon 
IKKα/β/γ IκB kinase α/β/γ 
IL interleukin 
IL1R interleukin-1 receptor 
IL1Ra interleukin-1 receptor antagonist  
iNOS inducible nitric oxide synthase  
ip38 p38 activity inhibitor SB202190  
IRAK1/2/4 interleukin 1 receptor-associated kinase 1/2/4 
IRF3/7 interferon-regulatory transcription factor 3/7  
IVCs individual ventilated cages 
IκB 
inhibitor of nuclear factor of kappa light polypeptide gene enhancer 
in B-cells  
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JNK c-Jun N-terminal kinase 
LAMP-2A lysosome-associated membrane protein type 2A 
LBP LPS-binding protein  
LC3 microtubule-associated protein 1 light chain 3 
lin- lineage negative  
LIR LC3 interacting region 
LPS lipopolysaccharide 
LRR leucine-rich repeat 
LysM LysMcre 
Lyz2 lysozyme 2 
MACS magnetic-activated cell sorting  
MAPK mitogen-activated protein kinase 
MAPKAP2/MK2 MAP kinase-activated protein kinase 2 
MCP1 monocyte chemotactic protein 1  
mCSF macrophage colony-stimulating factor  
MD2 myeloid differentiation factor 2  
MDP muramyl dipeptide 
MDSCs myeloid derived-suppressor cells 
MEFs murine embryonic fibroblasts 
MHC major histocompatibility complex  
MIP1α macrophage inflammatory protein 1 alpha  
MIP1β macrophage inflammatory protein 1 beta 
MKK3/6 MAPK kinase 3/6 
MLNs mesenteric lymph nodes 
MPO myeloperoxidase 
mRNA messenger Ribonucleic acid 
MSR1 macrophage scavenger receptor 1  
mTORC1 mammalian target of rapamycin complex 1  
MyD88 myeloid differentiation primary-response protein 88 
MyD88s spliced MyD88 
NaCl sodium chloride 
NADPH nicotinamide adenine dinucleotide phosphate 
NBR1 neighbor of BRCA1 gene 1 protein  
NDP52 nuclear dot protein 52 kDa  
NETs neutrophil extracellular traps  
NFE2L2 nuclear factor (erythroid-derived 2)-like 2 
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NF-κB nuclear factor 'kappa-light-chain-enhancer' of activated B-cells  
NK cell natural killer cell 
NLRP3 NOD-like receptor family, Pyrin domain containing 3  
NO nitric oxide  
OTU domain ovarian tumor domain 
Pam3 Pam3CSK4, synthetic triacylated lipopeptide 
PAMP pathogen-associated molecular pattern 
PBS phosphate-buffered saline 
PCR polymerase-chain reaction  
PI3P phosphatidylinositol 3-kinase  
Poly I:C polyinosinic:polycytidylic acid  
pp Peyer´s patches  
pro-Casp1 pro-Caspase-1  
PRR pattern recognition receptor 
PVDF polyvinylidene difluoride  
qPCR quantitative real-time PCR  
RANK receptor activator of nuclear factor κ B 
RANTES regulated on activation, normal T cell expressed and secreted  
rev reverse 
RIP1 receptor-interacting serine/threonine-protein kinase 1 
RNA ribonucleic acid 
ROS reactive oxygen species  
S.D. standard deviation 
S100A8 S100 calcium binding protein A8  
S100A9 S100 calcium binding protein A9 
Sca-1 stem cell antigen-1  
SNP single-nucleotide polymorphism 
SPF specific-pathogen-free  
SQSTM1/p62 sequestosome-1 
SSC sideward scatter  
ssRNA single-stranded RNA  
TAB1/2/3 TAK1 binding protein 1/2/3 
TAE Tris-acetate  
TAK1 transforming growth factor β-activated kinase 1  
TANK TRAF-associated NF-κB activator  
TBK1 TANK-binding kinase-1  
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TBS Tris-buffered saline 
TEMED N,N,N′,N′-Tetramethylethane-1,2-diamine 
temp temperature 
TGS Tris/Glycine/SDS  
TIR domain Toll-IL1 receptor domain 
TIRAP/Mal TIR domain-containing adaptor protein 
TLR Toll-like receptor 
TNFAIP3/A20 TNFα-induced protein 3 
TNFα tumor necrosis factor alpha 
TRAF3/6 TNF receptor-associated factor 3/6 
TRAM TRIF-related adaptor molecule 
TRIF TIR-domain-containing adapter-inducing interferon-β  
TTBS TBS supplemented with 0.1 % (v/v) Tween 20  
TUNEL terminal deoxynucleotidyl transferase dUTP nick end labeling  
UBD ubiquitin-binding domain  
ULK1/2 UNC51-like kinase 1/2 
VPS15/34 vacuolar protein sorting 15/34 
WD tryptophan-aspartic acid  
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